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Abstract 
Major depression is associated with multiple dysregulated biological pathways which are 
influenced by an array of lifestyle, psychological, environmental and biological factors. 
Nutraceuticals including curcumin, derived from the Indian spice turmeric, also have the 
potential to influence these depressogenic pathways. Consequently, the aims of this thesis 
were to: 
1. Review and integrate research on dysregulated biological pathways, namely those 
associated with neurotransmitter imbalances, immuno-inflammatory processes, 
hypothalamus-pituitary-adrenal axis dysregulation, oxidative and nitrosative stress, 
mitochondrial dysfunction and neuroprogression.  
2. Review research on the relationship between several lifestyle-based factors and 
depression, and examine their effects on these depressogenic pathways. More specifically, 
the influence of diet, exercise, sleep, vitamin D, omega 3 essential fatty acid deficiency, 
stress and trauma, obesity and smoking were appraised along with their potential to 
prevent and treat major depression. The influence of psychological and pharmaceutical 
interventions on these dysregulated biological pathways was also reviewed. 
3. Examine the antidepressant effects of curcumin. In animal-based models, curcumin has 
demonstrated antidepressant effects, although clinical studies are lacking. The efficacy of 
curcumin in an 8-week, randomised, double-blind, placebo-controlled study was 
examined in people with a major depressive disorder. Curcumin at a dose of 500 mg, 
twice daily, was compared with a placebo. The Inventory of Depressive Symptomatology- 
Self Report (IDS-SR30) and Spielberger State-Trait Anxiety Inventory were used to assess 
symptomatic change. Curcumin and placebo were equally effective in lowering depressive 
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and anxiety symptomatology from baseline to week 4, but from weeks 4 to 8 curcumin 
supplementation was associated with superior antidepressant efficacy. 
4. Review the potential role of peripheral biomarkers in major depression and examine 
biomarker changes following curcumin supplementation. Measurement of peripheral 
biomarkers has the potential to enhance diagnosis, evaluate treatment progress and 
facilitate treatment matching. In a randomised, double-blind, placebo controlled study, the 
influence of curcumin on several urinary, plasma and salivary peripheral biomarkers was 
examined. The efficacy of biomarkers to predict treatment efficacy from curcumin 
administration was also examined. Urinary leukotriene B4, thromboxane B2 and substance 
P were associated with changes following curcumin treatment, while higher baseline 
concentrations of plasma endothelin-1 and leptin were associated with greater treatment 
efficacy.  
Limitations associated with the clinical studies are reviewed and recommendations for future 
research are provided. 
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Chapter 1: 
Introduction 
Major depressive disorder affects one in seven Australians sometime in their life, with 
greater rates in women (17%) compared to men (10%) (Australian Bureau of Statistics., 2009). 
The World Health Organisation (WHO) has predicted that by 2030, depression will account 
for more disability than any other physical or mental disorder throughout the world (WHO, 
2008).  
Currently, major depressive disorder is treated primarily through pharmacological 
and/or psychological interventions. Pharmacological interventions mainly comprise serotonin 
reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and, to a 
lesser extent, tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MOAIs). 
From a psychological perspective, cognitive-behaviour therapy (CBT) is frequently utilised by 
mental health practitioners.  
On the whole, these interventions have comparable efficacy for the treatment of major 
depression (Cuijpers et al., 2013b). From several meta-analyses examining antidepressant 
therapies, it has most consistently been concluded that they have reasonable efficacy in 
treating moderate and severe depression but have minimal benefit for the treatment of mild 
depression (Kirsch et al., 2008; Undurraga and Baldessarini, 2012). For example, Fournier et al. 
(2010) concluded that the magnitude of benefit from antidepressant medication compared 
with placebo increased with the severity of depressive symptoms, but antidepressant 
medication had minimal or non-existent benefit in patients with mild or moderate symptoms. 
For patients with very severe depression, the benefit of medications over placebo was 
substantial.  
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CBT consists of several variations including traditional CBT, and third-wave cognitive 
behavioural therapies such as acceptance and commitment therapy, dialectical behaviour 
therapy and functional analytic psychotherapy. In a recent meta-analysis it was concluded 
that these variations were similarly effective for the treatment of major depression (Hunot et 
al., 2013). From a meta-analysis examining all forms of CBT with placebo, it was concluded 
that CBT had an effect size of 0.71 (Hedges g), although this level was significantly reduced 
(Hedges g = 0.53) when only high-quality studies were included in the analyses (Cuijpers et 
al., 2013a).  
Combined treatments incorporating both psychological and pharmacotherapy have 
greater rates of efficacy compared to stand-alone treatments. In a recent meta-analysis, the 
overall effect size in favour of combined treatments (incorporating pharmacotherapy and 
psychotherapy) compared to pharmacotherapy alone for the treatment of depression and 
anxiety was 0.43 (95% CI: 0.31-0.56), indicating a moderate magnitude of efficacy (Cuijpers et 
al., 2014). The effects of combined treatment compared with placebo were about twice as large 
as those of pharmacotherapy compared with placebo, underscoring the clinical advantage of 
combined treatment.  
While psychological, pharmacological and combined treatments have proven to be 
helpful for many people with major depression, their efficacy is far from perfect and efforts to 
improve response rates over the past decade have been disappointing. In a post hoc analysis of 
the Sequenced Treatment Alternatives to Relieve Depression trial data, it was found that 90% 
of patients who achieved remission from antidepressant treatment had at least one residual 
symptom (Nierenberg et al., 2010). This is significant as residual symptoms are predictive of 
relapse, even among those who meet the criteria for remission (Judd et al., 2000; Paykel et al., 
1995). 
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Incomplete symptom resolution and treatment resistance may partly be due to the 
significant heterogeneity associated with major depressive disorder. While major depression 
comprises a constellation of symptoms detailed in the Diagnostic and Statistical Manual of 
Mental Disorders, Fifth Edition (DSM-5), there is significant variability in reported symptoms. 
For example, appetite changes can comprise either hypo- or hyperphagia, sleep disturbances 
involve insomnia or hypersomnia, and weight can change in either an upward or downward 
direction. There is also significant variability in reports of fatigue, suicidal ideation, and 
anhedonia. The high comorbidity of depression with cardiovascular, metabolic and digestive 
illnesses is also likely to influence treatment outcome (Katon, 2011).  
Several solutions have been proposed to enhance treatment success. These include 
subtyping depression based on (1) symptoms (e.g., melancholia, psychotic depression, 
atypical depression and anxious depression); (2) aetiology (e.g., adjustment disorders, early 
trauma depression, reproductive depression, perinatal depression, organic depression and 
drug-induced depression); (3) time of onset (e.g., early and late onset depression, and seasonal 
affective disorder); (4) gender; and (5) treatment resistance (Baumeister and Parker, 2012). 
While research on depression subtyping continues, some findings have been promising 
(Baumeister and Parker, 2012). For example, melancholic depression is associated with greater 
treatment efficacy from antidepressant medication (Yang et al., 2013).  
Biological assessments have also been used to increase understanding of the mechanisms 
associated with depression and to facilitate treatment matching. For example, there has been 
increasing interest in genetic testing to assist decision making around options for 
antidepressant treatment (Tansey et al., 2012; Uher et al., 2013). Genetic testing is still in its 
infancy but so far has been disappointing (Uher et al., 2013). The use of peripheral biomarkers, 
such as those associated with oxidative and nitrosative stress (O&NS), inflammation, 
monoamine activity, neuroprogression and neuroendocrine activity, have also been 
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investigated to identify depressive subtypes and to improve treatment matching (Lopresti et 
al., 2014; Schmidt et al., 2011). The clinical application of biomarkers is still in an early stage 
but has provided initial clues into treatment resistance from antidepressant (Eller et al., 2008; 
Lanquillon et al., 2000) and psychological therapies (Harley et al., 2010).  
As a result of only moderate success in the treatment of major depression, interest in 
alternative treatment options has increased. This has included investigations into the potential 
of pharmaceutical anti-inflammatory agents such as acetyl-salicylic acid and cyclooxygenase-2 
(COX-2) inhibitors to enhance treatment outcome (Abbasi et al., 2012; Berk et al., 2013; Fond et 
al., 2014). The use of COX-2 inhibitors has shown some promise in enhancing treatment 
response and remission rates (Fond et al., 2014).  
There has also been interest in applying various nutraceuticals for the treatment of 
depression (Sarris et al., 2011). In the domain of mental health, natural and complementary 
therapies are a popular option sought by the general community. For example, in a sample of 
women with depression, 54% of respondents reported using complementary and alternative 
medicine over the past year. More specifically, 20% of the sample reported using herbal 
therapies, while 16% used vitamins and nutritional supplements to help overcome mental and 
physical ailments (Wu et al., 2007). In another study on participants being treated for 
depression, 63% of respondents reported taking at least one dietary supplement within the 
previous 12 months. On average, supplement users took 2.8 dietary supplements during the 
assessment period (Silvers et al., 2006).  
Research on nutraceuticals, such as St John’s wort (Rahimi et al., 2009), S-
adenosylmethionine (Papakostas et al., 2012), omega-3 fatty acids (Grosso et al., 2014), folate 
(Taylor et al., 2004) and saffron (Hausenblas et al., 2013; Lopresti and Drummond, 2014), have 
shown them to be promising stand-alone or adjunct treatments for depression. 
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As a result of increasing interest in natural therapies and the role of biomarker 
identification in major depression, the aims of this PhD were to: 
1. Review dysregulated biological pathways associated with major depression, namely 
those associated with inflammation, oxidative and nitrosative stress, neurotransmitter 
imbalances, hypothalamus-pituitary-adrenal (HPA) axis regulation and 
neuroprogression. This is detailed in Chapter 2 and in two published papers. 
2. Review the relationship between depression and several lifestyle factors; and through 
a literature review examine their potential influence on these depressogenic pathways. 
Stress and trauma, omega-3 deficiency, vitamin D deficiency and smoking are covered 
in Chapter 3. The role of diet, exercise, sleep and obesity are detailed in two published 
papers. 
3. Through a literature review, summarise the influence of psychological therapies and 
pharmacological antidepressants on these depressogenic pathways. This is covered in 
Chapter 4. 
4. Review the influence of curcumin on these dysregulated biological pathways, which is 
detailed in a published paper included in Chapter 5. 
5. Review research on peripheral biomarkers associated with immuno-inflammation and 
oxidative stress in major depression, and examine the potential of these markers to 
assess treatment response and facilitate treatment matching. This is covered in a 
published paper included in Chapter 6. 
The following hypotheses were investigated in a randomised, double-blind, placebo 
controlled trial: 
1. Curcumin is an effective antidepressant for the treatment of mild-to-moderate major 
depressive disorder (examined in a published paper included in Chapter 5). 
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2. The antidepressant mechanisms associated with curcumin can be evaluated through 
pre- and post-collections of peripheral biomarkers (examined in an unpublished paper 
included in Chapter 6). 
3. Curcumin will have greater antidepressant efficacy for specific subgroups of 
individuals with major depressive disorder. These subgroups can be identified 
through symptomatic profiles (e.g., atypical depression) and/or baseline biomarker 
concentrations. This has the potential to facilitate treatment matching and therefore 
increase treatment success rates (examined in papers included in Chapters 5 and 6). 
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Chapter 2: 
Biological mechanisms associated with major 
depression 
Several dysregulated biological mechanisms are associated with major depressive 
disorder. These include those associated with neurotransmitter disturbances, immuno-
inflammatory processes, HPA axis dysregulation, O&NS, mitochondrial dysfunction and 
neuroprogression. These depressogenic pathways are strongly interconnected, further 
exacerbating dysregulations or buffering against further disturbances. Each of these pathways, 
detailed in Figure 1, are described in the following sections. 
 
Figure 1. Biological pathways associated with major depressive disorder. Several biological 
pathways are associated with major depressive disorder. These pathways are strongly 
interconnected, up- or down-regulating further activity.  
 
Neurotransmitter disturbances 
A review of research on neurotransmitter disturbances in major depression is covered in 
published papers comprising Chapters 3 and 4 (Lopresti et al., 2012; Lopresti et al., 2013), and 
therefore will not be repeated here. However, an overview demonstrating the influence of 
monoaminergic activity on other dysregulated pathways is outlined below. 
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Monoaminergic activity and its relationship with depressogenic pathways 
A bi-directional relationship likely exists between monoaminergic activity and several 
depressogenic pathways. For example, mechanisms associated with serotonin metabolism 
including receptor density and sensitivity, and the availability of serotonin transporter (SERT), 
influence brain-derived neurotrophic (BDNF) concentration and expression (Calabrese et al., 
2013; Homberg et al., 2014). Serotonin also influences HPA activity by modifying the secretion 
of corticotropin-releasing factor (CRH), adrenocorticotropic hormone (ACTH) and cortisol, 
and impacts on glucocorticoid receptor (GR) sensitivity (Calogero et al., 1990; Griffiths et al., 
2012; Jorgensen, 2007). While inflammation and cytokine production influence serotonin 
activity, the reverse is also true. That is, serotonin is also involved in the modulation of 
cytokine production (Cloez-Tayarani et al., 2003; Durk et al., 2005). Serotonin also protects 
against mitochondrial death (Zhou et al., 2014). The neurotransmitter noradrenaline also 
influences several of these depressogenic pathways. For example, it inhibits 
lipopolysaccharide (LPS)-induced cytokine production (Goyarts et al., 2008), and provides 
neuroprotection against oxidative stress (Jhang et al., 2014). 
Immune-inflammatory dysregulation 
The immune response, which consists of the innate and adaptive systems, is an essential 
response to the presence of infection, cellular damage and stress. The innate immune system is 
the first line of defence and comprises cells and other mechanisms that defend the host from 
infection in a non-specific manner. The adaptive immune system, also known as the acquired 
immune system, comprises highly specialised, systemic cells and processes that eliminate or 
prevent pathogen growth. Adaptive immunity creates immunological memory after an initial 
response to a specific pathogen, leading to an enhanced response to subsequent encounters 
with that pathogen (Huether and McCance, 2004).  
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Both the innate and adaptive systems include humoral and cell-mediated immunity 
(CMI). Humoral immunity, also referred to as the antibody-mediated immune system, is the 
aspect of immunity that is mediated by macromolecules such as antibodies, complement 
proteins and certain antimicrobial peptides found in extracellular fluids (Huether and 
McCance, 2004). CMI entails the interaction between different immune cells, such as T 
lymphocytes and macrophages/ monocytes that do not involve complement proteins, the 
acute phase response or antibodies (Leonard and Maes, 2012). 
While essential for survival, several diseases, including major depressive disorder, are 
characterised by an inappropriate immune-inflammatory response. This is supported by the 
following observations: 
1. The prevalence of major depression is increased in people with inflammatory-related 
medical conditions. 
2. Major depressive disorder is associated with increased markers of inflammatory and 
immune responses. 
3. Anti-inflammatory agents are beneficial for the treatment of major depression. 
4. Inducing an inflammatory state can initiate a major depressive episode. 
5. Stress is a common trigger for major depression and can also increase inflammation. 
Increased rates of depression in people with inflammatory conditions  
While association does not confirm causation, rates of depression are increased in people 
with inflammatory-related diseases. Autoimmune diseases such as diabetes (Andreoulakis et 
al., 2012), inflammatory bowel disease (Mikocka-Walus et al., 2007), multiple sclerosis 
(Alschuler et al., 2013), psoriasis (Biljan et al., 2009; Schmitt and Ford, 2010), rheumatoid 
arthritis (Matcham et al., 2013), and systemic lupus erythematosus (Palagini et al., 2013) are all 
associated with an increased prevalence of depression. Cardiovascular diseases (Fenton and 
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Stover, 2006), metabolic syndrome (Butnoriene et al., 2014), obesity (Lopresti and Drummond, 
2013), and asthma (Ahmedani et al., 2013) are also accompanied by higher rates of depression. 
While the relationship may be accounted for by psychological, psychosocial and physical 
influences, inflammatory-related processes which affect neuroimmunological and 
neuroendocrine pathways are also likely to be important.  
Increased inflammatory and immune response in major depression 
Major depression is accompanied by an activated immuno-inflammatory response, 
including signs of low-grade inflammation and increased CMI. From several meta-analyses, it 
has been confirmed that major depression in community and clinic-based samples is 
associated with elevated levels of C-reactive protein (CRP) (Howren et al., 2009; Valkanova et 
al., 2013), tumour necrosis factor alpha (TNFα) (Dowlati et al., 2010; Liu et al., 2012), 
interleukin (IL)-6 (Dowlati et al., 2010; Hiles et al., 2012; Howren et al., 2009; Liu et al., 2012), 
IL-1 (Howren et al., 2009) and IL-2 receptor (sIL-2R) (Liu et al., 2012). 
Cytokines such as interferon-γ (IFN-γ), IL-1β and TNFα can induce the enzyme 
indoleamine-2,3-dioxygenase (IDO). IDO is involved in the catabolism of tryptophan into 
TRYCATs (tryptophan catabolites along the IDO pathway) such as kynurenine (KYN), 
kynurenic acid (KYNA), and quinolinic acid (QUIN). These catabolites have neuroprotective 
(e.g., KYNA) and neurotoxic properties (e.g., QUIN). Although evidence is mixed, in general 
major depression is associated with increased IDO activity and lowered KNYA (Myint, 2012; 
Myint and Kim, 2013). From the evidence to date, it seems that increased IDO activity is 
prevalent in people with somatisation (Maes et al., 2011a; Maes and Rief, 2012) and in 
depressed patients with a history of suicidal attempts (Sublette et al., 2011). 
Further support for an increased immune response in depression is provided by 
consistent discoveries of elevated immunoglobulin (Ig)M and IgA-mediated immune 
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responses against LPS from various Gram-negative bacteria (Maes et al., 2008; Maes et al., 
2012). This is suggestive of the presence of increased gut permeability (leaky gut) and bacterial 
translocation. 
Inducing an inflammatory state triggers depression 
Stimulation of an inflammatory response using vaccinations, endotoxins, LPS and 
interferon can induce depressive symptoms (Rosenblat et al., 2014). For example, IFN-α, 
which is commonly used for the treatment of hepatitis C, triggers the onset of depression in 25 
to 80% of patients (Raison et al., 2009; Udina et al., 2012; Wichers et al., 2005).  The 
administration of LPS can also influence mood and cognitive ability (Grigoleit et al., 2011). 
While these studies suggest that inflammation has a causative role in depression, these 
findings need to be tempered by the fact that INF-α therapy involves the administration of 
supraphysiologic doses that are far higher than levels seen in depression. Nevertheless, low-
dose LPS or typhoid vaccination are more modest but also yield depressive and anxiety 
symptoms (Raison and Miller, 2011). 
Stress triggers depression and induces inflammation 
Acute and chronic stressful events and traumatic experiences are common triggers for a 
major depressive episode (Muscatell et al., 2009; Tennant, 2002). Acute psychological stress is 
accompanied by an acute inflammatory response such as elevations in IL-6, IL-1β, TNFα, and 
CRP (Steptoe et al., 2007). Threats to social status (Kemeny, 2009), early life stress (Raposa et 
al., 2014) and bereavement (Cohen et al., 2013) are risk factors for the onset of depression and 
are also associated with increased inflammation. 
Anti-inflammatory treatments have anti-depressant effects 
Several medications with anti-inflammatory mechanisms have antidepressant effects. For 
example, used in conjunction with antidepressant medications, the COX-2 inhibitor celecoxib 
Chapter 2: Biological mechanisms associated with major depression 
 
- 14 - 
can enhance treatment response and remission rates (Abbasi et al., 2012; Fond et al., 2014). 
Omega-3 fatty acids, which have anti-inflammatory properties, have moderate efficacy for the 
treatment of depressive symptoms in people with major depression (Grosso et al., 2014). 
Acetyl-salicylic acid (Berk et al., 2013) and the tetracycline antibiotic minocycline also have 
demonstrated antidepressant effects (Dean et al., 2012; Soczynska et al., 2012). In addition to 
these findings, in several reviews it has also been confirmed that antidepressants have anti-
inflammatory properties (Hannestad et al., 2011; Leonard, 2013; Walker, 2013). 
While the reviewed studies support an association between depression and immuno-
inflammatory pathways, this does not necessarily imply causation. It seems that the 
relationship is likely bi-directional. However, support for inflammation as a causative factor is 
provided by consistent signs of depression following the induction of inflammatory processes 
(e.g via IFN-α and LPS). Control for moderating variables associated with inflammation and 
depression such as age, medical disease, smoking status and BMI, diminish the strength of the 
relationship but do not eliminate it. 
Immuno-inflammatory states and their relationship with depressogenic pathways 
The depressogenic mechanisms associated with dysregulated immune-inflammation 
have been comprehensively covered in several reviews. Immuno-inflammatory processes can 
influence neurotransmitter activity, contribute to HPA dysregulation, increase O&NS, impair 
mitochondrial function, and influence neuroprogression (Haroon et al., 2012; Leonard and 
Maes, 2012; Miller and Raison, 2008; Raison et al., 2006). A selection of inflammatory-induced 
mechanisms associated with these pathways is outlined below: 
 Neurotransmitter activity: Immuno-inflammatory processes can influence neurotransmitter 
metabolism through several mechanisms. For instance, cytokines such as IFN-γ, IL-1β and 
TNFα can activate IDO leading to the breakdown of tryptophan, reducing subsequent 
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serotonin availability and increasing the production of TRYCATs (Myint, 2014). Chronic 
inflammation also lowers concentrations of tetrahydrobiopterin (BH4), an enzyme cofactor 
involved in the production of dopamine, nitric oxide (NO), noradrenaline and serotonin 
(Sperner-Unterweger et al., 2014). Cytokines and their signalling pathways can also 
influence the reuptake of monoamines and induce changes in serotonin receptors 
(Leonard and Maes, 2012; Miller et al., 2009).  
 HPA activity: Cytokines disrupt HPA axis activity by up-regulating CRH, ACTH and 
cortisol release (Zunszain et al., 2011). Inflammatory cytokines can also disrupt GR 
function, contributing to glucocorticoid resistance (Pace and Miller, 2009).  
 Oxidative and nitrosative stress: While O&NS can induce an inflammatory and immune 
response, the reverse is also true. For example, pro-inflammatory cytokines such as TNFα 
and IL-1β can stimulate the production of reactive oxygen species (ROS) (Barth et al., 2009; 
Floyd et al., 1999). Neopterin, a marker of Th1-type immune response, also activates 
inducible nitric oxide synthase and NO production, and increases levels of hydrogen 
peroxide (Razumovitch et al., 2004; Schobersberger et al., 1995). IDO activation induced by 
an immune reaction lowers concentrations of tryptophan and serotonin, which are both 
strong antioxidants, and increase oxidative stress-producing TRYCATs such as 3-
hydroxykynurenine, 3-hydroxyanthranilic acid and quinolinic acid (Maes et al., 2011b). 
 Mitochondrial activity: Pro-inflammatory cytokines can directly influence mitochondrial 
activity which, in turn, exacerbates inflammatory responses. Adipocytes treated with IL-6 
had decreased mitochondrial membrane potential, decreased cellular ATP production, 
and increased intracellular ROS levels (Ji et al., 2011). The TRYCATs L-kynurenine, 3-
hydroxykynurenine, anthranilic acid and 3-hydroxyanthranilic acid also disturb 
respiratory parameters of mitochondria (Baran et al., 2003).  
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 Neuroprogression: Increased levels of pro-inflammatory cytokines and CMI-related 
cytokines may contribute to neuroprogression through several mechanisms (Moylan et al., 
2013). For instance, the stimulation of IDO produces several TRYCATs that can be 
neurotoxic to the central nervous system (CNS) (Myint and Kim, 2013); IFN-γ sensitises 
cortical and cerebellar neurons to neurotoxic peptides, and increases neuronal death (Bate 
et al., 2006; Lambertsen et al., 2004); and IFN-α decreases systemic BDNF levels (Kenis et 
al., 2011; Lotrich et al., 2013). 
HPA dysregulation 
A review of research on HPA axis dysregulation in major depression is covered in 
published papers in Chapters 3 and 4 (Lopresti et al., 2012; Lopresti et al., 2013), and therefore 
will not be repeated here. However, the influence of HPA activity on other dysregulated 
biological pathways is detailed below. 
HPA activity and its relationship with depressogenic pathways 
The importance of HPA activity in major depression is highlighted by its bi-directional 
relationship with several depressogenic biological pathways.  In relation to inflammatory 
processes, pro-inflammatory cytokines have a significant influence on the development of 
glucocorticoid resistance and can contribute to increased cortisol secretion (Silverman and 
Sternberg, 2012). Sustained or severe stress can also promote the inflammatory response via 
pathways associated with the sympathetic and parasympathetic nervous systems (Turnbull 
and Rivier, 1999; Zunszain et al., 2011). HPA activity can also influence the immune response 
via its effect on the production of TRYCATs. Along with the enzyme IDO, tryptophan-2,3-
dioxygenase (TDO), which is induced by cortisol, is also involved in the metabolism of 
tryptophan into TRYCATs (Altman and Greengard, 1966). Psychosocial stress can also 
increase free radical production and consequent oxidative stress; and sustained oxidative 
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stress via its damaging effects on brain centres, such as the hippocampus and hypothalamus, 
can impair HPA activity (Colaianna et al., 2013; Kobayashi et al., 2009). Severe or chronic 
exposure to stress, and consequent exposure to high cortisol levels during both early life and 
adulthood, can cause cell death, neuronal atrophy, and can affect hippocampal neurogenesis 
and plasticity (McEwen and Gianaros, 2011).  
Oxidative and nitrosative stress 
Oxidative and nitrosative stress (O&NS) and its relationship with major depression is 
summarised in published papers in Chapters 3 and 4 (Lopresti et al., 2012; Lopresti et al., 
2013), and therefore will not be covered here.  
O&NS and its relationship with depressogenic pathways 
O&NS can contribute to the aetiology of depression via multiple depressogenic pathways. 
O&NS can influence serotonin activity by altering serotonin receptor sensitivity and receptor 
binding, and can damage intracellular signalling (Karolewicz et al., 2001; Zhang et al., 2010). It 
can elevate the production of inflammatory mediators such as pro-inflammatory cytokines 
and chemokines by increasing nuclear factor-κB, activator protein-1 and mitogen-activated 
protein kinases (Moylan et al., 2014). O&NS can also initiate autoimmune responses due to its 
deleterious effects on cellular proteins, lipids, and DNA. By changing the function and 
chemical structure of membrane fatty acids and functional proteins, modified immunogenic 
epitopes or neo-epitopes are formed, mounting an autoimmune response (Maes et al., 2011c). 
O&NS can also affect HPA axis activity. For example, elevation of NADPH oxidase in the 
hypothalamus altered HPA-axis activity (Colaianna et al., 2013), and oxidative stress in the 
form of hyperoxia, thiobarbituric acid reactive substances, conjugated diene and lipid 
hydroperoxides, markedly increased HPA axis activity and reduced glucocorticoid receptor 
concentrations. These effects were ameliorated by vitamin E supplementation (Kobayashi et 
Chapter 2: Biological mechanisms associated with major depression 
 
- 18 - 
al., 2009). O&NS processes, including lowered antioxidant defences, are also a major cause of 
mitochondrial dysfunction (Gardner and Boles, 2011). The effects of O&NS on 
neuroprogression occur via most of the aforementioned pathways and through a complex 
series of events associated with excitotoxicity, calcium overload, and reduced neurotrophic 
factors (Kaur et al., 2005; Moylan et al., 2013; Numakawa et al., 2011).  
Mitochondrial dysfunction 
Published papers included in Chapters 3 and 4 (Lopresti et al., 2012; Lopresti et al., 2013) 
contain summaries of mitochondrial dysfunction in major depression and therefore will not be 
repeated here. 
Mitochondrial activity and its relationship with depressogenic pathways 
Mitochondrial dysfunction has a role in several depressogenic biological pathways. A 
deficiency in ATP production can contribute to fatigue and somatic symptoms associated with 
depression (Leonard and Maes, 2012). Mitochondria are very susceptible to damage by O&NS 
and, in turn, are major sources of ROS and reactive nitrogen species (RNS), further fuelling the 
O&NS process. ROS and RNS derived from mitochondria can also act as signal-transducing 
molecules that provoke an up-regulation of pro-inflammatory cytokines (Naik and Dixit, 
2011). Mitochondria can also affect neuroprogressive pathways via their effect on cell death 
and subsequent neurodegeneration. For example, mitochondrial dysfunction impairs neural 
progenitor cell function (Kirby et al., 2009) and impairs neurogenesis-dependent hippocampal 
plasticity (Steib et al., 2014). All of these processes interact with mitochondrial activity, leading 
to a further cascade of mitochondrial abnormalities (Gardner and Boles, 2011; Moylan et al., 
2013).  
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Neuroprogression 
A review of research on neuroprogression in major depression is detailed in published 
papers attached in Chapters 3 and 4 (Lopresti et al., 2012; Lopresti et al., 2013). 
Neuroprogression and its relationship with depressogenic pathways 
Several pathways are posited to influence neuroprogression in major depression. 
Increased pro-inflammatory cytokines and immune responses; neurotoxic TRYCATs; elevated 
O&NS and lowered antioxidant defences; reduced serotonin metabolism; omega-3 essential 
fatty acid deficiency; mitochondrial dysfunction; chronic stress; and HPA dysregulation are all 
believed to be important pathways to neuroprogression (Haroon et al., 2012; Leonard and 
Maes, 2012; Moylan et al., 2013). Reduced neurotrophic factors such as BDNF also contribute 
to further cascading problems, as these factors are involved in serotonin metabolism 
(Homberg et al., 2014), HPA axis activity (Nowacka and Obuchowicz, 2013), mitochondrial 
activity (Markham et al., 2014; Nowacka and Obuchowicz, 2013), inflammatory responses 
(Audet and Anisman, 2013; Takeda et al., 2013), and O&NS (Boyadjieva and Sarkar, 2013; 
Numakawa et al., 2011). 
Summary 
As detailed in this chapter, several dysregulated biological pathways are associated with 
major depressive disorder. These pathways are strongly interconnected, having a multi-
directional relationship. This can lead to a negative biological spiral, contributing to further 
dysregulation over time, and possible worsening of depressive symptoms. Although the 
original source of these disturbances is difficult to determine and may be unique to an 
individual, an understanding of the relationship between these pathways contributes to a 
greater understanding of the biological complexities associated with major depression.  
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Figure 2. Factors influencing biological pathways associated with depression. The depressogenic 
biological pathways associated with major depression (centre of figure) are influenced by 
several past and current lifestyle, psychological, and biological factors (left of figure). These 
factors may affect one or several biological pathways, leading to further dysregulation. A 
bi-directional relationship exists between depression and these etiological factors 
(represented by the top arrow), as suffering from depression can also contribute to 
depressogenic lifestyle choices. A feed-forward process ensues, leading to a further 
exacerbation of depressive symptoms. 
 
The depressogenic mechanisms associated with major depression reviewed in Chapter 2 
are influenced by an array of biological, psychological, lifestyle and environmental factors 
(Figure 2). In a recent paper by Berk et al. (2013), the influence of psychosocial stressors, poor 
diet, physical inactivity, obesity, smoking, altered gut permeability, atopic disease, dental 
health, sleep and vitamin D deficiency on inflammatory processes associated with depression 
was reviewed. The postpartum period, other inflammatory disorders (e.g., cardiovascular 
disorder, rheumatoid arthritis, systemic lupus erythematosus, diabetes, and metabolic 
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syndrome) and several biological vulnerability factors also increase the propensity to develop 
depression, including a leaky gut with increased LPS translocation through the gut wall, and a 
lowered omega-3 essential fatty acid (EFA) status (Maes et al., 2009c).  
A selection of important lifestyle-related factors (stress and trauma, omega-3 deficiency, 
vitamin D deficiency and smoking) associated with major depression is reviewed in the 
following sections with an examination of their influence on depressogenic biological 
pathways. Further lifestyle and physical influences such as diet, exercise, sleep and obesity are 
also reviewed in the attached published articles. 
Stress and trauma 
Psychosocial stressors, including acute psychological trauma, moderate chronic stressors, 
and early exposure to childhood trauma strongly increase the risk for major depression. In the 
6 months prior to their worst depressive episode, people with major depression reported 
increased exposure to several significant stressors, including serious illness, injury or an 
assault; death of a spouse or first-degree relative; death of a close family friend or other 
relative; separation due to marital difficulties or break up of a steady relationship; a serious 
problem with a close friend, neighbour or relative; job loss; and major financial crisis (Hosang 
et al., 2012). These stressors can impact on cognitive and emotional resiliency and also 
influence several depressogenic biological pathways. 
Stress and the immuno-inflammatory response 
There is substantial evidence through animal models comprising chronic mild stress and 
learned helplessness that stress increases systemic and CNS levels of inflammatory markers, 
such as IL-1β, TNFα, IL-6, nuclear factor κB, COX-2, and expression of Toll-like receptors 
(Kubera et al., 2011). Similar findings have been observed in human-based studies. In a recent 
systematic review, it was confirmed that childhood trauma is associated with increased 
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baseline levels of inflammatory markers, most notably CRP, TNFα and IL-6 in adulthood 
(Coelho et al., 2014). In addition, lower socioeconomic status (SES) or lower early life social 
class is associated with higher levels of inflammatory signalling (Miller et al., 2009), which 
may be buffered by protective factors such as maternal warmth (Chen et al., 2011). In a meta-
analysis it was also shown that acute psychological stress significantly augments levels of IL-6, 
IL-1β and CRP, but not TNFα (Steptoe et al., 2007). The effects of stress in people with major 
depression is of particular relevance as there is evidence that acute psychological stress is 
associated with an exacerbated inflammatory response in people with major depressive 
disorder (Miller et al., 2005; Pace et al., 2006). 
Stress and HPA activity 
Childhood trauma is consistently associated with dysregulated HPA activity, although 
the direction of activity is variable, with findings of both increased and decreased HPA 
activity. HPA axis functioning as measured by the cortisol awakening response was 
significantly increased in depressed patients with a history of childhood neglect compared to 
those without (Peng et al., 2014). In a non-clinical sample of women with minimal or no 
current psychopathology, a prior history of physical abuse was associated with a blunted 
cortisol response to a psychosocial stress task (Carpenter et al., 2011). However, postpartum 
women who reported experiencing adverse early life experiences exhibited a tendency toward 
higher levels of awakening cortisol compared to women with no adverse history (Gonzalez et 
al., 2009). In adults without diagnosable psychopathology, childhood maltreatment was 
associated with a diminished HPA axis response to a psychosocial stressor (Carpenter et al., 
2007). It is argued that childhood trauma may influence GR sensitivity by down-regulating 
glucocorticoid expression (McGowan et al., 2009). 
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Stress and oxidative and nitrosative stress 
Schiavone et al. (2012) reviewed animal and human based studies examining the influence 
of severe life stress on oxidative stress. Animal models of severe life stress comprised sleep 
deprivation, maternal separation and social isolation in rodents, and the establishment of a 
dominance hierarchy in non-human primates. Exposure to these differing forms of severe life 
stress was associated with decreased antioxidant enzymes such as glutathione peroxidase and 
superoxide dismutase. Rats exposed to social isolation also experienced increases in NADPH 
oxidase (NOX2) enzyme activity and increased markers of oxidative stress (Schiavone et al., 
2009). In humans, severe life stress caused by traumatic events such as child abuse, war, and 
divorce, is accompanied by increased oxidative stress in the CNS (Schiavone et al., 2012). 
Increased levels of nitric oxide, ROS-mediated brain changes and elevations in 8-hydroxy-2-
deoxyguanosine have been reported in soldiers exposed to war (Borovac Stefanovic et al., 
2014; Pall, 2001).  
Stress and neuroprogression 
While mild, acute stress can enhance learning and memory and facilitate brain plasticity, 
chronic or severe stress, as well as exposure to high doses of glucocorticoids, can be harmful to 
the CNS leading to several structural changes such as neuronal atrophy in the hippocampus 
and prefrontal cortex (Sapolsky, 2003). In animal studies it has been shown that exposure to 
repeated or chronic stress causes plastic remodelling of hippocampal circuitry, such as the 
shortening of dendrites, loss of dendritic spine synapses, and suppression of neurogenesis 
(McEwen and Gianaros, 2011). Differences in the corpus callosum identified by structural 
magnetic resonance imaging (MRI) have now been reliably reported in children who have 
experienced abuse, while differences in the hippocampus have been found in adults with a 
childhood history of maltreatment. In addition, there is preliminary evidence of amygdala 
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hyperactivity and atypical activation in the frontal regions of adults who have experienced 
childhood maltreatment (McCrory et al., 2011). Low SES, which is associated with increased 
stress, also correlates with smaller hippocampal volumes (Cavanagh et al., 2013; Raizada and 
Kishiyama, 2010), and high levels of chronic perceived stress over a 20-year period in 
postmenopausal women has been associated with reduced gray matter volume in the 
hippocampus and in a region of the lateral prefrontal cortex (Gianaros et al., 2007). 
Investigations into the effects of stress on neurotrophic factors have confirmed that 
chronic and severe stress has a detrimental effect on BDNF. The expression of BDNF is 
regularly reduced in experimental animals exposed to adverse experiences at early stages of 
life or during adulthood (Calabrese et al., 2009), and exposure both to early and later life 
trauma elicits significant down-regulation in BDNF mRNA and protein levels in the 
hippocampus CA1 subregion (Bazak et al., 2009).  
Stress and monoaminergic activity 
In animal models, stress alters serotonergic activity. For example, early life stress 
comprising prolonged maternal separation disturbed the serotonergic system by altering adult 
brain serotonergic transporter function and 5-HT1A receptor and SERT mRNA expression 
(Bravo et al., 2014; Ohta et al., 2014; Vicentic et al., 2006). The serotonergic system is also 
altered by acute physical stress (Choi et al., 2014), and exposure to excessive prenatal stress 
may induce a vulnerability to stress and disrupt the development of serotoninergic neurons 
(Miyagawa et al., 2014).  
Stress also influences dopaminergic activity. For example, maternal separation in rats 
altered dopamine transporter function (Womersley et al., 2011) and tyrosine hydroxylase-
immunoreactive dopaminergic neurons in the rat midbrain (Chocyk et al., 2011). Acute 
psychological stress comprising exposure to traumatic imagery in people with war-related, 
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chronic post-traumatic stress disorder (PTSD) lowered cerebrospinal fluid (CSF) levels of the 
dopamine metabolite homovanillic acid compared to exposure to neutral imagery (Geracioti et 
al., 2013). 
These reviewed studies confirm that acute and chronic stress can influence several 
depressogenic biological pathways. Although the influence of stress on each pathway has 
been discussed separately, they are strongly inter-connected. Other variables including age, 
gender, SES, ethnicity, body-mass index, cardiorespiratory fitness, sleep quality and quantity, 
caffeine consumption, smoking and alcohol consumption also likely influence these 
mechanistic pathways (O'Connor et al., 2009).  
Omega-3 deficiency 
A relationship between omega-3 essential fatty acids (EFA) and depression is supported 
by several lines of evidence. For example, omega-3 levels are often lower in depressed people 
compared to healthy controls; omega-3 status is often associated with depressive symptoms; 
and supplementation with omega-3 EFAs are regularly associated with improvements in 
depressive symptoms.  
Omega-3 status and depression 
In a meta-analysis of 14 studies, the levels of eicosapentaenoic acid (EPA), 
docosahexaenoic acid (DHA), and total omega-3 EFA were significantly lower in depressed 
patients compared to control subjects. However, there was no significant difference in 
arachidonic acid or total omega-6 levels between the two groups (Lin et al., 2010).  
After adjusting for body mass index, serum total cholesterol level and SES, the risk of 
developing depression increased up to 2.6-fold among females who rarely ate fish compared 
with regular fish eaters (Timonen et al., 2004). In a longitudinal population-based study on 
3317 African-American and Caucasian men and women, Colangelo et al. (2009) examined the 
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association between fish consumption and dietary intake of EPA and DHA with depressive 
symptoms. In the entire cohort, the highest quintiles of EPA, DHA, and EPA + DHA intake 
were associated with a lower risk of subsequent depressive symptoms with more pronounced 
associations observed in women. However, not all findings from cohort studies support a 
relationship between omega-3 consumption and depression. For example, in a 10-year 
prospective study on 54,632 women aged 50-77 years, the intake of omega-3 EFA from fish 
was not associated with subsequent depression risk, although α-linolenic acid intake was 
inversely associated with risk of depression (Lucas et al., 2011). Little evidence from a large 
prospective cohort was also found between intake of fish and post-partum depression (Strom 
et al., 2009).  
While omega-3 intake can provide an indicator of EFA status, blood concentrations of 
EFA can provide another marker. In several studies it has been confirmed that EFA 
concentrations in blood are lower in depressed populations compared to controls. For 
example, lower concentrations of total omega-3 EFA and DHA in red blood cells (Peet et al., 
1998) and omega-3 EFA in serum phospholipids (Maes et al., 1999) were found in depressed 
patients compared to healthy controls. Low red blood cell concentrations of omega-3 during 
late pregnancy was also associated with higher depression scores three months postpartum 
(Markhus et al., 2013).  
Supplementation with omega-3 PUFA is associated with improvements in depressive 
symptoms. 
Interest in the antidepressant effects of omega-3 supplementation in people with major 
depression has been high. Consequently, several systematic reviews and meta-analyses have 
been published over the past decade. On the whole, it has been confirmed that omega-3 
supplementation is beneficial for the alleviation of depressive symptoms (Appleton et al., 
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2010; Kraguljac et al., 2009). In a recent meta-analysis comprising 11 studies on patients with a 
DSM-defined diagnosis of major depressive disorder, and 8 trials on patients with depressive 
symptomatology but no diagnosis of major depression, significant clinical benefit from 
omega-3 treatment compared to the placebo was confirmed. In trials on people with 
diagnosed major depression, preparations containing greater concentrations of EPA compared 
to DHA were associated with greater clinical efficacy (Grosso et al., 2014b). Similar findings 
have been obtained from other meta-analyses, demonstrating greater benefits from 
supplements with greater EPA concentrations (Martins, 2009; Sublette et al., 2011). 
The relationship between omega-3 EFA and depression may be due to its influence on 
multiple antidepressant mechanisms of action. Omega-3 EFA influences several molecular 
pathways associated with inflammation. The anti-inflammatory actions of omega-3 EFA are 
thought to be mediated by the formation of their active metabolites (eicosanoids and other 
lipid mediators) as well as their regulation of the production of inflammatory mediators (e.g., 
adipocytokines, cytokines) and immune cell infiltration into adipose tissue (Grosso et al., 
2014a). Omega-3 EFAs mediate these effects by modulating several pathways, such as those 
involving nuclear factor-κB, peroxisome proliferator-activated receptors and Toll-like 
receptors (Fan et al., 2013). Higher dietary omega-3 intake is also associated with lower levels 
of inflammatory and endothelial activation biomarkers in cardiovascular disease, renal 
disease, sepsis and acute pancreatitis (Rangel-Huerta et al., 2012). The anti-inflammatory 
effects of omega-3 EFAs are also related to their influence on resolvins, which are potent anti-
inflammatory mediators that act as ‘stop-signals’ on the inflammatory response (Titos and 
Claria, 2013).  
The beneficial effects of omega-3 on depression may also occur via its influence on HPA 
activity and cortisol regulation. For example, in a randomised, placebo-controlled trial on 
abstinent alcoholics, fish oil supplementation was associated with reduced basal cortisol levels 
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(Barbadoro et al., 2013). In people with recurrent depression, cortisol levels correlated 
negatively with blood DHA concentration (Mocking et al., 2013). Fish oil supplementation also 
significantly blunted plasma ACTH and cortisol levels in healthy volunteers following an 
endotoxin challenge comprising LPS (Michaeli et al., 2007). EPA alone or in combination with 
fluoxetine, as well as fluoxetine alone, decreased serum cortisol after 8 weeks of treatment in 
patients with major depressive disorder (Jazayeri et al., 2010). Finally, supplementation with 
omega-3 EFAs inhibited increases in plasma epinephrine and cortisol elicited by acute mental 
stress in healthy men (Delarue et al., 2003). 
Omega-3 EFAs also have positive effects on neurogenesis in the hippocampus (Kang and 
Gleason, 2013; Kawakita et al., 2006). In animal models, exposure to omega-3 EFAs enhanced 
adult hippocampal neurogenesis, promoted synaptic plasticity and modulated synaptic 
protein expression (Crupi et al., 2013). In contrast, decreased DHA in the developing brain 
impairs neurogenesis, neurotransmitter metabolism, and alters learning in animals (Innis, 
2008). In further animal studies it has been confirmed that omega-3 supplementation during 
the prenatal period increases concentrations of BDNF and nerve growth factor (Sable et al., 
2013). Human-based studies are scarce, although in an open-label study on people with PTSD, 
fish oil supplementation was associated with increases in serum BDNF levels (Matsuoka et al., 
2011). However, no effect on BDNF was found in depressed, diabetic patients supplemented 
with fish oil (Bot et al., 2011). 
Vitamin D deficiency 
Vitamin D, the ‘sunshine vitamin’, is well known for its role in regulating calcium and 
phosphate metabolism and for skeletal health. Because most cells and organs in the body have 
a vitamin D receptor, vitamin D also influences several biological pathways. Vitamin D 
deficiency has been linked to many chronic diseases including autoimmune diseases, some 
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cancers, cardiovascular disease, infectious disease, and type 2 diabetes (Glade, 2013; Wacker 
and Holick, 2013). Research over the past decade also confirms a relationship with depression.  
In a systematic review and meta-analysis, Anglin et al. (2013) analysed one case–control 
study, ten cross-sectional studies and three cohort studies on depression and vitamin D 
deficiency (total of 31,424 participants). In the case-control study, vitamin D levels in women 
with depression were lower compared to healthy controls, represented by a standard mean 
difference of 0.60 (95% CI 0.23–0.97). In a meta-analysis on the ten cross-sectional studies, 
there was an increased but non-significant odds ratio of depression for the lowest compared to 
highest vitamin D categories (OR = 1.31, 95% CI 1.0-1.71). In the three identified cohort studies, 
there was a significantly increased hazard ratio of depression for the lowest versus highest 
vitamin D categories (HR = 2.21, 95% CI 1.40-3.49) (Anglin et al., 2013). In another meta-
analysis, 11 cross-sectional studies (43,137 participants) and 5 cohort studies (12,648 
participants) were identified for analysis. A 10 ng/ml increase in vitamin D level was 
associated with an 8% decrease in the incidence of depression in cohort studies and a 4% 
decrease in the risk of depression in cross-sectional studies (Ju et al., 2013). 
Several recent meta-analyses have also now been published examining the effects of 
vitamin D supplementation on depressive symptoms. In a meta-analysis of six randomised 
controlled trials consisting of 1203 participants (5 studies involving adults at risk of 
depression, and one using depressed patients), there was no identified significant effect for 
vitamin D supplementation compared to placebo on post-intervention depression scores (Li et 
al., 2014). In another meta-analysis on seven randomised controlled trials (3,191 participants), 
vitamin D supplementation again had no overall effect on depressive symptoms, although a 
subgroup analysis showed that vitamin D supplementation in participants with clinically 
significant depressive symptoms or depressive disorder had a moderate, statistically 
significant effect (2 studies: standardised mean difference, -0.60; 95% CI, -1.19 to -0.01; p = .046) 
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(Shaffer et al., 2014). Finally, in a meta-analysis by Spedding (2014), studies without 
methodological flaws were analysed. Methodological flaws were defined as follows: studies 
where vitamin D supplementation was associated with reduced or no change in post-
intervention vitamin D status; studies where the baseline vitamin D level was not measured in 
participants; and studies where the baseline vitamin D level indicated sufficiency at baseline. 
Using only studies with no methodological flaws, it was concluded that vitamin D 
supplementation (≥800 I.U. daily) was effective for the management of depression with the 
effect size comparable to that of anti-depressant medication.  
While further research is required, from the bulk of the evidence to date, it seems that 
vitamin D has a role in major depression. This relationship likely results from the multiple 
biological actions of vitamin D. For example, vitamin D can regulate serotonin synthesis by 
activating the transcription of the serotonin-synthesising enzyme, tryptophan hydroxylase 2 
(Patrick and Ames, 2014), and can influence dopamine production via its effect on the 
expression of the enzymes catechol-O-methyl transferase and tyrosine hydroxylase (Kesby et 
al., 2009; Partonen, 1998; Tekes et al., 2009). Vitamin D also influences the body's immune 
system by modulating the innate and adaptive immune systems, affecting the production of 
important endogenous antimicrobial peptides and regulating the inflammatory cascade 
(Arnson et al., 2007; Gunville et al., 2013). In a study by Arnoson et al. (2013), a course of 
treatment with vitamin D for 5 days attenuated the increase in circulating levels of 
inflammatory cytokines after an acute coronary event. Control patients had increased serum 
concentrations of cytokine and cellular adhesion molecules after 5 days (VCAM-1 levels, CRP, 
and IL-6), while the vitamin D-treated group had an attenuated elevation or a reduction in 
these parameters. Vitamin D can also affect HPA regulation through its influence on 
glucocorticoid action and glucocorticoid receptor sensitivity (Obradovic et al., 2006; Zhang et 
al., 2013). Finally, in animal studies, vitamin D depletion is also associated with altered 
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neurogenesis (Cui et al., 2007; Zhu et al., 2012). The neuroprotective effect of vitamin D is 
associated with its influence on neurotrophin production and release, neuromediator 
synthesis, intracellular calcium homeostasis, and prevention of oxidative damage to nervous 
tissue (Xu et al., 2006). 
Smoking 
In several population-based epidemiological studies, it has been confirmed that rates of 
cigarette smoking are significantly higher in depressed patients compared to non-depressed 
controls (Lasser et al., 2000; Lawrence et al., 2009). In the National Comorbidity Survey, 
approximately 59% of individuals with a life-time history of depression were current or past 
smokers, compared to less than 39% of those without a life-time history of depression (Lasser 
et al., 2000; Ziedonis et al., 2008).  
The relationship between depression and smoking is likely bi-directional as findings in 
most studies have shown that depression increases the likelihood of smoking onset, and 
smoking increases the risk of later depression. For example, in adolescence, depression and 
anxiety predicted the initiation of experimental smoking (Patton et al., 1998), and in a sample 
of 15 to 54 year olds, having an unremitted, pre-existing psychiatric disorder was associated 
with an increased risk of de novo smoking and progression to nicotine dependence (Breslau et 
al., 2004). Smoking also appears to be associated with an increased risk for later development 
of mood disorders. Using a case-control and retrospective cohort study design, Pasco et al. 
(2008) demonstrated that smoking increased the risk of de novo major depressive disorder by 
93%; and in a 13-year longitudinal study using a population-based sample of 13 to 27 year 
olds, nicotine-dependent young adults had an elevated risk for the development of anxiety, 
depression and parasuicide (Pedersen and von Soest, 2009). In addition to increased 
prevalence rates, people with current nicotine dependence also exhibit greater severity of 
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depressive symptoms and experience a slower recovery from depression compared to people 
without a history of nicotine dependence (Jamal et al., 2012; Leventhal et al., 2009). 
The effects of smoking on neurobiological depressogenic pathways have been described 
in several reviews (Berk et al., 2013; Moylan et al., 2013b; Nunes et al., 2013; Vargas et al., 
2013). Smoking influences monoaminergic activity, HPA axis regulation, immuno-
inflammatory processes, O&NS and mitochondrial activity. In particular, smoking has been 
associated with increased levels of acute phase proteins, including CRP, and pro-
inflammatory cytokines, such as IL-1β, IL-6 and TNFα (Yanbaeva et al., 2007). It also seems 
that the effects of smoking and depression are additive as inflammatory responses are 
enhanced in depressed smokers compared to non-depressed smokers (Nunes et al., 2012).  
The free radicals contained in cigarette smoke also lead to oxidative damage to cellular 
tissues, including those in the CNS. In several animal studies cigarette smoke increased 
markers of oxidative stress and decreased levels of antioxidants and antioxidant enzymes 
(Frost-Pineda et al., 2011; Stangherlin et al., 2009; Tuon et al., 2010). Cigarette smoking also 
influences neurotransmitter activity. For example, in a study by Malone, et al. (2003), an 
inverse relationship was observed between the amount of cigarette smoking and serotonin 
function in psychiatric patients. In an animal model, cigarette smoking influenced dopamine 
activity by increasing dopamine transporter expression (Li et al., 2004).  
Diet, Sleep, Exercise and Obesity 
In the following two published papers, the relationship between depression and diet, 
exercise, sleep and obesity are reviewed. Their potential impact on the depressogenic 
biological pathways is also examined. 
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Abstract 
Research on major depression has confirmed that it is caused by an array of 
biopsychosocial and lifestyle factors. Diet, exercise and sleep are three such influences that 
play a significant mediating role in the development, progression and treatment of this 
condition. This review summarises animal and human-based studies on the relationship 
between these three lifestyle factors and major depressive disorder, and their influence on 
dysregulated pathways associated with depression, namely neurotransmitter processes, 
immuno-inflammatory pathways, hypothalamic-pituitary-adrenal (HPA) axis disturbances, 
oxidative stress and antioxidant defence systems, neuroprogression, and mitochondrial 
disturbances. Increased attention in future clinical studies on the influence of diet, sleep and 
exercise on major depressive disorder and investigations of their effect on physiological 
processes will help to expand our understanding and treatment of major depressive disorder. 
Mental health interventions, taking into account the bidirectional relationship between these 
lifestyle factors and major depression are also likely to enhance the efficacy of interventions 
associated with this disorder. 
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Introduction 
Technological advances have changed how we communicate, the activities we engage in, 
our occupational and recreational pursuits, and even the foods that we eat. While sport and 
leisure activity levels have remained stable or increased slightly over time, physical activity 
associated with work, home, and transportation has declined significantly (Brownson et al., 
2005; Juneau and Potvin, 2010). In the United States it was estimated that over the past 50 
years occupation-related energy expenditure decreased by more than 100 calories/day 
(Church et al., 2011). Driving to work increased from 67% of the working north American 
population in 1960 to 88% in 2000 (Brownson et al., 2005) and, in U.S. schoolchildren, walking 
or riding bikes to school decreased from 40% in 1969 to 13% in 2001 (McDonald, 2007).  
Dietary changes are also significant as worldwide sugar consumption has increased by 74-
kcal/day per person from 1962 to 2000. Of this increase, 80% was derived from sugared 
beverages with additional contributions from restaurant and fast food sources (Popkin and 
Nielsen, 2003). Alarmingly, sugar consumption has increased most in children aged 6-11 years 
with an approximate 20% increase from 1988 to 2004 (Wang et al., 2008).  
These and other changes of modernity over the past few decades have coincided with a 
reported increase in the prevalence of many psychiatric problems, including major depression. 
Between 1991-92 to 2001-2, one-year prevalence rates of major depression increased from 
3.33% to 7.06% in a community population of American adults (Compton et al., 2006). 
Increases have also been observed in Australian communities with prevalence rates rising 
from 6.8% to 10.3% between 1998 and 2008 (Goldney et al., 2010). While these increased rates 
of depression may be due, in part, to improvements in diagnostic recognition, changes in 
diagnostic criteria and increased community acceptance of this condition, contemporary 
lifestyles might also explain why depression is on the rise. However, underlying mechanisms 
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are not well understood. This review provides a summary of three major lifestyle mediators - 
diet, exercise and sleep - associated with major depression and their impact on a range of 
relevant biological and physiological pathways.  
Methods 
Search strategy 
The PubMed, Google Scholar, and PsycInfo databases were searched from all years of 
record until August 2012. Most references were obtained from combinations of the following 
key terms: “depression”, “diet”, “nutrients”, “sleep”, “exercise”, “inflammation”, “oxidative 
stress”, “mitochondria”, “neurogenesis”, “BDNF”, “HPA”, “cortisol”, “serotonin” and 
“monoamines”. The reference lists of relevant papers were also examined to locate additional 
studies that were not identified by the database searches.  
Eligibility criteria 
Studies were included in this review if they were published in English, comprised animal 
or human investigations and examined areas of exercise, sleep or diet and their impact either 
on inflammation, hypothalamic–pituitary–adrenal (HPA) axis, neurotransmitters, 
neuroprogression and oxidative/nitrosative stress.  
Dysregulated pathways in major depression 
Major depression has a multifactorial etiology arising from environmental, psychological, 
genetic and biological factors. As outlined in figure 1, research over the past decade has 
clarified that depression is associated with neurotransmitter imbalances, HPA disturbances, 
dysregulated inflammatory pathways, increased oxidative and nitrosative damage, 
neuroprogression, and mitochondrial disturbances (Leonard and Maes, 2012; Lopresti et al., 
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2012; Maes et al., 2009c; Manji et al., 2001; Raison and Miller, 2011). While these disturbances 
will each be discussed briefly they are not mutually exclusive. 
 
Figure 1. Multiple pathways associated with major depression 
Neurotransmitter imbalances 
Imbalances in the production and transmission of neurotransmitters such as serotonin, 
dopamine, noradrenaline and glutamate are commonly observed in the central nervous 
system in major depression (Maletic et al., 2007). Deficiencies in serotonin availability, the 
most extensively studied neurotransmitter in depression, is supported by studies using 
tryptophan depletion models (which reduces central serotonin synthesis) (Hood et al., 2005; 
Toker et al., 2010) and findings of serotonin receptor abnormalities in depressed patients (Carr 
and Lucki, 2011). Depression is also associated with an increased availability of monoamine 
oxidase, an enzyme that metabolises serotonin and other monoamines in the brain (Meyer et 
al., 2006), and abnormalities in the expression of the enzyme tryptophan hydroxylase, which is 
involved in serotonin synthesis (Matthes et al., 2010). However, the strongest evidence of 
neurotransmitter imbalances in depression comes from the popular use and efficacy of 
pharmaceutical antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), which 
are thought to alleviate depression by increasing the availability of monoamines such as 
Chapter 3: Lifestyle influences on biological mechanisms associated with major depression 
Published Paper 
- 43 - 
serotonin, noradrenaline (i.e., norepinephrine) and, possibly, dopamine (Connolly and Thase, 
2012).  
HPA disturbances 
Dysfunction in the HPA axis is common in patients with major depression (Pariante and 
Lightman, 2008). This is characterised by heightened cortisol secretion in patients presenting 
with melancholic depression, and reduced levels in atypical depression (Gold and Chrousos, 
2002). Depression is also associated with hypersecretion of corticotropin-releasing hormone 
(CRH) and impairment in responsiveness to glucocorticoids (Pariante and Lightman, 2008). 
An increased size and activity of the pituitary and adrenal glands are also found in major 
depression (Nemeroff et al., 1992). Successful treatment with antidepressants is associated 
with a normalisation of HPA axis activity and restoration in glucocorticoid receptor function 
(Anacker et al., 2011a; Anacker et al., 2011b). 
Oxidative & nitrosative stress 
Decreased antioxidant status and elevated oxidative and nitrosative stress are found in 
patients with major depression (Maes et al., 2011a). This is evidenced by reduced plasma 
concentrations of important antioxidants such as vitamin C (Khanzode et al., 2003), vitamin E 
(Maes et al., 2000; Owen et al., 2005), and coenzyme Q10 (Maes et al., 2009b),  and by reduced 
antioxidant enzyme activity such as glutathione peroxidase (Maes et al., 2011e). These 
deficiencies in antioxidant defences impair protection against reactive oxygen species (ROS), 
leading to damage to fatty acids, proteins and DNA (Maes et al., 2011a).  
Depression is also associated with increased levels of lipid peroxidation, comprising 
elevations in malondialdehyde (Ozcan et al., 2004; Sarandol et al., 2007; Wei et al., 2009), and 
increased oxidative damage to DNA, characterised by increased levels of 8-hydroxy-2-
deoxyguanosine  (Forlenza and Miller, 2006; Maes et al., 2009a). Depression is also associated 
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with increased plasma levels of peroxides and xanthine oxidase (Herken et al., 2007; Maes et 
al., 2010). The efficacy of antioxidant therapies for depression is unknown, although N-
acetylcysteine, a powerful antioxidant, was found to be useful for depressive episodes in 
bipolar disorder (Berk et al., 2008; Magalhaes et al., 2011) and zinc, which serves as a strong 
antioxidant, also has antidepressant activity (Szewczyk et al., 2011). 
Neuroprogression 
Neurogenesis and neuronal plasticity are compromised in major depression, with 
subsequent neurodegeneration (Lee and Kim, 2010). This results in stress-induced alterations 
to the number and shape of neurons and glia in brain regions of depressed patients (Duman, 
2009) and decreased proliferation of neural stem cells (Eyre and Baune, 2012).  
Brain-derived neurotrophic factor (BDNF) is the most abundant and widely distributed 
neurotrophin in the central nervous system, involved in neuronal survival, growth and 
proliferation (Martinowich and Lu, 2008). BDNF levels are low in people with major 
depression (Duman, 2009; Lee and Kim, 2010). However, BDNF levels increase with chronic 
administration of several classes of antidepressants, including monoamine oxidase inhibitors, 
SSRIs, tricyclic agents, and SNRIs (Duman and Monteggia, 2006; Sen et al., 2008).  Early life 
and chronic stress, which is often typical in patients with major depression, also has 
detrimental effects on BDNF (Martinowich et al., 2007; Nagahara and Tuszynski, 2011). 
Mitochondrial disturbances 
Mitochondria are intracellular organelles that generate most of the cell's supply of 
adenosine triphosphate (ATP) and are also involved in a range of other processes such as 
signalling, cellular differentiation, cell death, and the control of the cell cycle and cell growth 
(McBride et al., 2006). High concentrations of mitochondria are found in the brain which 
increases its vulnerability to reductions in aerobic metabolism (Pieczenik and Neustadt, 2007). 
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Depression is associated with mitochondrial dysfunction or disease with evidence of 
deletions of mitochondrial DNA (Gardner and Boles, 2008a; Shao et al., 2008), and lower 
activities of respiratory chain enzymes and ATP production (Gardner et al., 2003). Depressed 
patients presenting with somatic complaints also have low ATP production rates in biopsied 
muscles (Gardner and Boles, 2008a; Gardner and Boles, 2008b). In addition, rates of depression 
are increased in patients with mitochondrial disorders (Fattal et al., 2007; Koene et al., 2009). 
Immuno-inflammation 
Increased inflammation in major depression has been confirmed in three recent meta-
analyses. Elevated levels of C-reactive protein (CRP), interleukin-1 (IL-1), and interleukin-6 
(IL-6) were reported in a meta-analysis on depression in clinic and community samples 
(Howren et al., 2009), levels of tumour necrosis factor-α (TNF-α) and IL-6 were significantly 
higher in depressed patients than controls (Dowlati et al., 2010), and  blood levels of soluble 
interleukin-2 receptors, TNF-α and IL-6 were higher in a meta-analysis on patients with major 
depressive disorder than controls (Liu et al., 2012b). Major depression is also characterised by 
a Th-1-like cell-mediated response, with evidence of increased production of interferon-γ 
(IFN-γ), increased IFN-γ/IL-4 ratios and increased neopterin levels (Maes et al., 1994; Myint et 
al., 2005). In addition, anti-depressant medications have anti-inflammatory effects (Hannestad 
et al., 2011).  
An elevated immuno-inflammatory response in major depression is further supported by 
investigations into kynurenine pathway metabolites or TRYCATS (tryptophan catabolites 
along the IDO pathway) (Dantzer et al., 2011; Maes et al., 2011d). As shown in Figure 2, 
TRYCATS are produced by the breakdown of tryptophan, involving the enzyme indoleamine 
2,3-dioxygenase (IDO). IDO is expressed in multiple cell types including macrophages, 
dendritic cells, astrocytes and microglia and is strongly activated by the pro-inflammatory 
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cytokine IFN-γ and to a lesser extent TNF-α, IL-1, and IL-6. These TRYCATS have both 
neurotoxic and neuroprotective qualities. Preliminary research has demonstrated a 
relationship between depression and low levels of the neuroprotective TRYCAT, kynurenic 
acid (KYNA) (Maes et al., 2011b; Myint et al., 2007; Wichers et al., 2005), and high levels of the 
excitotoxic TRYCAT, quinolinic acid (QUIN) (Raison et al., 2010a; Steiner et al., 2011). 
However, further research is warranted as Hughes et al., (2012) found no differences in IDO 
expression or plasma levels of TRYCATS between depressed patients and controls. 
 
Figure 2. Kynurenine pathway and its metabolites. The kynurenine 
pathway starts with the degradation of tryptophan by the enzyme, 
indoleamine 2,3-dioxygenase (IDO) which is upregulated by pro-
inflammatory cytokines (e.g. IFN-γ, TNF-α, IL-, IL-6). These TRYCATS 
(tryptophan catabolites along the IDO pathway) have neuroprotective 
and neurotoxic effects on the CNS and influence monoaminergic 
transmission. 
 
Lifestyle factors associated with major depression 
Dysregulation in the pathways reviewed above can be influenced by environmental, social, 
psychological, lifestyle, genetic and physiological factors (Hidaka, 2012; Leonard and Maes, 
2012). Diet, sleep and exercise are three such influences that play an important role in the 
etiology, progression and treatment of depression. A bidirectional relationship likely exists 
between depression and these mediators. 
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The relationship between diet and depression  
An association between diet and depression has now been confirmed in prospective and 
epidemiological studies. For example, in elderly men and women, the consumption of fish, 
vegetables, olive oil, and cereal correlated negatively with the severity of depressive 
symptoms (Mamplekou et al., 2010). The benefits from fish and olive oil intake remained 
significant even when adjusted for confounders such as age, sex, education status, BMI and 
physical activity status, as well as the presence of a number of medical conditions. In a 
prospective study, and after adjusting for sex, age, smoking status, BMI, physical activity 
levels and employment status, adherence to a Mediterranean diet comprising high levels of 
vegetables, fruit, nuts, cereal, legumes, and fish, a moderate alcohol intake, and a low 
consumption of meat or meat products and whole-fat dairy, was protective against the 
development of depression (Sanchez-Villegas et al., 2009). In a study by Jacka et al. (2010b), 
consuming a ‘traditional’ diet comprising vegetables, fruit, meat, fish, and whole grains was 
also associated with a 35% reduced risk of depression or dysthymia. Research into the diet of 
adolescents (Jacka et al., 2010a) and of low socio-economic, community dwelling, elderly 
people (German et al., 2011) has also provided evidence for an association between diet 
quality and depression. Depressive symptoms are also positively associated with the 
consumption of sweets (Jeffery et al., 2009). Similarly, high intake of fast food (hamburgers, 
sausages, pizza) and processed pastries (muffins, doughnuts, croissants) are associated with 
an increased risk of depression up to 6 years later (Sanchez-Villegas et al., 2012). 
High-quality treatment studies investigating the impact of diet on depression are scarce, 
although in a randomised-controlled trial, meat-eating adults placed on a two-week 
vegetarian diet reported significantly greater improvements in mood compared to participants 
who continued to eat meat, fish or poultry (Beezhold and Johnston, 2012). In another 
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randomised-controlled trial, six days on a low protein diet significantly decreased depressive 
symptoms in type 2 diabetics (Ciarambino et al., 2011), and in a randomised study on 
overweight and obese individuals, those placed on an energy-restricted, low-fat diet for one 
year experienced greater improvements in mood compared to participants on an energy-
restricted, low-carbohydrate diet (Brinkworth et al., 2009). These changes were independent of 
weight loss.  
Polyunsaturated fatty acids (PUFAs) and particularly omega-3 essential fatty acids (ω-3 
EFA) have received significant attention in relation to depression. In a meta-analysis of 14 
studies comparing the levels of PUFAs between depressed patients and control subjects, the 
levels of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and total ω-3 EFA were 
significantly lower in depressed patients than controls (corresponding to effect sizes of -0.18, -
0.35 and -0.51, respectively). There was no significant change in arachidonic acid (AA) or total 
ω-6 PUFAs (Lin et al., 2010). A meta-analysis of the effects of EPA supplementation in 15 
clinical trials in depressed populations revealed beneficial effects from fish oil containing high 
levels of EPA (effect size = 0.53) (Sublette et al., 2011).  
Other investigations on the relationship between nutrients and depression have 
demonstrated a role of folate (Farah, 2009; Gilbody et al., 2007; Morris et al., 2008), tryptophan 
(Cowen et al., 1989; DeMyer et al., 1981; Maes et al., 1987), zinc (Cope and Levenson, 2010; Lai 
et al., 2012; Szewczyk et al., 2011), iron (Maes et al., 1996; Stewart and Hirani, 2012; Vahdat 
Shariatpanaahi et al., 2007; Yi et al., 2011), CoQ10 (Maes et al., 2009b), vitamin B6 (Merete et 
al., 2008; Moorthy et al., 2012; Skarupski et al., 2010; Williams et al., 2005), vitamin B12 
(Hintikka et al., 2003; Moorthy et al., 2012), and selenium (Gao et al., 2012; Mokhber et al., 
2011; Pasco et al., 2012). However, findings on most of these nutrients require further 
investigation before definitive conclusions about their relationship with depression can be 
made. 
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Diet and its effect on inflammation 
There is now strong evidence in human studies that adherence to a Mediterranean diet is 
associated with reduced inflammatory markers (Camargo et al., 2012; Richard et al., 2012; 
Urpi-Sarda et al., 2012). In a study on people with metabolic syndrome, five weeks on a 
Mediterranean diet corresponded with lowered plasma CRP and an arbitrary inflammatory 
score that included CRP, IL-6, IL-18, and TNF-α. These changes were independent of any 
weight loss (Richard et al., 2012). Compared to participants placed on a low-fat diet, one year 
on a Mediterranean diet was associated with lowered plasma concentrations of IL-6, and two 
TNF receptors (Urpi-Sarda et al., 2012). In contrast, intercellular adhesion molecule-1 and TNF 
receptor concentrations were increased in people consuming a low-fat diet. In another 
intervention study, postprandial inflammatory gene expression in mononuclear cells 
decreased after three weeks on either a Mediterranean diet enriched with olive oil, a diet rich 
in saturated fatty acids, or a low-fat/high-carbohydrate diet enriched with ω-3 PUFU 
compared to the other diets (Camargo et al., 2012; Yubero-Serrano et al., 2012)). Luciano and 
colleagues (2012) also found that CRP levels were lower in an elderly population on a 
Mediterranean diet compared to a standard ‘healthy diet’ comprising a high intake of fruits 
and low consumption of eggs, spirits or liqueurs, and meats such as bacon, pork, lamb, and 
sausages . 
In relation to the anti-inflammatory effect of PUFAs, in a recent review of twenty-six 
randomised clinical trials, dietary ω-3 EFAs were found to be associated with lower plasma 
biomarker levels, reflecting lower levels of inflammation and endothelial activation (e.g., IL-6, 
CRP, TNF- α, sICAM-1 and GM-CSF) in cardiovascular disease and other chronic and acute 
diseases. Calder (2012) recently concluded that fatty acids were able to partly inhibit a number 
of aspects of inflammation including leukocyte chemotaxis, adhesion molecule expression and 
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leukocyte-endothelial adhesive interactions, production of eicosanoids from arachidonic acid, 
production of inflammatory cytokines, and T cell reactivity. 
Diet and its effect on neurotransmitters 
Diet quality is important in the production of monoamines such as serotonin and 
dopamine and can influence receptor sensitivity and neurotransmitter transporters. In animal 
studies, semi-starvation on a high carbohydrate or protein diet affected serotonin turnover in 
the brain (Schweiger et al., 1989). In addition, the consumption of sugar as part of a meal 
(Inam et al., 2006) or eating a high-carbohydrate diet (Buwalda et al., 2001) influenced 5-HT1A 
receptor sensitivity; and one week on a high fat, low carbohydrate diet decreased serotonin 
release in the hypothalamus (Banas et al., 2009). In contrast, the acute intake of a 
carbohydrate-rich food increased brain tryptophan and consequent brain serotonin levels 
(Fernstrom and Wurtman, 1971). This was likely due to carbohydrates acutely increasing brain 
tryptophan availability compared to other large neutral amino acids (Wurtman and Wurtman, 
1995).   
Dopaminergic systems are also influenced by diet as the consumption of combinations of 
dietary fat and sugar reduced D2 receptor signalling (Pritchett and Hajnal, 2011), the intake of 
a high fat diet altered dopamine-related gene expression (Lee et al., 2010; Vucetic et al., 2012), 
a high-fat diet during early life altered biochemical markers of dopamine signalling in the 
nucleus accumbens  (Teegarden et al., 2009), and the long-term consumption of a low protein-
high carbohydrate diet decreased D2 dopamine receptor density (Hamdi et al., 1992). Striatal 
dopamine levels were also increased in rats supplemented with strawberry, spinach, or 
vitamin E (Martin et al., 2000).  
Other nutrients which are altered in patients with major depression and that can influence 
neurotransmitter production include tryptophan (and other large neutral amino acids: valine, 
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leucine, isoleucine, phenylalanine and tyrosine) (Maes et al., 2011d; Markus, 2008; Toker et al., 
2010), folic acid (Miller, 2008; Stahl, 2008), zinc (Cichy et al., 2009; Szewczyk et al., 2011; 
Szewczyk et al., 2009), vitamin B12 (Bottiglieri, 1996; Deana et al., 1977), vitamin B6 (Calderon-
Guzman et al., 2004; Demisch and Kaczmarczyk, 1991; Hartvig et al., 1995) and iron 
(Baumgartner et al., 2012; Burhans et al., 2005; Coe et al., 2009). Omega-3 EFAs are also able to 
modify monoaminergic neurotransmission (Chalon, 2006; Su, 2009). 
Diet and its effect on oxidative stress 
Given the crucial role that diet plays in antioxidant intake, it comes as no surprise that diet 
quality influences levels of oxidative stress. In animal studies, rats fed a high-sugar/high-fat 
diet had increased lipid peroxidation in the brain (Ribeiro et al., 2009; Stranahan et al., 2011), 
elevated plasma malondialdehyde (MDA) concentrations (a marker of lipid peroxidation) 
(Panchal et al., 2011) and increased mRNA expression levels of genes involved in ROS 
production in both the liver and adipose tissue (Matsuzawa-Nagata et al., 2008). In obese 
adults with metabolic syndrome, reducing energy intake by 2000kJ, mainly via carbohydrate 
restriction, was associated with decreased oxidative stress and increased levels of antioxidant 
markers, alpha-tocopherol and ceruloplasmin (Skalicky et al., 2009).  However, placing adults 
with metabolic syndrome on a 12-week high-fat diet or low-fat, high complex-carbohydrate 
diet had no effect on markers of oxidative stress and inflammation (Petersson et al., 2010). 
The Mediterranean diet is associated with increased circulating plasma antioxidant levels 
and decreased oxidative stress (Azzini et al., 2011; Esposito et al., 2011; Yubero-Serrano et al., 
2011). The protective properties of this diet may be derived not only from its increased 
antioxidant concentration but also through its high raw food intake, lower production of 
cooking-related oxidants and consequent decreased use of nutritional and endogenous 
antioxidants, and increased fibre intake (Ghiselli et al., 1997). Olive oil, the main source of fat 
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in the Mediterranean diet, is also effective in lowering lipid peroxidation and oxidative stress 
(Alarcon de la Lastra et al., 2001; Fito et al., 2007) 
Diet and its effect on neuroprogression 
Diet quality is important for the brain given its capacity both to enhance neurogenic factors 
and to influence rates of neurodegeneration. In animal studies, brain levels of BDNF 
decreased in rats maintained on a high carbohydrate diet (Maioli et al., 2012) and high fat diet 
(Yamada-Goto et al., 2012). Human trials have also demonstrated a relationship between diet 
and BDNF. Compared to a low-fat diet, adherence to a Mediterranean diet was associated 
with an improvement in plasma BDNF concentration in individuals with depression 
(Sanchez-Villegas et al., 2011). In healthy adults, a high-fat meal decreased plasma BDNF by 
almost 30% (Karczewska-Kupczewska et al., 2011). The importance of diet on 
neuroprogression is further confirmed by a study on insulin-resistant, overweight and obese 
subjects where serum BDNF levels increased after three months on a reduced calorie diet 
(Araya et al., 2008).  
Investigations into the potential effects of ω-3 PUFAs have revealed that they may also play 
a role in neuroprogression. In animal studies, ω-3 PUFAs supplementation provided 
protection against reduced plasticity and normalised BDNF after traumatic brain injury (Wu 
et al., 2004). During pregnancy and lactation, supplementation with ω-3 PUFAs protected 
levels of BDNF and nerve growth factor (NGF) in female rats when they consumed a 
micronutrient-imbalanced diet (Sable et al., 2012), while brain levels of BDNF decreased 
during diets deficient in ω-3 PUFAs (Bhatia et al., 2011; Rao et al., 2007). In an human open-
label trial, 3 months of ω-3 PUFAs supplementation increased serum BDNF levels and 
prevented posttraumatic distress after accidental injury in patients presenting at an intensive 
care unit (Matsuoka et al., 2011). However, in a randomised, double-blind, placebo-controlled 
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study of diabetic patients with major depression, 12 weeks of ethyl-EPA supplementation or 
placebo, in addition to ongoing antidepressant therapy, failed to increase serum BDNF levels 
(Bot et al., 2011). 
Diet and its effect on the HPA axis 
Diet composition and timing have a significant influence on acute cortisol secretion due to 
the primary role of cortisol in gluconeogenesis.  However, the long-term effect of diet on HPA 
activity is not well understood. In a study on women living in a Mediterranean area, a 
disturbed HPA axis was associated with a higher content of fat and saturated fatty acids in the 
diet. In contrast, adherence to a dietary pattern closer to the Mediterranean diet was linked 
with smaller HPA axis disturbances (Garcia-Prieto et al., 2007). Investigations into the effect of 
ω-3 PUFAs on HPA activity have also provided some evidence of their capacity to lower 
cortisol activity. For example, Delarue et al. (2003) showed that after 3 weeks on a diet 
supplemented with ω-3 PUFAs, levels of plasma noradrenaline and cortisol stimulated by 
mental stress were significantly blunted. In another study on patients with major depression, 
serum cortisol levels decreased after 8 weeks of treatment with EPA alone or in combination 
with fluoxetine (Jazayeri et al., 2010). Finally, intravenous lipopolysaccharide-induced 
adrenocorticotropic hormone (ACTH) and cortisol plasma levels decreased significantly in 
healthy subjects supplemented with one month of fish oil compared to placebo (Michaeli et 
al., 2007).  
Diet and its effect on mitochondria 
Mitochondrial dysfunction is influenced significantly by nutrition (Civitarese et al., 2007; 
Hepple, 2009; Page et al., 2010; Vitetta and Anton, 2007). Increased fatty acid exposure, 
resulting from high fat diets or overfeeding, is linked both with decreased mitochondrial 
number and markers of oxidative phosphorylation. Conversely, caloric restriction can 
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stimulate mitochondrial biogenesis by elevating the transcriptional processes that regulate 
mitochondrial mass, improve mitochondrial efficiency, activate ROS scavenging mechanisms, 
and lower ROS production (Civitarese et al., 2007). Dietary antioxidants or caloric restriction, 
as well as chemical antioxidants, can lower mitochondrial ROS production (Vitetta and Anton, 
2007). Nutrients such as CoQ10, vitamin B2 and l-carnitine also have a significant influence on 
mitochondrial metabolism (Gardner and Boles, 2011). 
The relationship between sleep and depression 
In the general population approximately 30% of people report symptoms of insomnia, 10 to 
20% describe dissatisfaction with sleep, and approximately 6% have a formal diagnosis of 
insomnia (Leger et al., 2000; Ohayon, 2002). These rates are significantly increased in major 
depression, with as high as 90% of patients reporting sleep disturbances (Motivala et al., 2006; 
Riemann and Voderholzer, 2003). Insomnia is also one of the most common prodromal 
features of depression with sleep symptoms preceding an episode of depression in 40% of 
cases. A history of persistent insomnia is also associated with a significantly increased risk of 
developing a new depressive episode (Taylor et al., 2005). In a recent meta-analysis, compared 
to people with no sleep difficulties, non-depressed people with insomnia were predicted to 
have a twofold increased risk of developing depression (Baglioni et al., 2011). Depressed 
patients suffering from insomnia also have a poorer response to treatment and are at increased 
risk of relapse (Dombrovski et al., 2008).  
Further support for a relationship between sleep and depression is provided by studies 
documenting improvements in mood and depressive symptoms following insomnia-specific 
interventions. For example, in a randomised controlled study, Manber and colleagues (2008) 
found that augmenting antidepressant medication with a symptom-focused cognitive-
behavioural therapy for insomnia (CBTI) enhanced treatment outcomes in participants with 
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co-morbid major depression and insomnia. Compared to participants allocated to control 
treatment, people receiving CBTI experienced significantly greater remission rates in both 
depression (61.5% vs 33.3%) and insomnia (50% vs 7.7%). In women with insomnia and breast 
cancer, CBTI was also more effective in improving sleep, depression and anxiety symptoms 
than a control condition (Savard et al., 2005). Eight weeks of mindfulness-based cognitive 
therapy for treating insomnia symptoms also improved sleep, anxiety and depressive 
symptoms in patients with an anxiety disorder (Yook et al., 2008). 
Sleep and its effect on inflammation 
Sleep difficulties increase inflammatory mediators; conversely elevated inflammatory 
molecules heighten the risk of sleep problems. In particular, IL-1, IL-6 and TNF-α may be 
directly involved in sleep regulation (Santos et al., 2007). Data derived from 
electrophysiological, biochemical and molecular genetic studies demonstrate that these 
cytokines are sleep regulatory, as they support the regulation of spontaneous sleep-wake 
behaviour (Opp, 2005). Other cytokines that may also be involved in the regulation of sleep 
include IL-2, IL-8, IL-15, IL-18, epidermal growth factor, acidic fibroblast growth factor, colony 
stimulating factor, and interferons (Krueger, 2008).  
In patients with major depression, difficulty initiating sleep correlated with increased pre-
sleep levels of IL-6 (Motivala et al., 2005). In a study on 210 healthy young men and women, 
difficulty falling asleep was related to higher morning levels of CRP and IL-6, but only in 
women (Suarez, 2008). Sleep disturbances also occur in up to 30% of patients with chronic 
hepatitis C undergoing IFN-α therapy (Sockalingam et al., 2010), and its administration 
reduces sleep continuity and depth and induces a sleep pattern consistent with insomnia and 
hyperarousal (Raison et al., 2010b). Studies on patients diagnosed with primary insomnia offer 
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additional evidence for the relationship between sleep and inflammation, as circulating levels 
of IL-6 and TNF are higher than in healthy sleepers (Burgos et al., 2006; Vgontzas et al., 2002).  
Sleep restriction studies in animals and humans provide further confirmation for the 
association between sleep and inflammation. Although the relationship is not necessarily 
linear, there is evidence that in humans, sleep restriction increases levels of IL-6, TNF-α, CRP 
and IL-1β  (Motivala, 2011; van Leeuwen et al., 2009; Vgontzas et al., 1999; Vgontzas et al., 
2004). Five days of sleep deprivation in healthy adults also modified a number of kynurenine 
pathway metabolites in healthy adults, including 5-hydroxyindoleacetic acid (5-HIAA), 
xanthurenic acid and anthranilic acid (Kuhn et al., 1968). 
Sleep and its effect on neurotransmitters 
Surprisingly little research on the influence of sleep on monoamines such as serotonin and 
dopamine has been conducted, although sleep restriction may disrupt systems associated with 
monoamine communication. In an animal study, desensitisation in serotonin receptors was 
detected after eight days of sleep restriction. Despite unlimited recovery sleep, this 
desensitisation persisted for at least seven days (Roman et al., 2005b), and was independent of 
adrenal hormones (Roman et al., 2006). In addition, Novati and colleagues (2008) 
demonstrated that exposure to a schedule of chronic, partial sleep deprivation reduced 
sensitivity of 5HT1A receptors and/or receptors for CRH (Novati et al., 2008). 
Sleep and its effect on oxidative stress 
It has been proposed that cerebral free radicals accumulate during wakefulness and are 
removed during sleep (Reimund, 1994). This has been supported by animal studies where 
sleep loss caused oxidative damage in the brain (Ramanathan et al., 2002; Suer et al., 2011) and 
increased lipid peroxidation (Thamaraiselvi et al., 2012). However, some animal studies have 
found that one to two weeks of sleep deprivation had no effect on oxidative stress in any brain 
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region, including protein oxidation and lipid peroxidation (D'Almeida et al., 1997; 
Gopalakrishnan et al., 2004). These inconsistent findings are likely a reflection of differing 
sleep restriction protocols, and different markers of oxidative stress measured across studies. 
Most studies on oxidative stress in clinical sleep research have focused on obstructive sleep 
apnoea syndrome, which is known to increase oxidative stress produced by recurrent 
episodes of ischemia-reperfusion injury (Kent et al., 2011; McNicholas, 2009). However, 
several studies have also linked oxidative stress with insomnia. For example, levels of 
thiobarbituric acid reactive substances were elevated in postmenopausal women with 
insomnia, although blood concentrations of catalase, superoxide dismutase, and glutathione 
were found to be normal (Hachul de Campos et al., 2006). In an investigation on participants 
with primary insomnia, significantly lower GSH-Px (selenium-containing antioxidant 
enzyme) activity and higher MDA levels were found compared with controls (Gulec et al., 
2012). Further evidence of a relationship between sleep and oxidative stress is provided by a 
study revealing increased levels of myeloperoxidase-modified low-density lipoprotein 
following five nights of sleep restriction in healthy males (Boudjeltia et al., 2011). 
Sleep and its effect on neuroprogression 
Sleep problems may also contribute to depressive symptomatology via their effect on brain 
structure, neurogenesis and, in particular, hippocampal function (Lucassen et al., 2010; Meerlo 
et al., 2009; Novati et al., 2011). Experimental studies show that prolonged sleep restriction or 
disruption affects hippocampal integrity (Guzman-Marin et al., 2006; Kopp et al., 2006; 
McDermott et al., 2003; Roman et al., 2005a). For example, in young male rats, one month of 
chronic sleep restriction reduced dorsal hippocampal volume by 10% (Novati et al., 2011). 
Hippocampal cell proliferation was also affected by a single day of sleep deprivation in rats 
(Roman et al., 2005a). Clinical studies have also reported a reduction in hippocampal volume 
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in primary insomnia and sleep apnoea (Morrell et al., 2003; Riemann et al., 2007). Insomnia 
severity in a sample of patients with post-traumatic stress disorder was also associated with 
decreased volume in the CA3/dentate hippocampal subfield (Neylan et al., 2010).  
While sleep restriction itself may not be neurotoxic, it may enhance neuronal sensitivity to 
subsequent excitotoxic insults. Novati and colleagues (2012) found that after 30 days of sleep 
restriction in rats, there were no adverse effects on cholinergic cells in the nucleus basalis 
magnocellularis (NBM). However, an injection of a neurotoxic dose of N-methyl-d-aspartate 
into the NBM caused an accentuated loss of cholinergic NBM cells and cortical fibres in the 
sleep-restricted rats compared to controls. Thus, chronic sleep restriction may constitute a 
mild threat to the brain that does not lead to neurodegeneration by itself but increases 
vulnerability to subsequent neurotoxic challenges. 
Sleep and its effect on the HPA axis  
Insomnia appears to be associated with hyperarousal. In a study on patients with chronic 
insomnia, 24-hour urinary cortisol levels correlated positively with total wake time. Sleep 
quality also correlated negatively with urinary levels of catecholamine metabolites, thereby 
suggesting disturbances in both limbs of the stress system (i.e., the HPA axis and the 
sympathetic system) (Vgontzas et al., 1998). In another study, ACTH and cortisol secretions 
were significantly higher in insomniacs compared with normal controls, with greatest 
elevations in the evening and first half of the night. Cortisol levels were also positively 
correlated with the severity of reported sleep disturbance (Vgontzas et al., 2001). Increased 
evening and nocturnal plasma cortisol concentrations were also observed in patients with 
primary insomnia, with a strong positive correlation between evening cortisol secretion and 
the number of nocturnal awakenings both in insomniac patients and controls (Rodenbeck and 
Hajak, 2001).  
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Findings in sleep deprivation and restriction studies are less consistent, with several 
studies reporting mild elevations of cortisol (Leproult et al., 1997; Spiegel et al., 1999) while 
others have found no change or even slightly decreased levels (Follenius et al., 1992; Kant et 
al., 1984). In several animal studies, sleep deprivation led to mild activations of the HPA axis 
and elevated plasma levels of glucocorticoids (Meerlo et al., 2002; Suchecki et al., 1998), 
whereas others found little or no effect of acute sleep deprivation on glucocorticoid levels 
(Rechtschaffen et al., 1983). According to Meerlo et al. (2008) the available data from studies in 
laboratory animals suggest that sleep restriction may gradually change certain brain and 
neuroendocrine systems in a manner similar to that seen in stress-related disorders such as 
depression.  
Sleep and its effect on mitochondria 
Because of the important role of sleep on oxidative stress, it would seem logical to assume 
that mitochondria will be adversely affected by sleep deprivation. In support of this, sleep 
deprivation in mice reduced the activity of the complex I, II and III enzymes of the 
mitochondrial electron transport chain. Complex II and II-III activity was particularly 
decreased in the hypothalamus of mice during 24-hour recovery sleep (Andreazza et al., 2010). 
In a model developed by Andreazza et al. (2010), it was proposed that sleep restriction may 
lead to mitochondrial dysfunction which, in turn, increases the production of ROS, leading to 
increased oxidative damage to lipids, protein and DNA.   
The relationship between exercise & depression 
Depression is commonly associated with low levels of physical activity. While data derived 
from epidemiological and correlational studies do not necessarily confirm causation, a 
consistent relationship does exist across a number of populations. In adults, an active lifestyle 
was associated with reduced depressive symptoms independent of education and physical 
Chapter 3: Lifestyle influences on biological mechanisms associated with major depression 
Published Paper 
- 60 - 
health status. This relationship was stronger in women and those aged 40 years and older 
(Stephens, 1988). In overweight/obese adults, a reduced risk of depression was associated with 
increasing moderate-to-vigorous-intensity physical activity and decreasing sedentary time 
(Vallance et al., 2011). Another study on data from over 4,000 men and women aged 20 years 
or more confirmed that adults with depression spent significantly less time both in light and 
moderate physical activity than non-depressed adults (Song et al., 2012). In a longitudinal 
study of over 9,000 people, regular physical activity was associated with a reduced likelihood 
of depressive symptoms at follow-up (Azevedo Da Silva et al., 2012).  
Although not as extensive, investigations into sedentary behaviours have also largely 
confirmed a positive relationship with depression. In a systematic review of seven 
observational and four intervention studies on adult populations, Teychenne and colleagues 
(2010) confirmed that, on balance, sedentary behaviours such as watching television or using 
the computer were associated with an increased risk of depression. However, evidence was 
limited by methodological weaknesses in most studies.  
The efficacy of exercise as a treatment for depression is summarised in over a dozen recent 
reviews. In a meta-analysis on supervised and unsupervised physical activity interventions 
among healthy adults, Conn (2010) concluded that physical activity interventions had a 
moderate inhibitory effect on depressive symptoms in adults with and without clinical 
depression (mean effect size of 0.37 for supervised and 0.52 for unsupervised physical activity 
studies). Carek and colleagues (2011) maintained from a review of the literature that exercise 
compared favourably to antidepressant medications as a first-line treatment for mild-to-
moderate depression and also improved depressive symptoms when used as an adjunct to 
medications. Similar antidepressant effects were also found in trials comparing exercise with 
cognitive-behavioural therapy (Rimer et al., 2012). Despite these positive findings there is a 
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paucity of research demonstrating long-term beneficial effects of exercise in patients with 
clinical depression (Krogh et al., 2011). 
Exercise and its effect on inflammation 
Although a single bout of exercise provokes an acute inflammatory response, primarily in 
IL-6 (release from muscle increases up to 100-fold during contractile exercise), exercise is 
followed by an increase in anti-inflammatory cytokines (Pedersen and Fischer, 2007)  and a 
decreased production of the pro-inflammatory cytokines TNF-α and IL-1β (Pedersen et al., 
2003). Data also suggest that exercise-induced IL-6 inhibits TNF-α production in the presence 
of low-grade inflammation (Starkie et al., 2003).  
Four recent reviews have primarily revealed anti-inflammatory effects from long-term 
exercise (Beavers et al., 2010; Mathur and Pedersen, 2008; Ploeger et al., 2009; Thomas and 
Williams, 2008). In a systematic review of 19 studies on the inflammatory effects of acute and 
chronic exercise in children and adults, Ploeger et al. (2009) concluded that training programs 
can attenuate chronic inflammation in some patients with chronic inflammatory disease; 
however, the exercise training-induced response appeared highly dependent on the type of 
disease, severity of the disease and the frequency, duration and intensity of the exercise 
intervention.  
Lower inflammatory biomarker concentrations, particularly CRP, and to a lesser extent IL-
6, are observed across a wide range of individuals performing more frequent and intense 
physical activity (Plaisance and Grandjean, 2006; Taaffe et al., 2000). This inverse relationship 
between CRP and physical activity is consistently seen in men, and to a lesser extent in 
women (Beavers et al., 2010). In adults, investigations using self-reported measures of physical 
activity have demonstrated that physically-active individuals have CRP concentrations 19–
35% lower than less active individuals (Plaisance and Grandjean, 2006).  While these 
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inflammatory markers are attenuated following adjustment for adiposity, a significant 
relationship between inflammatory biomarkers and physical activity persists (Abramson and 
Vaccarino, 2002).  
In sum, while most studies demonstrate anti-inflammatory effects of exercise in adults and 
children, the relationship is influenced by a number of factors including the population 
studied, the type, frequency and duration of exercise, pre-existing medical conditions and 
initial levels of inflammation. Thus, further studies are required to enable more definitive 
conclusions, particularly in patients suffering from depression. 
Exercise and its effect on neurotransmitters 
The antidepressant effects of exercise may be due to its capacity to modify monoamine 
communication.  In animal studies, running increased plasma free tryptophan, brain 
tryptophan, and levels of the serotonin metabolite, 5-HIAA (Bailey et al., 1993; Chaouloff et 
al., 1985). Human trials also provide evidence of exercise and its serotonin-enhancing effects. 
For example, untrained participants randomly assigned to an aerobic exercise group 
experienced greater changes in serum serotonin levels compared to those in a stretching-
control group (Wipfli et al., 2011). Tryptophan availability, the precursor to serotonin, is also 
increased after acute exercise (Melancon et al., 2012). Three weeks of exercise training also 
influenced serotonin receptors and serotonin transporters in sedentary males as demonstrated 
by increased levels of 5-HT transporters (5-HTT) and 5-HT2A receptors on isolated platelet 
membranes. In contrast, four weeks of excessive training in well-trained athletes did not 
change 5-HTT, and 5-HT2A receptor density declined. This suggests that the impact of exercise 
on serotonin neurotransmission may depend on the training state of athletes and extent of 
exertion (Weicker and Struder, 2001). 
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Exercise is also able to modify dopamine and noradrenergic transmission as evidenced by 
increased tyrosine hydroxylase expression (Foley and Fleshner, 2008; Kim et al., 2011), 
elevated striatal dopamine D2 receptor expression (Vuckovic et al., 2010) and increased 
noradrenaline levels (Dishman, 1997) in rats exposed to chronic exercise. However, acute 
exercise comprising 30 minutes of vigorous exercise in healthy adult volunteers with a history 
of regular exercise did not change synaptic dopamine concentrations (Wang et al., 2000). 
Exercise and its effect on oxidative stress 
There is mounting evidence to suggest that exercise is accompanied by an increased 
generation of free radicals, resulting in measurable elevations in oxidative stress biomarkers 
after both acute aerobic (Benitez-Sillero et al., 2011; Bloomer, 2008; Fogarty et al., 2011) and 
anaerobic exercise (Bloomer and Goldfarb, 2004; Pittaluga et al., 2006; Vollaard et al., 2005). 
Given the substantial evidence for the protective effects of exercise on oxidative stress-
associated diseases, this seems paradoxical. However, it is argued that chronic exercise leads 
to exercise-induced adaptation and resistance (Cooper et al., 2002; Radak et al., 2008). The 
exercise-induced ROS formation evokes specific adaptation, comprising up-regulation in 
endogenous antioxidant defences, increased antioxidant/oxidative damage-repairing enzyme 
activity, increased resistance to oxidative stress, and lowered levels of oxidative damage. This 
adaptive response seems to be systemic, affecting skeletal muscle, liver, and the brain (Radak 
et al., 2008). Gomez-Cabrera et al (2008) argue that because exercise results in an up-regulation 
of powerful antioxidant enzymes, exercise itself can be considered an antioxidant despite 
generating free radicals.  
Exercise and its effect on the HPA axis 
The relationship between exercise and HPA activity is complex as it is influenced by 
duration, type, intensity and chronicity of exercise; characteristics of the stressor used; and 
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characteristics of the population studied (Campeau et al., 2010; Leal-Cerro et al., 2003; 
Mastorakos et al., 2005; Stranahan et al., 2008).  In an animal study, four weeks of swimming 
exercise was associated with reduced levels of serum corticosterone and depressive 
behaviours in rats exposed to high levels of glucocorticoids prenatally (Liu et al., 2012a). In 
another study, the HPA axis response to lower-intensity stressors decreased in rats exposed to 
6 weeks (but not 1 or 3 weeks) of intermittent, voluntary wheel running, although no change 
occurred following exposure to more intense stressors (Campeau et al., 2010).  The complexity 
of the relationship between exercise and HPA responsivity was further demonstrated by 
Droste et al. (2003) who reported that HPA responses in exercising mice were differently 
influenced by the stressor used and the novelty of the environment.  
Investigations into the relationship between exercise and HPA activity in human 
populations have primarily examined the effect of acute activity on measures such as cortisol 
and ACTH. Studies on the influence of chronic exercise on HPA activity, and in particular on 
the HPA response to stressors, are sparse. In general, acute exercise elevates cortisol levels, 
although this most consistently occurs following moderate-to-severe intensity activity (Hill et 
al., 2008). In a study on women of varying age and fitness, ACTH levels recovered slowly in 
older women, particularly those with low fitness levels (Traustadottir et al., 2004). In a study 
on female adolescents with mild-to-moderate depression, 8 weeks of an exercise regimen 
improved depressive symptoms and was associated with reductions in 24 hour urinary 
cortisol levels (Nabkasorn et al., 2006). In another study on patients with chronic low back 
pain, twelve weeks of high-intensity aerobic exercise was associated with reductions in pain, 
enhanced mood and improvements in HPA responsiveness to the dexamethasone suppression 
test (Chatzitheodorou et al., 2008).   
Exercise and its effect on neuroprogression 
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Evidence of the beneficial effects of exercise on brain function is summarised in three recent 
reviews (Cotman et al., 2007; Dishman et al., 2006; Vivar et al., 2012). Exercise is associated 
with enhanced adult hippocampal neurogenesis and increased activity-dependent synaptic 
plasticity. According to Cotman et al. (2007), enhanced hippocampal neurogenesis and 
increased synaptic plasticity are the most reproducible effects of exercise in the rodent brain. 
In both young and old animals, exercise stimulated neural progenitor populations, increased 
the number of new neurons, and promoted survival of these new cells (Brandt et al., 2010; 
Olson et al., 2006; Wu et al., 2008). In animal studies, exercise also increased BDNF in several 
brain regions, and there was increased insulin-like growth factor-1 (IGF-1) gene expression 
and peripheral circulating levels of IGF-1 (Ding et al., 2006; Schwarz et al., 1996). In a review 
on the effects of exercise on peripheral BDNF in human subjects, it was concluded that 
exercise temporarily elevated basal BDNF and possibly up-regulated BDNF cellular 
processing (i.e. synthesis, release, absorption and degradation) (Knaepen et al., 2010). 
However, there have been no reported findings of long-lasting BDNF responses to acute 
exercise or training. 
Human studies on the effects of exercise-induced BDNF changes in depressed populations 
are still preliminary, although BDNF levels were transiently increased in elderly women with 
remitted major depression (Laske et al., 2010) and in unmedicated patients suffering from 
major depressive disorder (Gustafsson et al., 2009).  
Exercise and its effect on mitochondria 
An accumulating body of literature has demonstrated that endurance exercise effectively 
stimulates mitochondrial biogenesis in a wide range of tissues including skeletal muscle, 
adipose tissue, liver, brain, and kidney (Little et al., 2011). Vina et al. (2009) concluded that 
exercise, and particularly aerobic exercise, activated mitochondriogenesis in young animals, 
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although its influence on older animals required further investigation. Eight weeks of 
treadmill training in a murine model augmented mitochondrial function, as reflected by 
increased mitochondrial enzyme activities, maximal rate of ATP synthesis in isolated 
mitochondria, and whole-body maximal O2 uptake (Chow et al., 2007). Lanza et al. (2009) 
reviewed a number of studies which demonstrated that older adults enrolled in exercise 
training programs respond with increased VO2 peak, mitochondrial content, oxidative enzyme 
activities, muscle protein synthesis rates, mitochondrial protein gene transcripts, and 
mitochondrial DNA copy number. 
Conclusion and directions for future research 
While the importance of lifestyle factors such as diet, exercise and sleep are generally 
acknowledged in the research literature on major depression, the mechanisms of their 
potential influence are often not fully appreciated. As illustrated in figure 3, diet, exercise and 
sleep can influence several physiological pathways associated with depression. A bi-
directional relationship likely exists between depression and these lifestyle factors, thereby 
creating a potentially increasing cycle of influence. Key symptoms of major depression include 
changes in appetite, sleep, energy and general motivation levels; all likely to have significant 
effects on diet, exercise and obviously sleep patterns. The importance of these lifestyle factors 
was highlighted in a recent paper by Jacka et al (2012) who argued that depression should be 
included under the umbrella of non-communicable diseases influenced by lifestyle factors, 
with increasing efforts directed toward prevention through the promotion of lifestyle changes.   
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Figure 3. Potential mechanisms of diet, sleep and exercise on major depression. Diet, sleep and 
exercise are associated with depression. These lifestyle factors influence a number of biological 
processes associated with major depression including neurotransmitter transmission, 
immuno-inflammation, oxidative and nitrosative stress, HPA balance, neuroprogression and 
mitochondrial health. Suffering from depression is also likely to lead to changes in diet, sleep 
and exercise, creating a vicious cycle of change. 
 
While these lifestyle factors are significant in the etiology and maintenance of depression, a 
multitude of other lifestyle influences may also be important. These include chronic stress, 
social influences, mental and physical effects associated with medical diseases, alcohol and 
other drug use, chronic pain and even exposure to sunlight/vitamin D. It is these influences, 
plus a large array of psychological, genetic and biological factors that often make the 
treatment of depression difficult. Basic interventions comprising attention towards one cause 
and/or one biochemical mechanism (e.g., targeting a single neurotransmitter disturbance) 
makes the goal of remission or recovery less likely. This was highlighted in a recent study 
where giving simple written recommendations about lifestyle changes for sleep hygiene, 
physical activity, diet, and sunlight exposure enhanced outcomes to standard antidepressant 
treatment (Garcia-Toro et al., 2012). Remission/response rates reached 60% in the combined 
treatment group compared with only 10% in the anti-depressant only group. 
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Future research needs to be directed toward better understanding the role that diet, 
exercise, sleep and other lifestyle factors play in depression and other mental health 
conditions. While this review provides a comprehensive coverage of the research literature, 
with a specific emphasis on the biological effects of these lifestyle factors on depression, a 
future more systematic review with well-defined search strategies and inclusion criteria 
would be beneficial to further elucidate the role these lifestyle factors play in depression, 
particularly those addressing diet.  
A limitation associated with many of the studies reviewed is that significant portions were 
correlational and/or epidemiological, thereby limiting conclusions about causation. Other 
influences such as general healthy lifestyle behaviours, socioeconomic status and medical 
illnesses are examples of confounding factors that may have influenced findings in some 
studies. Given these and other confounding influences, a significant barrier associated with 
studies on dietary intervention is being able to accurately provide direct evidence that dietary 
change causes improvements in mental health. Increasing attention toward randomised, 
placebo-controlled treatment studies may help to elucidate the mediating roles that these 
lifestyle factors play in major depression. A paucity of treatment studies has investigated 
dietary interventions in depressed populations; however, an inherent problem relates to 
identifying methods to blind such interventions for participants and investigators. While this 
may be possible with single nutrients or foods, it is likely that the benefits of diet are derived 
from consuming a range of complementary foods, particularly those characteristic of 
Mediterranean diets (Ghiselli et al., 1997{Milaneschi, 2011 #1450; Milaneschi et al., 2011).  It is 
also important that increasing attention be given to measuring changes in important 
biomarkers associated with inflammation, oxidative stress, HPA regulation, neuroprogression, 
monoamine and mitochondrial function. Measuring changes in biomarkers and assessing their 
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relationship with affective and behavioural changes should provide a greater understanding 
of mechanisms of action associated with depression. 
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Abstract 
Rates of obesity are higher than normal across a range of psychiatric disorders, including 
major depressive disorder, bipolar disorder, schizophrenia and anxiety disorders. While the 
problem of obesity is generally acknowledged in mental health research and treatment, an 
understanding of their bi-directional relationship is still developing. In this review the 
association between obesity and psychiatric disorders is summarised, with a specific emphasis 
on similarities in their disturbed biological pathways; namely neurotransmitter imbalances, 
hypothalamus–pituitary–adrenal axis disturbances, dysregulated inflammatory pathways, 
increased oxidative and nitrosative stress, mitochondrial disturbances, and neuroprogression. 
The applicability and effectiveness of weight-loss interventions in psychiatric populations is 
reviewed along with their potential efficacy in ameliorating disturbed biological pathways, 
particularly those mediating inflammation and oxidative stress. It is proposed that weight loss 
may not only be an effective intervention to enhance physical health but may also improve 
mental health outcomes and slow the rate of neuroprogressive disturbances in psychiatric 
disorders. Areas of future research to help expand our understanding of the relationship 
between obesity and psychiatric disorders are also outlined. 
 
List of Abbreviations: BMI, body mass index; BDNF, brain-derived neurotrophic factor; CBT, cognitive 
behaviour therapy; COX, cyclooxygenase; CNS, central nervous system; CRP, C-reactive protein; HPA, 
hypothalamus-pituitary-adrenal; IDO, indoleamine 2,3-dioxygenase; IFN, interferon; IL, interleukin;  PTSD, 
post-traumatic stress disorder; TNF, tumour necrosis factor. 
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Investigations into the biological mechanisms associated with psychiatric disorders such as 
major depressive disorder, bipolar disorder, schizophrenia and anxiety disorders have 
identified several mechanisms specific to each disorder. For example, dysregulation of the 
neurotransmitter serotonin is associated with major depressive disorder and, to a lesser extent, 
with several anxiety disorders (Cowen, 2008; Dantzer et al., 2011). Recently, increased 
attention into the kynurenine pathway has revealed that it is upregulated in major depressive 
disorder, and interest in its role in other psychiatric disorders such as schizophrenia is 
underway (Maes et al., 2011d; Myint, 2012; Myint et al., 2012). Other neurotransmitters such as 
glutamate are linked primarily with schizophrenia, and dopamine with bipolar and psychotic 
disorders (Abi-Dargham, 2004; Cousins et al., 2009; Seeman, 2009; Steele et al., 2012). Several 
genetic polymorphisms are also uniquely associated with different psychiatric disorders, such 
as polymorphisms in the serotonin transporter gene with depression (Kuzelova et al., 2010), 
and catechol-O-methyl transferase gene polymorphisms with schizophrenia and bipolar 
disorder (Sagud et al., 2010). 
Despite the unique characteristics of each disorder, they share several common 
dysregulated biological pathways.  As illustrated in Figure 1, these include neurotransmitter 
imbalances; hypothalamus–pituitary–adrenal (HPA)  axis disturbances; dysregulated 
inflammatory pathways; increased oxidative and nitrosative stress and reduced antioxidant 
defences; neuroprogression resulting in neurodegeneration, apoptosis, reduced neurogenesis 
and neuronal plasticity; and mitochondrial disturbances (Altamura et al., 2013; Anderson et 
al., 2013a; Anderson et al., 2013b; Berk et al., 2011; Moylan et al., 2013a; Moylan et al., 2012; 
Salim et al., 2012; Vieta et al., 2013). These dysregulated pathways interact significantly with 
each other, and their translation into specific psychiatric disorders is influenced by other 
biological mechanisms, environmental factors and genetic polymorphisms.  
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Figure 1. Common dysregulated biological pathways associated with psychiatric disorders 
While it is acknowledged that these disturbances are influenced by genetic and 
environmental factors,  psychological, lifestyle and social influences are also important 
(Anderson and Maes, 2013; Leonard and Maes, 2012; Lopresti et al., 2013; Maes et al., 2011c). 
One often overlooked influence concerns obesity. This review provides an overview of the 
relationship between obesity and psychiatric disorders, similarities in their disturbed 
biological pathways, and the potential of weight loss interventions not only to improve 
general health but also to enhance mental health outcomes in psychiatric patients.   
Is there an association between obesity and psychiatry 
disorders? 
Rates of obesity are greater than normal in psychiatric populations, particularly in women 
(Allison et al., 2009; McElroy, 2009). For example, Daumit et al. (2003) reported that 29% of 
men and 60% of women with severe and persistent mental illness were obese, compared to 
17.7% of men and 28.5% of women in the general population. Dickerson et al. (2006) found 
that 50% of a female, and 41% of a male psychiatric sample were obese, compared to 27% of 
women and 20% of men in a non-psychiatric matched comparison group. In a meta-analysis of 
15 longitudinal studies, Luppino et al. (2010) concluded that depression was associated with 
increased rates of obesity. More specifically, a bidirectional association was found between 
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depression and obesity with obesity increasing the risk of depression and prior depression 
increasing the likelihood of obesity.  Several studies have found that abdominal obesity in 
particular may be characteristic of depression (Carpiniello et al., 2012; Rivenes et al., 2009; van 
Reedt Dortland et al., 2013).  
After controlling for several demographic influences, Petry et al. (2008) concluded that 
obesity increased the odds of any mood, anxiety, and alcohol use disorder significantly, as 
well as any personality disorder, with odds ratios ranging from 1.21 to 2.08. In a large, 
nationally representative sample, Goldstein et al. (2011) found a nearly two-fold age-, race-, 
and sex-adjusted increased risk of obesity among adults with bipolar disorder versus controls. 
Obese participants with bipolar disorder also had greater comorbidity with anxiety disorders, 
longer depressive episodes, and significantly poorer physical and mental health functioning 
compared to non-obese people with bipolar disorder. 
Possible mediators of the relationship between obesity and 
psychiatric disorders 
Current and past unhealthy dietary patterns are associated both with obesity (Hsiao et al., 
2011; Rosenheck, 2008; Schroder et al., 2007) and psychiatric disorders (Jeffery et al., 2009; 
Sanchez-Villegas et al., 2009; Sanchez-Villegas et al., 2012) . Lower rates of physical activity 
and increased sedentary behaviours are also commonly observed in currently obese (Bailey et 
al., 2007; Tucker and Tucker, 2011) and psychiatric patients (Azevedo Da Silva et al., 2012; 
Song et al., 2012) and are also risk factors for the future development of both these conditions. 
Rates of sleep disorders such as insomnia and sleep apnoea are also increased in obesity and 
psychiatric disorders (Costa e Silva, 2006; Kalucy et al., 2013; Krystal et al., 2008; Leger et al., 
2000), and both obesity and psychiatric disorders are associated with a greater prevalence of 
cardiovascular diseases (Stanley and Laugharne, 2012), metabolic disorders (Leonard et al., 
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2012; Rotella and Mannucci, 2013; Yau et al., 2012) and autoimmune conditions (Aballay et al., 
2013). Early life trauma, including sexual and physical abuse, has also been identified as a risk 
factor for the development of obesity (Boynton-Jarrett et al., 2012; D'Argenio et al., 2009; 
Gunstad et al., 2006) and psychiatric disorders (Breslau, 2002; Chou, 2012).  
Can psychiatric medications account for the increased rates 
of obesity in psychiatric populations? 
Weight gain is a commonly reported side effect of many psychiatric medications. In a 
recent meta-analysis, the antidepressants amitriptyline, mirtazapine, and paroxetine were 
associated with the greatest risk of weight gain, with other investigated antidepressants 
having only transient or negligible effects on body weight in the short term (Serretti and 
Mandelli, 2010). However, the effect of each antidepressant may be influenced by several 
individual characteristics (e.g., sex, BMI, previous medication history, genetic polymorphisms) 
and generally becomes more evident over the long term (Dent et al., 2012). Weight gain is also 
a common problem associated with many atypical antipsychotics such as clozapine and 
olanzapine, and also increases the risk of metabolic disorders such as diabetes mellitus and 
dyslipidaemia (Dent et al., 2012; Gautam and Meena, 2011; Newcomer, 2005; Rummel-Kluge 
et al., 2010). 
Increasing evidence suggests that genetic factors may be particularly important in 
medication-induced weight gain. This is supported by monozygotic twin and sibling studies 
(Wehmeier et al., 2005), and several genetic polymorphisms have also been identified as risk 
factors for weight gain (Muller et al., 2013). Serotonin and histamine receptors have received 
most attention as they seem to play important roles in eating behaviour and may contribute to 
weight gain via their influence on lipolytic activity (Deng et al., 2010). For example, at least 17 
studies have reported an association between the 759 T/C SNP in the 5HT2C gene and 
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antipsychotic medication-induced weight gain. This effect was particularly strong in patients 
treated with clozapine and olanzapine, both of which have high affinity to 5HT2C receptor 
(De Luca et al., 2007).  The 2548 A/G variant of the leptin gene has also been associated with 
long-term (but not short term) weight gain (Ellingrod et al., 2007; Templeman et al., 2005). 
Although medication-induced weight gain may partly account for the increased prevalence 
of obesity in psychiatric populations, it seems unlikely to totally explain this relationship. For 
example, in a systematic review and meta-analysis, Luppino et al. (2010) confirmed that 
obesity at baseline increased the risk of onset of depression at follow-up. This finding was also 
supported in a review by Berkowtiz and Fabricatore (2011). Childhood overweight and 
obesity is associated with an increased risk of mood disorder in adulthood (Sanderson et al., 
2011), and higher rates of overweight and obesity have been observed in medication-naïve 
patients with bipolar disorder (Maina et al., 2008).  
Thus, the increased risk of psychiatric disorder in obese individuals is likely caused by a 
combination of psychological, social, lifestyle, genetic and biological factors, with the latter 
cause being the primarily focus of this review.  
What effect does obesity have on treatment outcomes? 
Surprisingly little research has investigated the effects of obesity on treatment resistance in 
psychiatric disorders; however, studies conducted to date have shown that obesity is 
associated with an increased likelihood of treatment failure. Studies on antidepressant 
therapies have found that higher body weight, but not obesity, was associated with a poorer 
response to fluoxetine (Papakostas et al., 2005), a higher body mass index (BMI) and obesity 
predicted poorer response to nortripitlyine but had no influence on the response to 
escitalopram (Uher et al., 2009), and individuals with higher BMI experienced a slower clinical 
response to general antidepressant treatment (Kloiber et al., 2007). Khan et al. (2007) also 
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found that depressed, obese men experienced little or no therapeutic benefit from 
antidepressant treatment. An investigation on patients with rapid-cycling bipolar disorder 
also showed that obesity was associated with a poorer treatment response to lithium and 
valproate (Kemp et al., 2010). Inflammation and increased pro-inflammatory cytokine 
production, commonly observed in obesity, are also associated with a poor antidepressant 
treatment response (Eller et al., 2008; O'Brien et al., 2007; Yoshimura et al., 2009). No studies 
have been identified investigating the effect of obesity on psychological and other non-drug 
treatments for psychiatric disorders.  
How obesity influences biological pathways associated with 
psychiatric disorders 
As summarised in Figure 2, studies over the past two decades have confirmed that obesity 
is associated with increased inflammation, oxidative stress, HPA disturbances, 
neurotransmitter imbalances, mitochondrial disturbances and neuroprogression.  
White adipose tissue, the main site for long-term fat storage in the body, contains 
adipocytes that secrete a variety of hormones and inflammatory cytokines (referred to as 
adipocytokines or adipokines). These include leptin, resistin, vistfatin, interleukin-6 (IL-6), 
tumour necrosis factor- α (TNF-α) and chemokines (Shelton and Miller, 2010). These are all 
consistently elevated in obesity, as are acute phase proteins such as c-reactive protein (CRP) 
(Das, 2001; Gregor and Hotamisligil, 2011; Shelton and Miller, 2010). Obesity is also associated 
with upregulation of the kynurenine pathway, evidenced by reduced concentrations of 
plasma tryptophan (Breum et al., 2003) and an increased kynurenine/tryptophan ratio 
(Brandacher et al., 2007). Upregulation in the kynurenine pathway influences 
neurotransmitter production (particularly serotonin) and is associated with increased 
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oxidative stress and neurodegeneration. This pathway is dysregulated in major depressive 
disorder, and may also be important in schizophrenia and bipolar disorder (Myint, 2012).   
Fat accumulation is also associated with systemic oxidative stress, demonstrated by 
elevations in lipid and protein peroxidation (Furukawa et al., 2004; Vincent et al., 2007). An 
altered mitochondrial energy production, particularly in skeletal muscles (Rogge, 2009), and 
dysregulation in the HPA axis are also observed in obese people (Duclos et al., 2001; Salehi et 
al., 2005). Support for neurotransmitter disturbances in obesity is obtained by findings of 
decreased availability of dopamine D2 receptors in the CNS of obese individuals (Wang et al., 
2001; Wang et al., 2009). Animal studies have shown that serotonin transporter mRNA levels 
are significantly down-regulated in neurons in the dorsal raphe nucleus of obese mice (Collin 
et al., 2000), while overeating has been associated with decreased release of serotonin in the 
hypothalamus (Svec et al., 2002). Obesity is also associated with unhealthy diets, excess calorie 
intake and inactivity, which can influence pathways associated with depression and other 
psychiatric disorders (Lopresti et al., 2013). 
Investigations into structural brain changes has largely confirmed that obese and 
overweight individuals have a smaller hippocampal size compared to healthy individuals 
(Fotuhi et al., 2012; Mueller et al., 2012; Raji et al., 2010; Taki et al., 2008). A higher mid-life 
BMI also increases the rate of hippocampal atrophy in late life (Jagust et al., 2005; Taki et al., 
2008). Low total brain volumes are also observed in overweight individuals and in those who 
have a normal BMI but a large abdominal diameter (Kurth et al., 2012). Brain derived 
neurotrophic factor (BDNF), which has a key role in regulating neuronal development and 
synaptic function, also plays a part in the control of energy balance by the central nervous 
system. BDNF deficiency is associated with increased weight in mice and humans (Noble et 
al., 2011; Schwartz and Mobbs, 2012). 
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Figure 2. Obesity and its influence on pathways associated with psychiatric disorders. Obesity influences several 
biological pathways associated with psychiatric disorders including immuno-inflammatory processes, 
oxidative stress, neuroprogression, mitochondrial disturbances, HPA axis imbalances and neurotransmitter 
imbalances. A bi-directional relationship likely exists (represented by the bidirectional arrow) between obesity 
and psychiatric disorders, as obesity increases the risk of psychiatric disorders, and suffering from a 
psychiatric disorder increases the likelihood of obesity. Suffering from both these conditions is likely to have 
an additive influence on these pathways. While psychiatric disorders share many commonalities in 
dysregulated pathways, genetic, environmental, lifestyle and psychological factors will determine the specific 
disorder(s) suffered [c-reactive protein (CRP), interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), 
indoleamine 2,3 dioxygenase (IDO)] 
 
Does weight loss improve dysregulated pathways 
associated with psychiatric disorders? 
Weight loss interventions are regularly associated with lower markers of inflammation 
such as CRP, IL-6 and TNF-α (Bougoulia et al., 2006; Illan-Gomez et al., 2012; Nicklas et al., 
2004; Pakiz et al., 2011). These effects are often enhanced when interventions include an 
exercise component (Pakiz et al., 2011), although this is not always found (Church et al., 2010). 
Many studies have demonstrated that anti-inflammatory effects of weight loss may not be 
observed for up to 6 months (Snel et al., 2011), but then continue despite participants gaining 
weight and returning to baseline weight levels (Olszanecka-Glinianowicz et al., 2012; Snel et 
al., 2011). After a 5 year follow-up, significant decreases in TNF-α and IL-6 obtained after 
initial weight loss treatment were maintained. This even occurred in women who regained all 
their weight (Olszanecka-Glinianowicz et al., 2012). Reductions in inflammatory markers such 
as CRP and IL-6 have even been observed after weight loss as little as 5% (Imayama et al., 
2012), although Madsen et al. (2008) found that over a 3-year period weight loss needed to 
Chapter 3: Lifestyle influences on biological mechanisms associated with major depression 
Published Paper 
- 93 - 
exceed 10% to induce a significant improvement in inflammatory markers. Weight loss is also 
associated with reduced markers of oxidative stress such isoprostane, thiobarbituric acid 
reactive substances and malondialdehyde (Boesing et al., 2010; Bougoulia et al., 2006; Ozcelik 
et al., 2005; Wycherley et al., 2008), and increased antioxidant enzymes such as glutathione 
peroxidase and catalase (Boesing et al., 2010; Bougoulia et al., 2006). 
Is weight loss possible in psychiatric patients? 
Investigations into weight loss programs on psychiatric populations have confirmed that 
weight loss is an achievable goal. In a study by Faulconbridge et al. (2012), overweight 
patients suffering from depression and type 2 diabetes lost 8.6% of their initial weight after a 
one year intensive lifestyle intervention. Severity of depressive symptoms at baseline did not 
influence the magnitude of weight lost (Faulconbridge et al., 2012). Obese females diagnosed 
with major depressive disorder receiving weekly group behavioural weight management for 
16 weeks, combined with cognitive behaviour therapy (CBT) for depression, lost 11.4% of their 
initial weight (Faulconbridge et al., 2011) and, compared to a non-depressed sample, 
depressed, obese individuals achieved similar weight loss following participation in a 
behavioural weight loss treatment (Linde et al., 2011). Significant weight loss can also be 
achieved in depressed and bipolar patients following gastric bypass surgery (Deliopoulou et 
al., 2013; Malone et al., 2011; Steinmann et al., 2011). Furthermore, taking antidepressant 
medication prior to surgery did not affect weight loss outcomes at 12 months (Malone et al., 
2011). 
In patients with schizophrenia and psychotic disorders, weight loss and weight 
maintenance is also an achievable goal (Daumit et al., 2011; Pendlebury et al., 2007). In a meta-
analysis on randomised, controlled, cognitive-behavioural weight loss trials, Bonfioli et al 
(2012) concluded that in patients with psychosis, a weight loss of 0.98 points in BMI 
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(corresponding to a loss of 3.12% of initial weight) was demonstrated from pooled data. 
Weight loss programs can also prevent weight gain associated with antipsychotic use and 
even promote weight loss (Chen et al., 2009; Gabriele et al., 2009; Menza et al., 2004; Vreeland 
et al., 2003). In a study by Zhang et al. (2012), patients with psychotic spectrum disorders 
experienced a greater percent baseline weight loss at 12 months, and greater percent BMI loss 
at 9 and 12 months than people suffering from other psychiatric disorders and no psychiatric 
disorder. Furthermore, weight loss of 5% or more occurred in 42.6% of patients with psychotic 
spectrum disorders compared to 18.4% and 23.0% in patients suffering from other psychiatric 
disorders and no psychiatric disorders, respectively. 
Does weight loss improve mental health? 
Investigations into the effect of weight loss on mental health outcomes have primarily 
investigated its effect on depressive symptoms. In a meta-analysis of 31 studies, Fabricatore et 
al. (2011) concluded that lifestyle modification was superior to control and non-dieting 
interventions in reducing symptoms of depression, and was marginally better than dietary 
counselling and exercise-alone programs. Bariatric surgery in obese individuals also improved 
symptoms of depression and lowered rates of antidepressant use, but had no effect on 
anxiolytic use (Rutledge et al., 2012). Intragastric balloon insertion was also effective in 
lowering depressive symptoms in a subsample of depressed adults (Deliopoulou et al., 2013). 
Using a depressed population of obese women, participation in a behavioural weight loss 
program or a combined weight loss and depression program led to a reduction in depressive 
symptoms and modest weight loss in both groups. Interestingly, there were no differences in 
outcomes between the two treatment groups (Linde et al., 2011). Little is known about the 
effect of weight loss programs on mental health outcomes in other psychiatric disorders such 
as schizophrenia, bipolar and anxiety disorders. However, in a study by Chen et al. (2009) on 
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patients with schizophrenia and antipsychotic-related obesity, participation in a 10-week 
multimodal weight control program led to weight loss that was mostly maintained at 12-
months follow up.  Completers also reported significant improvements in measures of quality 
of life, general health, bodily pain, depression and other emotional subscales. Significant 
improvements were also reported in positive and negative symptoms as measured by the 
positive and negative symptom scale. In a study on obese participants suffering from post-
traumatic stress disorder (PTSD), weight loss after a 16-week weight loss intervention was 
associated with a significant decline in PTSD and depressive symptoms (Deliopoulou et al., 
2013).  
Conclusion and directions for future research 
Psychiatric disorders are common in obese and overweight people, with both disorders 
sharing several common dysregulated physiological pathways. These include heightened 
inflammation and oxidative stress, HPA imbalances, mitochondrial disturbances and 
neurotransmitter imbalances. Both disorders are also associated with neuroprogression as 
evidenced by decreased neurogenesis and changes in brain structure, particularly in the 
hypothalamus. Several studies have also confirmed that obesity is associated with increased 
treatment resistance, although weight loss is achievable in psychiatric patients and is often 
associated with improvements in mental health symptoms. Weight loss also leads to 
improvements in a number of physiological pathways that are disturbed in mental health 
disorders.  
It is generally accepted that obesity is caused by an array of genetic, biological, 
environmental and psychological factors that influence each other. While this review has been 
limited to the discussion of a few key biological pathways, it is acknowledged that a range of 
other factors are important in the development and maintenance of the obesity-psychiatric 
Chapter 3: Lifestyle influences on biological mechanisms associated with major depression 
Published Paper 
- 96 - 
disorder relationship (Grimm and Steinle, 2011; Karasu, 2012; Power et al., 2007; Soczynska et 
al., 2011). This genetic-biological-environmental-psychological interaction will significantly 
influence food choices, activity patterns, hunger and satiety cues, self-regulation around food 
and exercise, lifestyle habits, belief systems, and numerous physiological processes associated 
with both obesity and psychiatric disorders. Other hormones which are important but have 
not been the focus of this review includes leptin, insulin, adiponectin, ghrelin, cholecystokinin, 
and neuropeptide Y (Grimm and Steinle, 2011; Soczynska et al., 2011). 
While our understanding of the relationship and psychiatric disorders is increasing, there 
remain an array of unanswered questions that require further investigation. These include the 
following: 
1. Is there a bi-directional relationship between obesity and psychiatric disorders? 
Research to date, particularly in the area of depression, suggests a bi-directional 
relationship between obesity and psychiatric disorders (Luppino et al., 2010). Longitudinal 
studies will help further elucidate this relationship. Does suffering from obesity increase 
the likelihood of suffering from a psychiatric disorder and, if so, what are the important 
mechanisms that underlie this? Alternatively, does suffering from a psychiatric disorder 
increase the likelihood of experiencing future obesity and is this due to medication use or 
are other biological and lifestyle factors involved? Understanding other mediators involved 
in the relationship between obesity and psychiatric disorders such as dietary and lifestyle 
factors will also be important areas of investigation.  
2. If weight loss is an important treatment goal in psychiatric populations, what is the most 
appropriate form of intervention?  
Sustained weight loss remains an elusive goal for the general population; however, studies 
do show positive health benefits associated with modest weight losses of 5 to 10 percent 
(Imayama et al., 2012; Madsen et al., 2008). What is most promising is that many markers of 
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inflammation and oxidative stress remain low even after all weight lost has been regained 
(Olszanecka-Glinianowicz et al., 2012; Snel et al., 2011).  However, the question remains as 
to the most appropriate weight loss intervention for psychiatric populations. A range of 
options are available including behavioural weight loss programs (with or without an 
exercise component), individual and/or group formats, inpatient or outpatient programs, 
weight loss medications, and bariatric surgeries. The length and intensity of treatment to 
achieve optimal results in psychiatric populations also requires investigation. 
3. Does weight loss have positive effects for all psychiatric disorders and symptoms? 
Investigations into the mental health benefits of weight loss have primarily investigated 
its effect on depressive symptoms. Given the positive influence of weight loss on a 
number of physiological pathways found to be disturbed in a range of psychiatric 
disorders, weight loss may also have positive benefits on manic, psychotic, anxiety and 
other affective and behavioural symptoms. However, this is an area that has received 
very little attention.  
4. Are mental health benefits from weight loss short-lived or long standing? 
The durability of positive changes in psychiatric symptoms following weight loss 
requires investigation. Most studies have assessed changes immediately following a 
weight loss intervention. However, long-term follow-up studies are required to 
determine whether these changes persist. 
5. Are improvements in psychiatric symptoms the result of changes in physiological, psychological, or 
environmental processes, or a combination? 
If mental health improvements occur following weight loss treatments, an understanding 
into the specific mechanisms that underlie change would be useful. Are positive changes 
the result of changes in inflammatory, neurogenic and oxidative stress pathways or are 
they mediated by changes in diet, physical activity, belief systems, social acceptance, or 
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other lifestyle factors? For example, exercise is an effective treatment for moderate 
depression and anxiety, and healthier diets, particularly adherence to a mediterranean 
diet, is associated with improvements in mental health (Lopresti et al., 2013; Moylan et al., 
2013a). Changes in these areas are major components of weight- loss programs. To 
answer this question, ongoing measurement of psychological, social, lifestyle, and 
behavioural changes, and measurement of relevant biomarkers over time will be 
required. 
6. How much weight loss is required for mental health benefits to be achieved?  
This will assist practitioners to develop appropriate treatment goals with patients. Given 
the increasing awareness of lifestyle factors such as diet, exercise and sleep in mental 
health problems (Jacka et al., 2012; Lopresti et al., 2013), it may be that weight loss is not 
an essential outcome for mental health benefits, but rather the crucial component is 
lifestyle changes. 
7. Are there dangers associated with weight loss interventions undertaken in psychiatric populations? 
Developing appropriate guidelines for inclusion in weight loss programs will be 
important. Are there particular psychiatric disorders where weight loss interventions are 
not appropriate? Are there specific characteristics that would increase the likelihood of 
harm associated with participation in a weight loss program, or should participation be 
open to anyone who is motivated to attend?  
8. What inflammatory and oxidative stress changes occur in psychiatric populations after weight loss?  
Most research into the effects of weight loss on inflammatory and oxidative stress 
biomarkers has been undertaken in non-psychiatric populations. Resolving this is 
important as there is substantial evidence of increased inflammation and oxidative stress 
in psychiatric disorders. The relationship between changes in these biomarkers and 
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mental health symptoms will also provide valuable information for researchers and 
clinicians. 
9. Do obese and overweight psychiatric populations require specialised or additional interventions to 
enhance treatment gains?  
This issue is particularly pertinent given the increasing awareness of neuroprogression in 
both psychiatric disorders and obesity. Potentially, suffering from both conditions may 
increase neuroprogressive pathways and lead to worsening treatment outcomes, relapse 
or treatment resistance. Adjunct interventions that may be considered include the 
addition of anti-inflammatory drugs such as COX-2 inhibitors (Muller and Schwarz, 2008) 
and the TNF antagonist, infliximab (Raison et al., 2013), medications with neuroprotective 
properties (e.g., antidepressants, mood stabilisers) (Dodd et al., 2013; Lee et al., 2012; 
Malhi et al., 2012), herbs and nutrients with anti-inflammatory and antioxidant properties 
(e.g., curcumin, resveratrol, omega-3 fatty acids, green tea, n-acetyl cysteine, CoQ10, 
selenium, zinc, alpha lipoic acid and vitamins such as A, C and E) (Alappat and Awad, 
2010; Floyd, 1999; Kim et al., 2008; Lopresti et al., 2012; Magalhaes et al., 2011; Scapagnini 
et al., 2012) and lifestyle changes known to enhance neurogenesis (e.g., sleep hygiene 
interventions, meditation, yoga, relaxation therapies and exercise) (Doraiswamy and 
Xiong, 2007; Kiecolt-Glaser et al., 2010; Lopresti et al., 2013).  
10. What effect do psychotropic medications have on weight gain, overall health status and relevant 
biomarker changes in psychiatric patients?  
As discussed previously, a significant problem associated with many psychiatric 
medications is weight gain. This is a serious issue for many patients who often cite this as 
a major reason for their discontinued drug use (Serretti and Mandelli, 2010). As proposed 
in Figure 3, drug-induced weight gain may potentially contribute to worsening mental 
health through both physiological and psychological effects associated with increased 
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adiposity. Weight loss interventions and the prevention of weight gain may therefore be 
especially germane for such patients as it could lead to enhanced medication compliance 
and improved treatment outcomes.  
Although weight gain is linked with several psychiatric medications, part of this 
weight gain may also be due to the psychiatric illness. This overlooked area requires 
consideration in future studies on weight gain, obesity and psychiatric disorders. 
 
 
Figure 3. The problem of medication-induced weight gain in psychiatric disorders. A significant 
problem associated with many psychiatric medications is weight gain. While medications may lead 
to mental health improvements for some patients, weight gain can have detrimental effects on 
several biological pathways (e.g., inflammation, oxidative stress, HPA imbalances, neuroprogression, 
HPA axis imbalances, mitochondrial disturbances). Weight gain may also contribute to changes in 
lifestyle, self-concept and other psychological processes that can further compound problems 
associated with psychiatric disorders. The end result is relapse or treatment resistance. (The dotted 
arrow represents patients who do not benefit from psychiatric medication) 
 
While only preliminary, alpha lipoic acid (a potent antioxidant) holds some promise 
as an effective agent in preventing antipsychotic-induced weight gain in patients with 
schizophrenia (Kim et al., 2008; Ratliff et al., 2013). The medications metformin, d-
fenfluramine, sibutramine, topiramate, and reboxetine were also confirmed in a recent 
meta-analysis to attenuate antipsychotic-related weight gain (Maayan et al., 2010). While 
these findings are positive, the effects of these medications on mental health outcomes 
and inflammatory and metabolic parameters in psychiatric patients require further 
investigation. 
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While our understanding of the relationship between obesity and psychiatric disorders is 
expanding, it is evident from this review that there are significant gaps in research. The 
dangers of obesity and the importance of weight loss are often discussed in relation to chronic 
illnesses such as diabetes and cardiovascular disease. However, their importance in mental 
health prevention and treatment should also be recognised. 
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Chapter Summary 
As detailed in this chapter, several lifestyle factors are associated with major depressive 
disorder. While these lifestyle-related behaviours influence psychological and social elements 
important in major depression, they also impact on the reviewed depressogenic biological 
pathways. It is these multiple lifestyle influences that contribute to the complexities associated 
with the prevention and treatment of major depression. Further compounding difficulties are 
the onset of depressive symptoms (e.g., fatigue, poor sleep, and anhedonia) that often promote 
negative lifestyle changes that exacerbate the severity of depressive symptoms. 
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While lifestyle factors can influence the previously mentioned dysregulated pathways, 
there is evidence that antidepressant medications and psychological therapies also play a 
significant role. In a meta-analysis by Hannestad and colleagues (2011) it was concluded that 
antidepressant medications, particularly SSRIs, were associated with reductions in IL-6 and 
IL-1β. There is also evidence that antidepressant medications can increase antioxidant status 
and decrease markers of oxidative stress both in animal- (Abdel-Wahab and Salama, 2011; 
Battal et al., 2014) and human-based studies (Bilici et al., 2001; Herken et al., 2007; Khanzode et 
al., 2003; Kotan et al., 2011). Although findings are mixed, in a systematic review and meta-
analysis on 1504 subjects it was confirmed that BDNF levels increased significantly after 
antidepressant treatment (effect size 0.62). In addition, there were significant correlations 
between changes in BDNF concentrations and changes in depression scores (Brunoni et al., 
2008). Chronic antidepressant treatment also promotes adult hippocampal neurogenesis, 
synaptogenesis and neuronal maturation (Lee and Kim, 2010; Neto et al., 2011). 
Antidepressants also influence HPA activity through their effect on mineralocorticoid and 
glucocorticoid receptors (Mason and Pariante, 2006) and their normalising effects on cortisol 
concentrations (Dziurkowska et al., 2013; Hinkelmann et al., 2012). It is likely that a 
combination of these mechanisms of change at least partly accounts for the relatively slow 
symptom-relieving effects of antidepressant medications, despite their rapid influence on 
monoamine activity. 
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There are findings from several studies confirming that participation in CBT influences 
many of the depressogenic biological pathways. For example, women with first-episode 
depression experienced reductions in IL-6 after seven sessions of CBT (Gazal et al., 2013). CBT 
offered to depressed women following coronary artery bypass graft surgery was accompanied 
by improvements in natural killer cell cytotoxicity and decreased IL-6, CRP, and postoperative 
infectious illnesses (Doering et al., 2007). In a further study on depressed patients, 
participation in CBT was associated with reductions in Toll-like receptor-4 signalling, with 
larger reductions in pro-inflammatory markers associated with greater clinical improvements 
(Keri et al., 2014). CBT is also accompanied by reductions in cortisol concentrations. For 
example, CBT was associated with cortisol reductions in women with functional hypothalamic 
amenorrhea (Michopoulos et al., 2013) and in caregivers of Alzheimer’s patients (Aboulafia-
Brakha et al., 2014). CBT applied in a forest environment is especially accompanied by 
lowered cortisol concentrations in people with major depressive disorder (Kim et al., 2009) 
and elderly patients with hypertension (Sung et al., 2012).   
In relation to other psychological and relaxation-based interventions, reductions in 
hyperglycaemic- and exercise-induced oxidative stress have been demonstrated following a 
period of diaphragmatic breathing (Martarelli et al., 2011a; Martarelli et al., 2011b). Six months 
of yoga practice in healthy male volunteers elevated concentrations of glutathione and 
increased total antioxidant status (Sinha et al., 2007). Meditation practice also influences 
inflammatory pathways by lowering neurogenic inflammation (Rosenkranz et al., 2013) and 
cortisol concentrations (Bottaccioli et al., 2014; Turakitwanakan et al., 2013). Meditation 
practice may also positively influence brain plasticity (Xiong and Doraiswamy, 2009), with 
time spent engaging in mindful-attention training positively correlating with hippocampal 
volume (Desbordes et al., 2014). 
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Despite the positive influence of psychological and pharmacological interventions on 
several biological pathways, it has been demonstrated that baseline disturbances in some of 
these pathways are associated with a poorer response to treatment. For example, people with 
chronic fatigue syndrome and low cortisol levels experienced a poorer response to CBT, 
reflected by minimal changes in fatigue, disability and psychiatric symptoms (Roberts et al., 
2010). Among older adults with depression, higher daily outputs of cortisol and flatter diurnal 
slopes were associated with minimal improvements in depressive symptoms following CBT 
(Holland et al., 2013). A poorer treatment response from CBT and interpersonal therapy also 
occurred in depressed patients with elevated levels of baseline CRP (Harley et al., 2010). In 
relation to antidepressant treatments, elevated cytokine concentrations of IL-6, TNFα and IL-1 
receptor antagonist were associated with lowered treatment efficacy from antidepressant 
medications (Eller et al., 2008; Lanquillon et al., 2000; Maes et al., 1997; O'Brien et al., 2007). 
Lower baseline vascular endothelial growth factor and monocyte chemoattractant protein-1 is 
also accompanied by a reduced response to antidepressant medications (Carvalho et al., 2013). 
These findings indicate that inflammatory-related factors lower the efficacy of pharmaceutical 
and psychological treatments. Therefore, more comprehensive interventions possibly 
comprising a combination of antidepressant and psychological therapy, and/or the addition of 
nutraceutical and lifestyle-based interventions, may be necessary for such individuals. 
Summary 
While research is still preliminary, it seems that psychological and pharmaceutical 
treatments for depression are associated with positive influences on several depressogenic 
biological pathways. However, further research is certainly required, particularly in the area 
of psychological treatments. What is noteworthy are findings of treatment resistance 
associated with significant baseline dysregulations in some of these biological pathways, 
particularly those associated with immuno-inflammation and HPA activity. Greater 
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understanding of the relevance of these findings is required, with the need for stronger 
controls for lifestyle and physical-related factors that are often associated with these biological 
disturbances.  
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Chapter 5:  
An examination of curcumin for the treatment 
of major depression 
In addition to the more consistently utilised pharmacological and psychological 
interventions, certain nutraceuticals may also influence pathways associated with major 
depression. Curcumin, derived from the Indian spice turmeric, is one agent that has been 
demonstrated through in vitro and in vivo studies to influence all of these depressogenic 
pathways and therefore has the potential to be an effective treatment for major depressive 
disorder (Lopresti et al., 2012). In this chapter, two published papers are included. The first is 
a review of in vitro and in vivo studies examining the effects of curcumin on depressogenic 
biological pathways. It was the findings from this review that led to the hypothesis that 
curcumin may be an effective agent for the treatment of major depression. This was 
subsequently investigated in a randomised, double-blind, placebo controlled study, and 
details are included in the second published paper. 
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Abstract 
Curcumin is the principal curcuminoid of the popular Indian spice turmeric and has 
attracted increasing attention for the treatment of a range of conditions. Research into its 
potential as a treatment for depression is still in its infancy, although several potential 
antidepressant mechanisms of action have been identified. Research completed to date on the 
multiple effects of curcumin is reviewed in this paper, with a specific emphasis on the 
biological systems that are compromised in depression. The antidepressant effects of 
curcumin in animal models of depression are summarised, and its influence on 
neurotransmitters such as serotonin and dopamine is detailed. The effects of curcumin in 
moderating hypothalamus-pituitary-adrenal (HPA) disturbances, lowering inflammation, and 
protecting against oxidative stress, mitochondrial damage, neuroprogression and intestinal 
hyperpermeability, all of which are compromised in major depressive disorder, are also 
summarised. With increasing interest in natural treatments for depression, and efforts to 
enhance current treatment outcomes, curcumin is presented as a promising novel, adjunctive 
or stand-alone natural antidepressant. 
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Major depression is one of the most common psychiatric disorders in the Western World 
and is the leading cause of disability (as measured by years lived with a disability). In the year 
2000 it was the 4th leading contributor to the global burden of disease and by the year 2020 is 
projected to be second only to ischemic heart disease in the amount of disability experienced 
by sufferers (WHO, 2008).   
Major depression is a heterogeneous disorder recognised as having a complex and 
multifactorial aetiology originating from the interaction between environmental and genetic 
factors. As depicted in figure 1, these lead to a range of disturbances including: 
neurotransmitter imbalances associated with lowered serotonin, dopamine and noradrenaline, 
and increased glutamate activity; HPA disturbances typically characterised by increased HPA 
activity and glucocorticoid resistance; dysregulated inflammatory pathways as evidenced by 
increased levels of proinflammatory cytokines, acute phase proteins and kynurenine pathway 
metabolites; increased oxidative and nitrosative damage associated with reduced antioxidant 
defences; neuroprogression resulting in neurodegeneration, apoptosis, reduced neurogenesis 
and neuronal plasticity; and mitochondrial disturbances in the form of increased damage to 
mitochondria and mitochondrial DNA, and lowered ATP production. (Leonard and Maes, 
2012; Maes et al., 2009c; Manji et al., 2001; Raison and Miller, 2011). It is these multiple 
pathways that make the effective treatment of depression difficult, with current therapies 
achieving far from optimal remission rates of between 20 to 40 percent (Warden et al., 2007). 
This has motivated a search for alternative pharmacological, psychological, environmental, 
and even nutraceutical treatment options to enhance current treatment outcomes. 
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Given the multifactorial nature of depression, an enhancement of treatment efficacy is 
likely to occur from therapies that target multiple mechanisms. This is likely to be achieved by 
combining therapies and/or utilising treatments with multiple mechanisms of action. 
Curcumin, derived from the spice turmeric, is a potential natural substance that may at least 
partly fulfil this criterion.  As demonstrated in figure 2, curcumin has been shown to have a 
large array of molecular targets of action which may prove to be beneficial for the treatment 
and prevention of depression and other diseases (Aggarwal and Sung, 2009; Gupta et al., 
2012). This has already led to two published brief reviews highlighting the potential 
antidepressant effects of curcumin (Kulkarni et al., 2009; Kulkarni and Dhir, 2010). 
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Interest in the benefits of curcumin has increased dramatically over the past decade with a 
number of clinical studies currently underway investigating its efficacy for treating and 
preventing a range of diseases including certain cancers (e.g., 
http://clinicaltrials.gov/ct2/show/NCT00094445) , Alzheimer’s disease (e.g.,  
http://www.anzctr.org.au/trial_view.aspx?id=336793) and musculoskeletal conditions (e.g.,   
http://clinicaltrials.gov/ct2/show/NCT00752154)In addition, at least one unpublished study 
has been completed investigating the antidepressant effects of curcumin 
(http://clinicaltrials.gov/ct2/show/NCT01022632), although the outcomes of this study have 
not yet been released. The research completed to date on the multiple effects of curcumin is 
reviewed in this paper, with a specific emphasis on the biological systems that are 
compromised in depression. The antidepressant effects of curcumin in animal models of 
depression is summarised, and its effect on neurotransmitters, HPA disturbances, 
inflammation, oxidative stress, mitochondria, neuroprogression and intestinal 
hyperpermeability, all of which are disturbed in depression, are detailed. 
Animal behavioural models of depression 
Despite the fact that no animal model is able to incorporate all aspects of depressive 
symptoms in humans, the forced swimming test (FST) is a reliable and valid tool for screening 
the antidepressant effects of drugs (Petit-Demouliere et al., 2005). Animals (typically rats and 
mice) are subjected to two trials where they are forced to swim in an inescapable cylinder 
filled with water. The time animals spend immobile in the second trial provides a measure of 
despair, and has been shown to be reduced by antidepressant drugs (Petit-Demouliere et al., 
2005).  
The tail suspension test (TST) is another animal model of depression that has good 
reliability and predictive validity (Cryan et al., 2005). In the TST, animals are subjected to the 
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short-term, inescapable stress of being suspended by their tail, with time spent in an immobile 
posture providing a measure of depressive behaviour. Various antidepressant medications 
have been shown to reverse immobility and to promote escape-related behaviour (Steru et al., 
1985).  
Antidepressant effects of curcumin in animal models 
The antidepressant effects of curcumin have been evaluated through the FST and TST in 
over a dozen studies in the past decade. These have consistently demonstrated that both acute 
(Arora et al., 2011; Chimakurthy and Talasila, 2010; Gilhotra and Dhingra, 2010; Kulkarni et 
al., 2008; Sanmukhani et al., 2011; Wang et al., 2008) and chronic (Bhutani et al., 2009; Huang et 
al., 2011; Li et al., 2009; Sanmukhani et al., 2011; Xia et al., 2007; Xu et al., 2005b) 
administration of curcumin to rats and mice reduces immobility time.  
For example, both in the acute models of FST and TST, and the chronic model of FST with a 
water wheel, curcumin had significant antidepressant-like activity compared with a vehicle 
control. The effects of curcumin were similar to that of fluoxetine and imipramine although 
when administered in combination, antidepressant effects were not enhanced (Sanmukhani et 
al., 2011). Similar results have been found in other animal models of depression, with 
curcumin having similar antidepressant efficacy to fluoxetine (Li et al., 2009; Wang et al., 
2008). 
Bilateral olfactory bulbectomy in rats causes changes in behaviour, and in the endocrine, 
immune and neurotransmitter systems, that lead to many characteristics seen in patients with 
major depression. Bulbectomy is believed to cause major dysfunction in the cortical-
hippocampal-amygdala circuit similar to that seen in people suffering from major depression 
(Song and Leonard, 2005). Chronic, but not acute administration of antidepressants corrects 
most of the changes evoked by bulbectomy (Song and Leonard, 2005).  A study assessing the 
Chapter 5: An examination of curcumin for the treatment of major depression    
Published Paper 
- 128 - 
effects of curcumin demonstrated that its chronic administration was also able to reduce 
immobility time and reverse the behavioural abnormalities induced by bulbectomy (Xu et al., 
2005a). 
By depleting monoamines and increasing oxidative stress, reserpine is a drug that increases 
pain and depressive symptoms. An investigation into the protective effects of curcumin on the 
reserpine-induced pain-depression dyad in rats demonstrated that curcumin was effective in 
ameliorating a number of behavioural changes induced by reserpine (Arora et al., 2011). 
Finally, depressive-like behaviours characterised by a decrease in sugar consumption and an 
increase in immobility time were induced by 3 weeks of corticosterone injections in rats. 
Concurrent treatment with curcumin reduced depressive-like behaviours, demonstrated by a 
46% increase in sucrose consumption and a 57% reduction in immobility time compared with 
rats receiving corticosterone injections alone (Huang et al., 2011). 
Based on the studies reviewed, in animal models of depression, oral and intraperitoneal 
curcumin appear to have potent antidepressant properties with effects similar to 
antidepressants such as the serotonin reuptake inhibitor fluoxetine and the tricyclic 
imipramine. 
Depression and immuno-inflammation 
Interest in the association between major depression and inflammation was triggered by 
studies demonstrating increased levels of inflammatory mediators in depression. This led to 
the development of inflammatory models of depression and prompted initial comparisons 
between the symptoms of depression and ‘sickness behaviours’ such as anorexia, soporific 
effects, reduction of locomotor activity and exploration, anhedonia and cognitive disturbances 
(Dantzer et al., 2011; Raison et al., 2006). These were later confirmed to be distinct conditions, 
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with sickness behaviour an adaptive, acute state, whereas depression is a disabling, 
progressive disorder (Maes et al., 2012a)  
Three recent meta-analyses have all confirmed that depression is associated with elevated 
levels of pro-inflammatory cytokines and other inflammatory mediators. Howren et al. (2009) 
concluded that depression in clinic and community samples was associated with high levels of 
C-reactive protein (CRP), interleukin-1 (IL-1), and interleukin-6 (IL-6). In a meta-analysis by 
Dowlati et al. (2010), levels of tumour necrosis factor-α (TNF-α) and IL-6 were significantly 
higher in depressed patients than controls. Finally, a meta-analysis by Liu et al. (2012) 
demonstrated that the blood levels of soluble interleukin-2 receptors (sIL-2R), TNF-α and IL-6 
were all significantly higher in patients with major depressive disorder than in controls. There 
is also evidence that major depression is characterised by a Th-1-like cell-mediated response, 
as evidenced by increased production of interferon-γ (IFN-γ), increased IFN-γ/IL-4 ratios and 
increased neopterin levels (Maes et al., 1994; Myint et al., 2005). 
Further support for the relationship between depression and inflammation is provided by a 
meta-analysis on the anti-inflammatory effects of antidepressant medications, which 
concluded that antidepressants reduced levels of cytokines IL-1β and possibly IL-6, but not 
TNF-α (Hannestad et al., 2011b). The N-methyl-D-aspartate (NMDA) receptor antagonist 
ketamine, which has rapid antidepressant effects in treatment-resistant patients with major 
depressive disorder, also has anti-inflammatory effects (Loix et al., 2011; Mathew et al., 2012)  
While increased inflammation is not found in all patients with depression, it is argued that 
its effects may be relevant to a subset of patients (Raison and Miller, 2011). Researchers have 
also become increasingly interested in the impact of inflammation on kynurenine pathway 
metabolites which have both neurotoxic and neuroprotective qualities (Dantzer et al., 2011; 
Maes et al., 2011c).  
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Immuno-inflammatory effects of curcumin 
Effects of curcumin on inflammatory pathways 
Extensive research using a wide range of in vitro models has indicated that curcumin can 
reduce the inflammatory response by regulating the production of a range of inflammatory 
molecules (Basnet and Skalko-Basnet, 2011; Srivastava et al., 2011). Research performed in 
animals also provides strong evidence for the beneficial effects of curcumin in various diseases 
associated with inflammation including inflammatory bowel disease, obesity, cardiovascular 
disease and certain cancers (Gupta et al., 2012).  
Evidence of anti-inflammatory effects in human studies is accumulating and has so far 
been promising. For example, in a clinical trial on osteoarthritis patients, the administration of 
a patented form of curcumin (Meriva®) significantly reduced a number of inflammatory 
markers including IL-1β, IL-6, and the erythrocyte sedimentation rate (ESR) (Belcaro et al., 
2010). In another randomised clinical trial, curcumin (BCM-95®) given to patients with 
rheumatoid arthritis significantly reduced the ESR to levels similar to that obtained from the 
non-steroidal anti-inflammatory drug, diclofenac sodium (Chandran and Goel, 2012). Further 
evidence of the anti-inflammatory effects of curcumin was demonstrated in a randomised, 
double-blind, placebo-controlled study on patients with overt type 2 diabetic nephropathy 
where curcumin administration reduced serum levels of TGF-β and IL-8, and urinary IL-8 
(Khajehdehi et al., 2011). Finally, in another study on patients with type 2 diabetes, curcumin 
lowered levels of IL-6 and TNF-α significantly more than placebo (Usharani et al., 2008). 
COX-2 selective inhibitors are a form of non-steroidal anti-inflammatory drug (NSAID) 
that directly targets COX-2, an enzyme responsible for the production of prostaglandin E2 
(PGE2). PGE2 is a pro-inflammatory chemical messenger involved in pain, fever and swelling. 
In normal conditions, COX-2 is not expressed in most cells, but elevated levels are found 
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during inflammation which, in turn, stimulates the production of PGE2. As a co-factor, COX-2 
is associated with the increased expression of IDO (Basu et al., 2006; Cesario et al., 2011; Lee et 
al., 2009) and with inflammatory cytokines (Abbasi et al., 2012).  
Studies in the area of depression have provided evidence of increased PGE2 production 
and COX-2 expression in depressed people. For example, increased concentrations of PGE2 in 
the saliva of patients with major depressive disorder were identified (Ohishi et al., 1988). 
Moreover, increased levels of PGE2 were reported both in the CSF and serum of depressed 
patients (Calabrese et al., 1986; Linnoila et al., 1983). Increased expression of the genes 
encoding for COX-2 were also found in the peripheral blood cells of patients with recurrent 
depression (Galecki et al., 2012). The antidepressants fluoxetine and amitriptyline also inhibit 
cytokine-induced PGE2 production by inflammatory cells (Yaron et al., 1999). Recent interest 
in the potential of COX-2 inhibitors to augment antidepressant therapies also show promise, 
with a number of positive findings from animal models of depression and from preliminary 
human clinical trials (Muller and Schwarz, 2008).  
In a six-week double-blind, placebo-controlled trial, depressed patients treated with a 
combination of fluoxetine and the COX-2 inhibitor, celecoxib, experienced greater 
improvement in mood compared with those treated with a combination of fluoxetine and 
placebo (Akhondzadeh et al., 2009). In a double-blind, add-on study using the noradrenergic 
reuptake inhibitor reboxetine as the antidepressant, Muller et al. (2006)  obtained a similar 
outcome. The combination of reboxetine and celecoxib led to significantly greater 
improvements compared with the reboxetine-alone treated group. Also, in an open-label pilot 
study, the mixed COX-1/COX-2 inhibitor acetylsalicylic acid accelerated the antidepressant 
effect of fluoxetine and increased the response rate in depressed non-responders to fluoxetine 
(Mendlewicz et al., 2006). More recently, celecoxib enhanced the efficacy of the serotonergic 
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antidepressant sertraline in 40 depressed patients. Patients in the celecoxib and sertraline 
group experienced a significantly greater response (95%) and remission (35%) rate compared 
with those receiving placebo and sertraline (50% response and 5% remission) (Abbasi et al., 
2012). 
Investigation into the biological activities of curcumin have demonstrated that it can down-
regulate COX-2 expression and PGE2 synthesis (Hong et al., 2004; Lee et al., 2011; Moriyuki et 
al., 2010; Plummer et al., 1999), therefore providing an alternative natural option as a COX-2 
inhibitor. While further human clinical studies are required in this area, the promising 
antidepressant findings of pharmaceutical COX-2 inhibitors provides another potential 
mechanism of action of for the antidepressant effect of curcumin. 
Effects of curcumin on immune pathways 
 
IDO is an enzyme expressed in multiple cell types including macrophages, dendritic cells, 
astrocytes and microglia and is strongly activated by the pro-inflammatory cytokine IFN-γ 
and to a lesser extent TNF-α, IL-1, and IL-6. IDO can also be induced by lipopolysaccharides 
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(LPS) (Chen and Guillemin, 2009; Stone et al., 2012). As shown in Figure 3, IDO is important in 
depression as it reduces serotonin synthesis by catabolising tryptophan, the primary amino-
acid precursor of serotonin, into kynurenine pathway metabolites.  The role of serotonin in 
depression is already well recognised; however, accumulating research shows that a number 
of kynurenine pathway metabolites can impact on several mechanisms associated with 
depression (Maes et al., 2011c; Maes et al., 2007). For example, excess levels of the NMDA 
agonist and kynurenine pathway metabolite, quinolinic acid (QUIN), are excitotoxic, leading 
to degenerative changes in the central nervous system. It can increase the generation of free 
radicals and induce lipid peroxidation. The damaging effects of QUIN can also contribute to 
mitochondrial degeneration and in experimental models QUIN has anxiogenic effects (Stone 
et al., 2012). Excess QUIN levels were found in depression (Raison et al., 2010; Steiner et al., 
2011), and in neurological conditions such as Alzheimer’s disease, Parkinson’s disease and 
multiple sclerosis (Kincses et al., 2010; Zádori et al., 2009). 
Another kynurenine pathway metabolite and NMDA antagonist, kynurenic acid (KYNA), 
is considered neuroprotective and inversely regulates dopaminergic activity. Its balance with 
QUIN is important as it is considered protective against the excitotoxicity of QUIN (Myint, 
2012). KYNA levels were found to be low in depression (Maes et al., 2011b; Myint et al., 2007) 
and, more recently, were observed to be particularly low in patients with somatization (Maes 
et al., 2011b; Maes and Rief, 2012). KYNA levels were also associated with an increased risk of 
depression in people undergoing IFN-α treatment for hepatitis C virus (Wichers et al., 2005). 
Research into the effects of curcumin on IDO expression is only preliminary. However, 
studies identified to date have been positive. One study demonstrated that curcumin 
significantly inhibited the expression and activity of IDO in IFN-γ-stimulated bone marrow 
dendritic mice cells (Jeong et al., 2009). In a study on cancer cells induced by IFN-γ, curcumin 
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was also reported to inhibit the expression of IDO (Zhang et al., 2008). Finally, in an in vitro 
and in vivo investigation, curcumin delivered to mice significantly attenuated LPS-induced 
increases in IDO expression in bone marrow-derived dendritic cells (Jung et al., 2010). 
Further evidence of curcumin’s immuno-modulating effects are demonstrated by its ability 
to lower Th-17 autoimmune responses (Kanakasabai et al., 2012; Xie et al., 2009) which have 
recently been shown to be upregulated in major depression (Chen et al., 2011). Curcumin also 
decreases the expression of Th-1 cytokines (e.g., IFN-γ, TNF-α) and increases the expression of 
Th-2 cytokines (e.g., IL-4 and IL-10) (Bereswill et al., 2010; Zhang et al., 2006). This may prove 
to be beneficial for the treatment of depression given consistent findings of increased Th-1-like 
cell-mediated responses in major depression (Maes, 2011; Maes et al., 1994; Myint et al., 2005).  
Several studies have also investigated the influence of curcumin on the lipopolysaccharide 
(LPS)-induced immune response. One such study revealed that the systemic administration of 
LPS to rabbits increased core temperature and hypothalamic levels of glutamate and hydroxyl 
radicals along with increased plasma levels of TNF-α, IL-1β, and IL-6. Pre-treatment with 
curcumin one hour before an intravenous dose of LPS significantly reduced the LPS-induced 
overproduction of circulating TNF-α, IL-1β, and IL-6, and brain glutamate, PGE2, and 
hydroxyl radicals (Huang et al., 2008). 
Depression and neurotransmitters 
The monoamine-deficiency theory is the most recognised and investigated causative model 
of major depression. It is postulated as the primary mechanism of action of popular 
pharmaceutical antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and 
serotonin-noradrenaline reuptake inhibitors (SNRIs), is to increase the availability of 
monoamines such as serotonin, noradrenaline (i.e., norepinephrine) and, possibly, dopamine. 
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According to this theory, the underlying pathophysiological basis of depression is a depletion 
of these neurotransmitters in the central nervous system (Maletic et al., 2007).  
Serotonin is the most extensively studied neurotransmitter in depression, with evidence of 
its deficiency emerging from studies using tryptophan depletion (which reduces central 
serotonin synthesis) (Toker et al., 2010), studies demonstrating abnormalities in serotonin 
receptors in depressed patients (Carr and Lucki, 2011), research showing increased availability 
of monoamine oxidase, an enzyme that metabolises serotonin and other monoamines in the 
brain of depressed people (Meyer et al., 2006), and evidence of abnormalities in the expression 
of the enzyme tryptophan hydroxylase, which is involved in serotonin synthesis (Matthes et 
al., 2010). The monoaminergic theory has prompted research into the potential of curcumin in 
altering neurotransmitters such as serotonin, dopamine and noradrenaline. A selection of 
these studies is reviewed. 
Effects of curcumin on serotonin, dopamine and noradrenaline 
Both animal and in vitro studies conducted over the past decade have now confirmed that 
curcumin is able to influence levels of serotonin, dopamine and noradrenaline in the central 
nervous system.  For example, in a chronic unpredictable mild stress (CUMS) model with rats, 
curcumin reduced serum corticosterone levels and attenuated CUMS-induced reductions of 
serotonin (Li et al., 2009).  Curcumin administered to mice for 21 days prior to the FST was 
also shown to markedly attenuate FST-induced decreases in concentration of serotonin, the 
serotonin metabolite 5-hydroxyindoleacetic acid, noradrenaline and dopamine, as well as 
increases in serotonin turnover (Xia et al., 2007).  Similar results were found following the 
acute administration of curcumin to mice one hour prior to the FST. Curcumin dose-
dependently increased serotonin, and at higher doses increased dopamine levels.  However, 
no changes in noradrenaline levels were found. The researchers demonstrated that curcumin 
Chapter 5: An examination of curcumin for the treatment of major depression    
Published Paper 
- 136 - 
was able to inhibit the monoamine oxidase enzymes (both MAO-A, and at higher doses MAO-
B) and when co-administered with piperine, a bioavailability enhancing agent, the effects of 
curcumin on pharmacological, biochemical, and neurochemical activities were potentiated 
(Kulkarni et al., 2008). Similar findings were obtained when rats were subjected to chronic 
unpredictable stress. Curcumin treatment for 21 days significantly reversed the chronic 
unpredictable stress-induced behavioural (increase in immobility period), biochemical 
(increase in monoamine oxidase activity) and neurochemical (depletion of brain monoamine 
levels, except noradrenaline) alterations. The combination of piperine with curcumin again 
showed significant potentiation of its anti-immobility, neurotransmitter enhancing (serotonin 
and dopamine) and MAO-A effects compared to curcumin administration alone (Bhutani et 
al., 2009). 
In an animal study on the effects of curcumin on serotonin (5-HT) receptors, the 
antidepressant-like effects of curcumin in the FST were related to the serotonergic system, 
possibly due to an interaction with 5-HT1A/1B and 5-HT2C receptors (Wang et al., 2008). Further 
evidence of the monoamine effects of curcumin has been demonstrated in rats submitted to a 
bilateral olfactory bulbectomy. The administration of curcumin completely reversed induced 
reductions in serotonin and noradrenaline in the hippocampus and frontal cortex (Xu et al., 
2005a). Curcumin also reversed reseperine-induced reductions in dopamine, noradrenaline 
and serotonin in rats (Arora et al., 2011). Pre-treatment with curcumin reversed haloperidol-
induced reductions of dopamine, noradrenaline and serotonin in rats (Bishnoi et al., 2008). In a 
follow-up study, the co-administration of piperine significantly enhanced the effect of 
curcumin on these monoamines (Bishnoi et al., 2011).  
Collectively, these animal studies provide strong support for the monoaminergic effects of 
curcumin. Curcumin enhances levels of serotonin and dopamine and, to a lesser extent, 
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noradrenaline, following exposure to acute and chronic stress. The studies reviewed in this 
section indicate that curcumin has an inhibitory effect on monoamine oxidase and influences 
5-HT1A/1B and 5-HT2C receptors, all of which play a role in depression. 
Effects of curcumin on glutamate 
Glutamate is the major excitatory synaptic neurotransmitter in the central nervous system 
and plays a vital role in the regulation of synaptic plasticity, learning, and memory (McEntee 
and Crook, 1993).  Increasing research has demonstrated altered levels of glutamate in plasma, 
cerebrospinal fluid (CSF) and various areas of the brain in people with depression. An 
increasing number of reports also suggest potential antidepressant effects of anti-
glutamatergic agents, such as ketamine, amantadine, and riluzole (Gao and Bao, 2011; 
McNally et al., 2008).  
Curcumin inhibited the release of glutamate evoked by exposing synaptosomes to the K+ 
channel blocker 4-aminopyridine (4-AP) (Lin et al., 2011).  Because the inhibitory effect of 
curcumin on glutamate release was completely abolished by the antidepressant ﬂuoxetine, it 
was concluded that these two substances may use a common intracellular mechanism to 
inhibit glutamate release from rat prefrontal cortex nerve terminals. When the effects of 
curcumin and fluoxetine were compared, curcumin had significantly greater inhibitory effects 
on glutamate release than fluoxetine (Lin et al., 2011).  
Depression and HPA disturbances 
The hypothalamic, pituitary and adrenal (HPA) axis plays a significant role in the body’s 
stress response and is initiated by the secretion of corticotrophin releasing hormone (CRH) 
and arginine-vasopressin (AVP) from the hypothalamus. This, in turn, activates the secretion 
of adrenocorticotropic hormone (ACTH) from the pituitary gland, which then stimulates the 
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secretion of glucocorticoids (cortisol in humans and corticosterone in rodents) from the 
adrenal cortex. These glucocorticoids impact on their receptors and are involved in the 
negative feedback control of CRH and AVP release from the hypothalamus (Zunszain et al., 
2011). 
Abnormalities in the activity of the HPA axis have long been observed in major depression 
(Pariante and Lightman, 2008). This has been characterised by heightened cortisol secretion in 
patients presenting with melancholic depression, and reduced levels in people presenting 
with atypical depression (Gold and Chrousos, 2002). Increasing research has also 
demonstrated that depression is associated with a hypersecretion of CRH and impairment in 
the responsiveness to glucocorticoids, a phenomenon known as glucocorticoid resistance 
(Pariante and Lightman, 2008). Depression is also associated with an increased size  and 
activity of the pituitary and adrenal glands (Nemeroff et al., 1992). 
Effects of curcumin on HPA disturbances 
A few studies have examined the effect of curcumin in regulating HPA disturbances, 
namely its effect in moderating the hypersecretion of corticosterone and subsequent 
neuroprotection. For example, rats subjected to 3 weeks of corticosterone injections exhibited 
depressive-like behaviours, as demonstrated by a significant decrease in sucrose consumption 
and an increase in immobility time in the FST. These behaviours were significantly reduced in 
those rats treated concurrently with curcumin (Huang et al., 2011). In a study on rats exposed 
to 4 weeks of chronic unpredictable mild stress, curcumin was able to moderate increases in 
serum corticosterone at levels similar to those obtained by fluoxetine (Li et al., 2009). In a final 
study, exposure of corticosterone to rat neurons decreased mRNA levels for three serotonin 
receptor subtypes, 5-HT1A, 5-HT2A and 5-HT4. Pre-treatment with curcumin one hour prior to 
corticosterone exposure reversed this effect on 5-HT1A and 5-HT4 receptors, but not for the 5-
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HT2A receptor. Moreover, curcumin significantly reduced neuronal loss, indicating that it 
could protect cells from corticosterone-induced toxicity. Curcumin also inhibited 
corticosterone-induced morphological changes such as increases in soma size, dendritic 
branching and dendritic spine density, and elevated synaptophysin expression in cortical 
neurons.  The antidepressant fluoxetine also provided a protective effect against the toxicity of 
corticosterone and reversed corticosterone-induced down-regulation of mRNA levels for three 
receptors: 5-HT1A, 5-HT2A and 5-HT4 (Xu et al., 2011). 
In sum, these studies highlight the potential protective effects of curcumin on stress-
induced cortisol production. HPA imbalances in depression may prove to be at least partly 
ameliorated by curcumin, although further studies are required. 
Depression and neuroprogression 
Neurogenesis is the process by which new neurons are formed from populations of neural 
stem or progenitor cells residing in discrete regions of the CNS (Abdipranoto et al., 2008). 
Recent research into neuroanatomy and neurochemistry has increasingly demonstrated that 
major depression is associated with impaired neurogenesis, neuronal plasticity, and 
subsequent neurodegeneration. This is indicated by stress-induced alterations to the number 
and shape of neurons and glia in the brain regions of depressed patients (Duman, 2009). 
Depression is also associated with a decrease in proliferation of neural stem cells (Eyre and 
Baune, 2012).  
Neuronal plasticity is influenced by a range of neurotrophic factors, such as brain-derived 
neurotrophic factor (BDNF), which is the most abundant and widely distributed neurotrophin 
in the central nervous system (Martinowich and Lu, 2008). BDNF plays a role in regulating a 
large array of functions including neuronal survival, growth and proliferation, and levels 
usually are low in people suffering from major depression (Duman, 2009; Lee and Kim, 2010). 
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Chronic administration of several classes of antidepressants, including monoamine oxidase 
inhibitors, SSRIs, tricyclic agents, and SNRIs increases BDNF levels (Duman and Monteggia, 
2006; Sen et al., 2008).  The detrimental effects of early life and chronic stress on BDNF, and 
evidence of increased levels of BDNF following physical exercise and electroconvulsive 
therapy, provides further support for a role of BDNF in the pathogenesis of depression 
(Martinowich et al., 2007; Nagahara and Tuszynski, 2011). 
Neuroprotective effects of curcumin 
Preliminary investigations into the neuroprotective effective of curcumin have provided 
evidence of its ability to enhance BDNF and attenuate stress-induced neurodegeneration. 
Repeated corticosterone injections were shown to significantly decrease BDNF levels in the 
hippocampus and frontal cortex of rats, which curcumin was able to significantly ameliorate 
(Huang et al., 2011). In another study, rats exposed to a range of daily stressors over a 20-day 
period were administered either 3 doses of curcumin orally or the antidepressant imipramine. 
Curcumin administration at higher doses reversed the stress-induced decrease in 
hippocampal neurogenesis in stressed rats at levels similar to imipramine treatment. 
Curcumin also reversed the stress-induced decrease in BDNF and 5-HT1A mRNA levels across 
all hippocampal subfields. These effects were similar to those obtained from imipramine (Xu 
et al., 2007). Further evidence for the neuroprotective effects of curcumin was demonstrated in 
a recent study where pre-treatment with curcumin reversed the effect of corticosterone-
induced neuronal changes in rats (Xu et al., 2011). Curcumin also attenuated quinolinate-
induced excitotoxicity on primary cultures of human neurons (Braidy et al., 2011). 
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Depression and mitochondrial disturbances 
Mitochondria are intracellular organelles found in most eukaryotic cells which generate 
most of the cell's supply of adenosine triphosphate (ATP). They are also involved in a range of 
other processes, such as signalling, cellular differentiation, cell death, as well as the control of 
the cell cycle and cell growth (McBride et al., 2006). Because of the brain’s significant energy 
demands, high concentrations of mitochondria are found in this region making the brain 
susceptible to reductions in aerobic metabolism (Pieczenik and Neustadt, 2007). 
Malfunction in the biochemical cascade and damage to the mitochondrial electron 
transport chain can lead to mitochondrial dysfunction or disease which has been implicated in 
a range of neuropsychiatric disorders such as depression, bipolar disorder and schizophrenia 
(Gardner and Boles, 2011; Rezin et al., 2009). In depression, mitochondrial disturbances such 
as deletions of mitochondrial DNA (Gardner and Boles, 2008a; Shao et al., 2008) and lower 
activities of respiratory chain enzymes and ATP production (Gardner et al., 2003) have been 
found. Gardner and Boles (2008a; 2008b) also showed that in depressed individuals with 
somatic complaints, the majority had lowered ATP production rates in biopsied muscles. 
Further support for mitochondrial dysfunction in depression is demonstrated by increased 
rates of depression in patients with mitochondrial disorders. For example, the lifetime 
diagnosis of depression in patients with mitochondrial disorders was 54% (Fattal et al., 2007). 
Greater rates of depression were also detected in adolescents with mitochondrial disorders 
(Koene et al., 2009). 
It has been argued that because depression is associated with increased oxidative and 
nitrosative stress, increased inflammatory pathways, and lowered antioxidant defences, this 
may be a major cause of mitochondrial dysfunction in major depression (Gardner and Boles, 
2011; Maes et al., 2012c). Kynurenine pathway metabolites such kynurenic acid, 3-
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hydroxykynurenine and 3-hydroxyanthranilic acid, which are dysregulated in major 
depression, can also impair mitochondrial ATP production (Baran et al., 2003).  
Effects of curcumin on mitochondrial function 
Altering the pathogenic cascade associated with mitochondrial dysfunction in major 
depression may be a potential avenue to enhance treatment outcomes in depression. 
Curcumin, with its numerous molecular effects, may be a useful option with a number of 
studies demonstrating protective effects on mitochondria. Curcumin was able to attenuate 
oxidative damage in rat cortical neurons by reducing intracellular production of reactive 
oxygen species (ROS) and protecting mitochondria from oxidative damage (Zhu et al., 2004). 
Treatment with curcumin also lowered aluminium-induced oxidative stress and 
mitochondrial dysfunction in the rat brain, likely by several mechanisms such as activation of 
Heme oxygenase-1, maintenance of glutathione metabolism or by scavenging ROS (Sood et 
al., 2011). Curcumin and its analogues were also able to inhibit ROS-induced lipid 
peroxidation and protein damage in mitochondria (Wei et al., 2006). Nuclear factor erythroid 
2-related factor 2 (Nrf2), which mediates neuroprotection against mitochondrial complex I and 
II inhibitors, is also activated by curcumin (Greco and Fiskum, 2010; Jiang et al., 2011) 
Depression and nitric oxide 
Nitric oxide (NO) is an intercellular messenger in the brain, synthesised from the amino 
acid L-arginine by the enzymatic action of nitric oxide synthase (NOS). Three NOS isoforms 
are known to exist in mammals — neuronal NOS (nNOS), inducible NOS (iNOS), and 
endothelial NOS (eNOS) (Alderton et al., 2001). NO plays an important role in various 
physiological and pathological processes, and there has been increasing interest in its role in 
depression and other mental health conditions (Dhir and Kulkarni, 2011; McLeod et al., 2001; 
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Pinto et al., 2008). According to Dhir & Kulkarni (2011), support for a role of NO in the 
pathogenesis of major depression is provided by studies showing that levels of plasma NO 
and its metabolites are elevated in suicidal and depressed patients (Lee et al., 2006; Suzuki et 
al., 2001), evidence that decreasing or blocking the synthesis of NO can induce antidepressant-
like effects (Joca and Guimaraes, 2006), research demonstrating that NO modulates the 
production of neurotransmitters such as noradrenaline, serotonin, and dopamine (Dhir and 
Kulkarni, 2011), and evidence of  lower levels of nNOS in the locus coeruleus of people 
suffering from major depression than in normal controls (Karolewicz et al., 2004). Further 
indirect evidence for NO involvement in major depression is derived from the characterisation 
of circulating antibodies against NO-epitopes. Highly reactive substances such as NO-
tyrosine, NO-tryptophan and NO-arginine are formed by nitration reactions, and increased 
IgM antibody levels against these NO-adducts have been found in depressed patients (Maes et 
al., 2008b; Maes et al., 2011d). These results suggest that increased NO and/or activation of 
nitration reactions and consequent increases in nitrated containing proteins may be involved 
in the pathophysiology of depression (Maes et al., 2011a).  
Effects of curcumin on nitric oxide 
Several studies have now confirmed that curcumin can regulate levels of nitric oxide. 
Immobilisation-induced restraint stress lasting six hours significantly increased plasma nitrite 
levels in mice, which was attenuated by intraperitoneal delivery of curcumin. This effect was 
enhanced when curcumin was jointly delivered with aminoguanidine, an iNOS inhibitor, 
thereby suggesting curcumin’s possible inhibitory effect on iNOS (Gilhotra and Dhingra, 
2010). In cultured human neurons, quinolinic acid induced nNOS activity and consequently 
increased nitrite levels. Curcumin dose-dependently decreased nNOS activity in human 
neurons (Braidy et al., 2010). Further evidence of curcumin’s nitric oxide inhibitory effect was 
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demonstrated in a study on rats subjected to 72 hours of sleep deprivation. This led to 
increases in nitrite levels, along with several markers of oxidative damage. Intraperitoneal 
treatment with curcumin for 5 days had anxiolytic effects and restored nitrite levels. This 
effect was, however, abolished by pre-treatment with L-arginine, a precursor to nitric oxide, 
but only with the lower dose of curcumin of 10mg/kg. The researchers concluded that nitric 
oxide modulation is involved in the protective effect of curcumin in ameliorating sleep 
deprivation-induced behavioural alterations and oxidative damage (Kumar and Singh, 2008).  
Depression and oxidative stress 
In a review paper, Maes et al. (2011a) confirmed that major depression was accompanied 
by a decreased antioxidant status and by the induction of oxidative and nitrosative pathways. 
This was supported by studies showing significantly reduced plasma concentrations of 
important antioxidants such as vitamin C (Khanzode et al., 2003), vitamin E (Maes et al., 2000; 
Owen et al., 2005), and coenzyme Q10 (Maes et al., 2009b) in depressed patients.  Depression 
was also accompanied by a lowered total antioxidant status (Cumurcu et al., 2009; Sarandol et 
al., 2007) and reduced antioxidant enzyme activity such as glutathione peroxidase (Maes et al., 
2011e). Such deficiencies can impair protection against reactive oxygen species (ROS), causing 
damage to fatty acids, proteins and DNA (Maes et al., 2011a). In fact, increased levels of 
malondialdehyde, a measure of lipid peroxidation,  were found in depressed patients (Ozcan 
et al., 2004; Sarandol et al., 2007; Wei et al., 2009), as have increased levels of 8-hydroxy-2-
deoxyguanosine (8-OH-dG), a measure of oxidative damage to DNA (Forlenza and Miller, 
2006; Maes et al., 2009a). 
Further support for an association between oxidative stress and depression is provided by 
a few studies that demonstrate antioxidant properties of antidepressant medications. 
However, not all studies have uniformly identified reductions in oxidative markers following 
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antidepressant medications, necessitating further research in this area (Ng et al., 2008). Clinical 
studies into the efficacy of antioxidant therapies to alleviate depressive symptoms are lacking 
although N-acetylcysteine (NAC), a powerful antioxidant, was found to be useful for 
depressive episodes in bipolar disorder (Magalhaes et al., 2011). Zinc, which serves as a strong 
antioxidant, also has evidence of antidepressant activity (Szewczyk et al., 2011). 
Antioxidant effects of curcumin 
Investigations into the pharmacodynamics of curcumin have consistently demonstrated it 
to be a potent antioxidant (Ak and Gulcin, 2008; Menon and Sudheer, 2007), at least ten times 
more active as an antioxidant than vitamin E (Ak and Gulcin, 2008). In relation to a selection 
of the oxidative markers associated with depression, curcumin is able to lower levels of 
malondialdehyde (Rai et al., 2010), 8-OH-dG (Naik et al., 2011; Rai et al., 2010; Shih and Lin, 
1993), and increase the activity of the antioxidant enzymes superoxide dismutase and 
glutathione peroxidase (Manikandan et al., 2011; Naik et al., 2011). Curcumin also attenuated 
increased markers of oxidative stress in rats undergoing chronic stress (Bhatia et al., 2011). In 
recent studies, curcumin also up-regulated Nrf2, a transcription factor that induces the 
expression of various genes including those that encode for several antioxidant enzymes 
(Scapagnini et al., 2011; Yang et al., 2009). 
Depression and intestinal hyperpermeability 
The intestinal epithelium is the largest mucosal surface in the human body and provides an 
interface between the external environment and the host (Fasano and Shea-Donohue, 2005). 
Normally, the intestinal epithelium provides a semi-permeable wall which allows nutrients to 
be absorbed while preventing larger, potentially toxic, antigenic, or pathogenic molecules or 
organisms from passing into the bloodstream. However, the permeability of the intestinal 
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epithelium can become compromised leading to a condition known as intestinal 
hyperpermeability or ‘leaky gut.’ This results in an increased diffusion of antigenic food 
molecules and translocation of bacteria from the gut into extra-intestinal sites which can then 
trigger an immune response (Miller, 1997).  
Lipopolysaccharides (LPS) are large molecules found in the outer membrane of Gram-
negative bacteria and, during a state of intestinal hyperpermeability, are known to translocate 
into the systemic circulation in greater quantities (Maes et al., 2008a). Once the LPS are 
translocated into the blood, an inflammatory process is generated and is associated with 
increased neuroinﬂammation and secretion of proinﬂammatory cytokines, such as IL-1β, IL-6 
and TNF-α (Dunn, 2006; Henry et al., 2008; Huang et al., 2008; Qin et al., 2007). LPS are also 
able to activate IDO production leading to increased kynurenine metabolites and tryptophan 
breakdown (Dobos et al., 2012; Fu et al., 2010; O'Connor et al., 2009). 
Research into the relationship between LPS, intestinal permeability and depression has 
demonstrated that LPS have the capacity to induce depressive behaviour in animals (Henry et 
al., 2008; Yirmiya, 1996). Interestingly, antidepressants such as fluoxetine and imipramine 
attenuate behavioural responses to immune challenges, such as LPS (Yirmiya et al., 2001). In a 
recent study, the reverse was demonstrated where LPS reduced the antidepressant effects of 
fluoxetine in a chronic, unpredictable mild stress model in mice (Wang et al., 2011). 
Investigations into the incidence of intestinal hyperpermeability in patients with major 
depressive disorder have confirmed an increased translocation of LPS from Gram- negative 
enterobacteria in depressed patients. This was demonstrated by increased serum IgM and IgA 
levels directed against LPS of Gram-negative enterobacteria (Maes et al., 2012b; Maes et al., 
2008b).   Maes and colleagues concluded that depressive disorder was accompanied by 
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increased gut permeability which was associated with an immune response directed against 
LPS produced by enterobacteria.  
Effects of curcumin on the LPS-induced immune response 
Several studies have investigated the protective effects of curcumin on LPS administration. 
In two separate studies, curcumin decreased NO production in LPS-stimulated microglial cells 
in a dose-dependent manner (Jung et al., 2006; Tocharus et al., 2012). Both pre- and post-
treatment with curcumin diminished LPS-induced dopamine neurotoxicity in a dose-
dependent manner. LPS-induced production of many proinflammatory factors and their gene 
expressions such as TNF-α, NO, PGE2 and IL-1β was also dramatically reduced following 
curcumin treatment. Curcumin also decreased LPS-induced activation of two transcription 
factors - nuclear factor kappaB and activator protein-1 (Huang et al., 2008). The benefits of 
curcumin may also occur through its ability to reduce the translocation of bacteria into 
extraintestinal sites, such as mesenteric lymph nodes, liver, spleen, and/or bloodstream 
(Karatepe et al., 2010)Given the potential of LPS to induce depressive-like behaviour in 
animals, and an increased translocation of LPS in depressed patients resulting from increased 
intestinal hyperpermeability, the ameliorating effects on LPS-induced inflammation provides 
another potential antidepressant mode of action of curcumin. 
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Conclusion 
 
While clinical trials on the antidepressant effects of curcumin are required to determine the 
efficacy of this natural substance, this paper highlights the multiple potential antidepressant 
modes of action of curcumin. As discussed above and summarised in Figure 4, curcumin has 
been shown through in vitro and in vivo studies to influence a range of neurotransmitters and 
hormones commonly observed to be disturbed in major depression. It also has the potential to 
provide neuroprotective effects, and shows some promise as a protective agent from stress-
induced neurotoxicity. Curcumin’s anti-inflammatory and antioxidant effects are already 
well-recognised and may prove to be another potential mode of action in treating depression. 
Unfortunately, a commonly cited problem associated with curcumin relates to its poor 
bioavailability via oral ingestion, limiting its potential clinical application (Anand et al., 2007). 
However, recent efforts to enhance its bioavailability have shown significant promise. For 
example, blood levels of the patented formulation BCM-95®CG was found to be 6.93 times 
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higher than standard curcumin, and 6.3-fold higher than a curcumin-lecithin-piperine formula 
(Antony et al., 2008). In another human study on the patented curcumin formula, Meriva®, its 
total curcuminoid absorption was shown to be 29-fold higher than an unformulated 
curcuminoid mixture (Cuomo et al., 2011). Curcumin administered with the agent piperine 
also increases oral bioavailability (Shoba et al., 1998). While no research has yet assessed 
whether this increased absorption is associated with increased clinical efficacy, it is hoped that 
these methods of delivery may at least partly overcome problems associated with curcumin’s 
poor oral absorption and therefore enhance its utility in clinical settings. 
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Abstract 
BACKGROUND: Curcumin, the principal curcuminoid derived from the spice turmeric, 
influences several biological mechanisms associated with major depression, namely those 
associated with monoaminergic activity, immune-inflammatory and oxidative & nitrosative 
stress pathways, hypothalamus-pituitary-adrenal (HPA) axis activity and neuroprogression. 
We hypothesised that curcumin would be effective for the treatment of depressive symptoms 
in individuals with major depressive disorder.  
METHODS: In a randomised, double-blind, placebo-controlled study, 56 individuals with 
major depressive disorder were treated with curcumin (500 mg twice daily) or placebo for 8 
weeks. The primary measure was the Inventory of Depressive Symptomatology self-rated 
version (IDS-SR30). Secondary outcomes included IDS-SR30 factor scores and the Spielberger 
State-Trait Anxiety Inventory (STAI). 
RESULTS: From baseline to week 4, both curcumin and placebo were associated with 
improvements in IDS-SR30 total score and most secondary outcome measures. From weeks 4 
to 8, curcumin was significantly more effective than placebo in improving several mood-
related symptoms, demonstrated by a significant group x time interaction for IDS-SR30 total 
score (F1,53 = 4.22, p = .045) and IDS-SR30 mood score (F1,53 = 6.51, p = .014), and a non-
significant trend for STAI trait score (F1,48 = 2.86, p = .097). Greater efficacy from curcumin 
treatment was identified in a subgroup of individuals with atypical depression. 
CONCLUSIONS: Partial support is provided for the antidepressant effects of curcumin in 
people with major depressive disorder, evidenced by benefits occurring 4 to 8 weeks after 
treatment.  
LIMITATIONS: Investigations with larger sample sizes, over extended treatment periods, 
and with varying curcumin dosages are required.  
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Introduction 
Disturbances in monoaminergic neurotransmission, particularly around serotonin 
availability, were originally posited as the primary cause of major depression (Cowen, 2008). 
However, studies now confirm that major depression is associated with a large array of 
biological disturbances. These include dysregulation in the hypothalamus-pituitary-adrenal 
(HPA) axis, activation of immune-inflammatory pathways, increased oxidative and nitrosative 
stress, neuroprogression, and mitochondrial dysfunction (Leonard and Maes, 2012; Maes et 
al., 2011c). Consequently, this has sparked interest in compounds that target these pathways. 
Examples include anti-inflammatory treatments influencing immuno-inflammation such as 
cyclooxygensase-2 (COX-2) inhibitors, aspirin, minocycline and polyunsaturated fatty acids 
(Berk et al., 2013a; Fond et al., 2014; Muller, 2013) and antioxidant therapies to increase 
antioxidant defences and lower free radical damage such as n-acetyl cysteine, Ebselen, vitamin 
E and coenzyme-Q10 (Berk et al., 2013b; Scapagnini et al., 2012). Interestingly, despite 
pharmaceutical antidepressants originally being heralded as targeting monoaminergic actions, 
there is also evidence that they can modulate immuno-inflammation, reduce oxidative stress, 
enhance neurotrophic factors and influence HPA activity (Abdel-Wahab and Salama, 2011; 
Andrade and Rao, 2010; Hannestad et al., 2011a; Kocki et al., 2012; Schule, 2007). 
Curcumin is the most active compound of the Indian spice turmeric and comprises 2-8% of 
most turmeric preparations (Sharma et al., 2005). Curcumin [1,7-bis-(4-hydroxy-3-
methoxyphenyl)-1,6-heptadiene-3,5-dione] is a low molecular weight polyphenol, first 
chemically characterised in 1910 by Milobedzka et al. (1910) and influences all of the 
aforementioned biological mechanisms (Aggarwal and Harikumar, 2009; Lopresti et al., 2012). 
More specifically, curcumin is a potent antioxidant that can lower markers of oxidative stress 
(Naik et al., 2011; Rai et al., 2010), modulate immuno-inflammation by acting as a COX-2 
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inhibitor (Lee et al., 2011; Plummer et al., 1999) and lower pro-inflammatory cytokines (Basnet 
and Skalko-Basnet, 2011; Belcaro et al., 2010), provide significant neuroprotection (Huang et 
al., 2011; Xu et al., 2007), modulate HPA activity (Huang et al., 2011; Li et al., 2009) and 
influence monoamine transmission through its effect on serotonergic and dopaminergic 
activity (Bhutani et al., 2009; Kulkarni et al., 2008; Xia et al., 2007). In animal studies, 
antidepressant effects of curcumin have been attributed to its serotonergic, dopaminergic, 
neuroprotective and HPA-modulating effects (Huang et al., 2011; Kulkarni et al., 2008; Xu et 
al., 2006). Two clinical trials have also now been completed investigating the antidepressant 
effects of curcumin in people with major depression. In the first study, curcumin as an add-on 
to antidepressant therapy did not enhance treatment outcome (Bergman et al., 2013), whereas 
in the second trial curcumin demonstrated similar antidepressant efficacy to fluoxetine 
(Sanmukhani et al., 2014). However, the latter study lacked a placebo-control and volunteers 
were not blinded. 
The purpose of this study was to expand investigation into the antidepressant effects of 
curcumin supplementation in people with major depressive disorder. It was hypothesised that 
treatment with curcumin would lead to greater antidepressant benefits than a placebo, 
reflected by reductions in the administered depression and other mood-related self-report 
questionnaires. Curcumin was also hypothesised to have greater benefits for participants with 
atypical depression as it is associated with dysregulated immune-inflammatory pathways 
(Hickman et al., 2013; Lamers et al., 2013). 
Materials and Methods 
Study design 
This study was an 8-week, randomised, double-blind, placebo-controlled clinical trial 
(Figure 1). The trial protocol was approved by the Human Research Ethics Committee at 
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Murdoch University, Western Australia. The trial was registered with the Australian New 
Zealand Clinical Trials Registry (no. 12612001260819) and participants were recruited between 
February and November 2013, across the Perth, Western Australia metropolitan area. 
Recruitment occurred through advertisements and promotions in community newspapers and 
a health magazine, and after interviews with local radio media outlets.  
Participants were randomly and equally allocated into two groups (placebo and curcumin) 
using a randomisation calculator (http://www.randomization.com). Both curcumin and 
placebo capsules were packed in identical containers labelled by participant code numbers 
and were allocated according to order of participant enrolment in the study. 
Participants 
Inclusion criteria: Male and female participants aged 18 to 65 years were eligible to 
participate if they met the DSM-IV criteria for current major depressive disorder and had an 
Inventory of Depressive Symptomatology self-rated version (IDS-SR30) score ≥ 14. The 
diagnosis of major depression was made by the first author, an experienced clinical 
psychologist, using The Mini International Neuropsychiatric Interview 6.0 (MINI 6.0) 
(Sheehan et al., 1998). Pharmaceutical antidepressants, the use of the contraceptive pill and no 
more than once a week use of analgesics were permissible. If participants were on 
pharmaceutical antidepressants, the drug dosage or type must have been stable for the past 8 
weeks and throughout the duration of the study. Only non-smokers were included in the 
study and volunteers were not currently taking turmeric/ curcumin supplements. If 
volunteers were receiving psychological therapy, the treatment must have commenced at least 
8 weeks prior to participating in the study. 
Exclusion criteria: participants with a psychotic disorder, bipolar disorder, comorbid 
obsessive-compulsive disorder, posttraumatic stress disorder, eating disorder, or any 
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substance abuse or dependence disorder were excluded, as were participants assessed as 
having high risk of suicide. Volunteers were also excluded if they suffered from medical 
illnesses including diabetes, autoimmune diseases, cardiovascular disease, hypertension, 
neurodegenerative disorders (e.g., Alzheimer’s disease, Parkinson’s disease, stroke, and 
multiple sclerosis), chronic fatigue syndrome, fibromyalgia and asthma; were pregnant or 
intended to fall pregnant; currently breastfeeding; had suffered from an infection or illness 
over the past month; were currently taking any antiplatelet or anticoagulant medications; or 
had been diagnosed with any coagulation disorder. 
Interventions 
Placebo (cellulose) and curcumin capsules were supplied by Arjuna Natural Extracts Ltd. 
(Kochi, India), and were identical in appearance. Curcumin was provided in a 500 mg capsule 
(BCM-95®) containing total curcuminoids 88% (curcumin, bisdemethoxycurcumin, 
demethoxycurcumin) and volatile oils 7% from rhizomes of Curcuma longa Linn. Participants 
were directed to take one capsule, twice daily with or without food for 8 weeks. Curcumin 
was used at a dose of 1000 mg/day. Medication compliance was measured by volunteer-
reported pill count at weeks 4 and 8. 
Outcomes 
Self-report questionnaires 
Inventory of Depressive Symptomatology self-rated version (IDS-SR30): The IDS-SR30 was used as 
the primary outcome measure. It contains 30 items measuring depressive symptoms based on 
the DSM-IV criteria for major depressive episode (Rush et al., 1986; Rush et al., 1996).  
Respondents are asked to rate the severity and frequency of specific symptoms present over 
the past 7 days. The IDS-SR30 has acceptable psychometric properties in depressed outpatients 
(Rush et al., 2000; Rush et al., 1996; Trivedi et al., 2004) and correlates highly with common 
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depression inventories such as the HRSD17, BDI, and MADRS (Corruble et al., 1999; Rush et 
al., 2000; Rush et al., 1996). 
In a factor analytical study on the IDS-SR30, two dimensions were identified: a 
‘mood/cognition’ factor representing affective and cognitive symptoms (IDSm), and an 
‘anxiety/arousal’ factor indicating arousal and somatic complaints (IDSa) (Wardenaar et al., 
2010). In addition, items in the IDS-SR30 associated with ‘atypical’ and ‘melancholic’ 
depression have been used for the clinical subtyping of these two subtypes of depression (Gili 
et al., 2012). This item analysis was used to categorise volunteers into atypical or melancholic 
depression.  
The Spielberger State-Trait Anxiety Inventory (STAI): The STAI is a self-report tool for 
assessing anxiety consisting of two subscales (state and trait anxiety) each containing 20 items 
(Spielberger, 1983). The STAI is among the most widely researched and commonly used 
measures of general anxiety and has good reliability and validity (Metzger, 1976; Okun et al., 
1996). The STAI was considered an appropriate measure given its strong correlation with 
measures of depression (Kennedy et al., 2001). 
Statistical analysis 
Treatment condition on mood measures 
Two successive analyses were conducted. The first compared curcumin versus placebo 
groups. Second, as an exploratory analysis, volunteers with atypical depression were 
compared across treatment groups (curcumin versus placebo). Analysis of volunteers with 
melancholic depression could not be completed due to limited numbers (n = 3). 
Independent samples t-tests were used to compare demographic variables across the 
treatment groups for continuous variables, and Pearson Chi-squared tests (or Fisher exact test 
for low cell counts) were used to compare categorical data. Individual mood measures (IDS-
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SR30, STAI, and relevant sub-scores) were assessed for differences between baseline, mid-point 
(week 4) and end-point (week 8) by a mixed repeated-measures analysis of variance 
(ANOVA).  
Analyses for time (baseline, midpoint and post-treatment) within each treatment condition, 
and treatment (curcumin and placebo) x time (baseline, midpoint and post-treatment) effects 
were conducted. Planned contrasts were also conducted to compare mood changes at 
differing time points (i.e., baseline to week 4; week 4 to week 8). There were no significant 
outliers in data as assessed by the visual inspection of Q-Q plots, although questionnaire data 
was not normalised. The repeated measures ANOVA was considered appropriate for 
statistical analyses as it is relatively robust to violations of normality when group sample sizes 
are equivalent (Tabachnick and Fidell, 2007).  Data from all participants were included in 
analyses (intention to treat, with multiple imputation for missing values). 
For all the tests, statistical significance was set at P< 0.05 (two-tailed). All data were 
analysed using SPSS (version 21; IBM, Armonk, NY). 
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Results 
Study Population 
 
Figure 1: Systematic illustration of study design 
Baseline questionnaire and demographic information 
Seventy-seven people were screened for participation in the study and 56 met inclusion/ 
exclusion criteria and were enrolled to participate. Twenty-eight people were randomised into 
the placebo group and 28 into the treatment (curcumin) group. Fifty-two participants 
completed up to week 8. There were 4 drop-outs, one from the placebo group and three from 
the curcumin group, with no significant difference between the dropout rate in each group. 
Reasons for withdrawal included an unexpected visit overseas for family purposes (1 in the 
curcumin group), flare up of digestive complaints (1 in the curcumin group), and inconsistent 
intake of allocated capsules (1 each in the curcumin and placebo group). As shown in Tables 1 
and 2, there were no significant differences between the two groups for any baseline mood 
questionnaire scores or demographic variables, except for distribution of medical illnesses, 
with greater reported medical illnesses in the placebo (n=15) versus curcumin (n=5) group (Χ2 
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(1) = 7.78, p- = .011). Medical illness was therefore included as a covariate in the repeated 
measures ANOVA analyses. 
Table 1. Demographic characteristics of curcumin and placebo 
participants. 
 
Placebo Curcumin 
p-value 
n=28 n=28 
Age, years mean (SD) 48.54 (11.73) 44.04 (11.94) 0.16† 
BMI (kg/m2)mean (SD) 27.06 (4.76) 26.12 (5.48) 0.51† 
Sex n 
Female 20 20 
1.00# 
Male 8 8 
Marital Status n 
Single 7 11 
.551# 
Married 12 11 
De facto* 5 4 
Divorced 2 2 
Widowed 2 0 
Educational Status n 
Secondary 6 9 
.658# Tertiary 17 15 
Post-graduate 5 4 
General Health n 
Great 9 7 
.194# Average 19 18 
Poor 0 3 
Medical Illness n 
Yes 15 5 
.011# 
No 13 23 
Antidepressant Medication n 
Yes 9 10 
1.00# 
No 19 18 
Antidepressant class n 
SSRI 7 6 
.628# 
SNRI 2 4 
Depression episodes n 
Single episode 11 7 
.391# 
Recurrent episodes 17 21 
Exercise Frequency n 
Never/Rarely 6 4 
.421# 
1-2 times week 9 10 
3-5 times week 11 14 
6+ times week 2 0 
Injuries causing regular pain  n 
Yes 14 10 
.418# 
No 14 18 
*Domestic partner outside marriage 
†Independent samples T-test; #Chi-square Test 
SSRI= selective serotonin reuptake inhibitor; SNRI= selective serotonin-
norepinephrine reuptake inhibitor 
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Table 2. Baseline questionnaire scores between curcumin and 
placebo participants. 
 
Placebo n=28 Curcumin n=28 
p-value† 
mean (SD) mean (SD) 
STAI state 50.25 (13.02) 52.00 (13.17) 0.62 
STAI trait 55.89 (13.24) 56.29 (8.30) 0.90 
IDS 33.14 (9.39) 33.04 (9.39) 0.97 
IDS mood 14.64 (5.67) 13.93 (5.37) 0.63 
IDS arousal 6.68 (2.79) 6.82 (2.40) 0.84 
†Independent samples T-test 
Data are shown as mean (SD) 
 
Exploratory analyses were conducted on 18 participants identified as suffering from 
atypical depression (placebo, n =8; curcumin, n=10). There were no significant differences 
between the two treatment groups for any baseline mood questionnaires. Demographic 
characteristics were also similar across treatment groups, except for differences in mean age 
(placebo, 𝑥 = 50.75; curcumin, 𝑥 = 40.80). The difference, 9.95, 95% CI [0.81, 19.09] was 
significant (t(16) = 2.31, p = .035). Age was therefore included as a covariate in repeated 
measures ANOVA analyses on the atypical depression sample.  
Outcome Measures 
Treatment effects on mood measures 
IDS – Depression measures 
Changes in IDS scores across both treatment groups and repeated measures ANOVA 
significance values are listed in Table 3. There was a significant reduction in all IDS scores 
across both groups for time although there were no significant group x time interactions for 
any IDS measure across the full 8 weeks of treatment. However, contrasts revealed a 
significant group x time interaction from week 4 to week 8 for IDSm (F1,53 = 6.51, p = .014) and 
IDS total (F1,53 = 4.22, p = .045).  
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Further ANOVA analyses revealed that from baseline to week 4 there were significant 
changes in all IDS scores, in both the curcumin and placebo group. However, there were no 
significant changes in any IDS scores from week 4 to week 8 in the placebo group. In the 
curcumin group, there were significant changes in IDS total (F1,27 = 5.50, p = .026), and IDSm 
(F1,27 = 6.07, p = .020) over this time. This indicates that in the placebo group, all improvements 
in IDS depressive scores occurred in the first 4 weeks of treatment, while improvements 
continued in the curcumin condition. 
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Table 3. Changes in questionnaire scores over time. 
 
Treatment Baseline Week 4 Week 8 
Treatment x Time effect (p-value) 
  Baseline-week 4 week 4- week 8 Baseline - week 8 
STAI- State, mean (SD) 
Placebo (n=28) 50.25 (13.02) 43.14b (13.30) 43.21f (12.94) 
.687 .255 .595 
Curcumin (n=28) 52.00 (13.17) 45.89b (12.65) 42.29d,g (12.21) 
STAI- Trait, mean (SD) 
Placebo (n=28) 55.89 (13.25) 49.82b (12.79) 50.21f (9.41) 
.516 .097 .358 
Curcumin (n=28) 56.29 (8.30) 50.75c (9.46) 47.96d,f (11.32) 
IDS - Total, mean (SD) 
Placebo (n=28) 33.14 (11.88) 25.82c (14.55) 25.89f (13.43) 
.313 .045* .189 
Curcumin (n=28) 33.04 (9.39) 26.61c (11.87) 22.71d,f (9.36) 
IDS- Mood, mean (SD) 
Placebo (n=28) 14.64 (5.67) 10.50c (6.88) 11.00f (6.60) 
.496 .014* .192 
Curcumin (n=28) 13.93 (5.37) 11.00c (5.34) 9.25d,f (4.42) 
IDS- Arousal, mean (SD) 
Placebo (n=28) 6.68 (2.79) 5.64c (3.37) 5.25e (3.12) 
.282 .312 .489 
Curcumin (n=28) 6.82 (2.40) 5.57c (3.18) 4.71f (2.81) 
Medical illness included as covariate 
ap < . 05; bp < . 01; cp < . 001 - within group significant time effects from baseline to week 4 
dp < . 05 - within group significant time effects from week 4 to week 8 
ep < . 01; fp < . 001 - within group significant time effects from baseline to week 8 
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STAI – Anxiety measures 
Changes in STAI scores across both treatment groups and repeated measures ANOVA 
significance values are listed in Table 3. There were significant reductions in STAIs and STAIt 
scores across both groups for time (p<0.001; for all scores across time). There were no 
significant group x time interactions for either STAIs or STAIt across the full 8 weeks of 
treatment.  
Further ANOVA analyses revealed that from baseline to week 4 there were significant 
changes in both STAIs and STAIt scores, in both the curcumin and placebo group. However, 
from week 4 to week 8, in the placebo group, there were no significant changes in either score. 
In the curcumin group, there was a significant change in STAIt (F1,27 = 4.36, p = .046), and non-
significant trend for STAIs (F1,27 = 3.64, p = .067) over this time. This indicates that in the 
placebo group, improvements in STAI anxiety scores occurred in the first 4 weeks of 
treatment, while improvements continued in the curcumin condition. 
Atypical Depression Sub-group 
IDS – Depression measures 
There was a significant reduction in most IDS scores across both groups for time. In the 
placebo group, there were significant time effects for IDS total (p<0.05), IDSm (p<0.05), but not 
IDSa (p>0.05). In the curcumin group, there were significant time effects for IDS total (p<0.01), 
IDSm (p<0.001), and IDSa (p<0.01). There were no significant group x time interactions in any 
IDS measure across the full 8 weeks of treatment (IDSm, F2,32 = 2.40, p = .110; IDSa F2,32 = 0.62, p 
= .670) although there was a non-significant trend for IDS total (F2,32 = 2.73, p = .088). Contrasts 
revealed a significant group x time interaction from week 4 to week 8 for IDS total (F1,16 = 7.78, 
p = .013) and IDSm (F1,16 = 10.61, p = .006). 
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In Figure 2, changes in IDS scores are detailed for each treatment condition. Further 
ANOVA analyses revealed that from baseline to week 4 there were significant changes in IDS 
total (F1,7 = 6.13, p = .043) in the placebo group. In the curcumin group there were significant 
changes in IDS total (F1,9 = 8.74, p = .016), IDSm (F1,9 = 10.30, p = .011) and IDSa (F1,9 = 9.11, p = 
.015) over this time period. From week 4 to week 8, there were no further significant changes 
in any IDS score in the placebo group. However, in the curcumin group there were significant 
changes in IDS total (F1,9 = 8.62, p = .017), IDSm (F1,9 = 9.86, p = .012), and IDSa (F1,9 = 6.42, p = 
.032) scores over this time. This indicates that in the placebo group, all improvements in IDS 
depressive scores occurred in the first 4 weeks of treatment, while improvements continued in 
the curcumin condition. 
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Figure 2. Atypical depression - Change in mood scores over time (± 1 Std. error) across curcumin 
and placebo groups. * (p<.05); **(p<.01) indicates significant group x time interaction for specified 
period 
 
STAI – Anxiety measures 
There were significant reductions in STAIs and STAIt scores across both groups for time 
(p<0.001; for all scores across time). There was no significant group x time interactions for 
36
39
42
45
48
51
54
57
Baseline Week 4 Week 8
ST
A
Is
  S
co
re
Placebo Curcumin
42
45
48
51
54
57
60
63
66
Baseline Week 4 Week 8
ST
A
It
  S
co
re
*
16
19
22
25
28
31
34
37
40
43
Baseline Week 4 Week 8
ID
S 
to
ta
l  
Sc
o
re
7
9
11
13
15
17
19
Baseline Week 4 Week 8
ID
Sm
  S
co
re
3
4
5
6
7
8
9
10
Baseline Week 4 Week 8
ID
Sa
  S
co
re
* ** 
Chapter 5: An examination of curcumin for the treatment of major depression 
Published Paper 
- 175 - 
either STAIs across the full 8 weeks of treatment. However, contrasts revealed a significant 
group x time interaction from week 4 to week 8 for STAIt (F1,15 = 6.00, p = .027). In Figure 2, 
changes in STAI scores are detailed for each treatment condition. Further ANOVA analyses 
revealed that from baseline to week 4 there were significant changes in STAIt scores, in the 
curcumin group only (F1,9 = 11.62, p = .008). Continued significant changes in STAIt occurred 
from weeks 4 to 8 in the curcumin group only (F1,9 = 7.24, p = .025).  
Adverse events 
Details of adverse events reported by participants are included in Table 4. All reported 
adverse events were of minor severity and only one participant in the curcumin intervention 
withdrew from the study as a result of reported side effects. This participant experienced an 
exacerbation of pre-existing digestive complaints (stomach bloating and pain). There were no 
significant differences between reported adverse events between placebo and curcumin 
groups. 
Table 4: List and frequency of adverse events reported by participants. 
CURCUMIN PLACEBO 
Frequency Reported complaints Frequency Reported complaints 
16 No adverse events 14 No adverse events 
7 
Digestive: stomach bloating, 
nausea, mild diarrhoea 
6 
Digestive: appetite change, 
bloating, mild diarrhoea 
0 Respiratory: none 1 
Respiratory: breathing 
problems 
3 
Dermatological: dry skin, 
flaking skin 
2 
Dermatological: dry skin, 
flaking skin, itchy skin 
2 
Neurological: headaches, 
dizziness 
2 
Neurological: memory 
slower, tingling in hands 
2 Pain: joint pain, back pain 4 
Pain: joint pain, back pain, 
neck pain 
2 
Cardiovascular: racing heart, 
chest pain 
0 Cardiovascular: none 
3 
Visual: sore eyes, dry eyes, 
blurry vision 
0 Visual: none 
1 Auditory: ringing in ears 2 Auditory: ringing in ears 
2 Oral: dry mouth, sore gums 2 
Oral: dry mouth, mouth 
ulcers 
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Discussion 
The results of this study provide partial support for the antidepressant and anxiolytic 
effects of curcumin in people suffering from major depressive disorder. While curcumin and 
placebo were equally effective in reducing depressive and anxiety symptoms in the first four 
weeks of treatment, curcumin was significantly more effective than placebo in lowering self-
reported depressive and anxiety symptoms from weeks 4 to 8. When examining the effects of 
curcumin in people with atypical depression, curcumin had even greater antidepressant and 
anti-anxiety efficacy compared to placebo. Again, equivalent improvements in mood occurred 
from baseline to week 4 in both placebo and curcumin-treated individuals. However, from 
weeks 4 to 8, curcumin was significantly more effective in lowering total depressive 
symptoms (total IDS score), mood/cognitive depressive symptoms (IDSm), arousal-related 
symptoms (IDSa) and trait anxiety (STAIt). 
While greater antidepressant effects of curcumin compared to placebo were observed from 
weeks 4 to 8, when evaluating the whole treatment period (i.e., baseline to week 8), curcumin 
was not found to be significantly more effective than placebo in reducing depressive and 
anxiety symptoms. Several explanations could account for this overall non-significant 
treatment effect: (1) it may be that curcumin lacks a true antidepressant effect in people with 
major depressive disorders, at least at the dose prescribed (i.e., 500mg twice daily). However, 
this argument is countered by significant and near significant changes in several mood 
measures in the second half of treatment; (2) it is a reflection of the placebo response, typical in 
placebo-controlled trials. From a statistical point of view, when performing the analyses on 
the whole treatment period, the positive placebo response in the first month of treatment 
masked the positive gains from curcumin over the second study period (weeks 4 to 8).  
Placebo responses in depression trials are common and it has been suggested that true drug 
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responses are characterised by a 2-week delay, with continued improvement thereafter, 
whereas placebo effects are characterised by abrupt, transient improvements (Rothschild and 
Quitkin, 1992).  Although assessments were not completed until week 4, this study confirms a 
similar pattern of change – that is, in placebo-treated individuals, a response in the first 
month, followed by no change, or even worsening of symptoms thereafter. In contrast, 
curcumin-treated individuals continued to experience improvements over the course of the 
study; (3) the antidepressant effects of curcumin may not begin until after 4 weeks of intake, 
reflecting a slow acting, possibly longer term treatment for depression. It is feasible that 
specific mechanistic changes need to be set in motion and maintained for a period of time 
before mood changes prevail. The high portion of recurrent depressed sufferers enrolled in the 
study (approx. 70 percent) may also contribute to curcumin’s slow action in this trial. These 
possibilities require exploration through follow-up studies with larger sample sizes, and 
extended treatment periods. 
The antidepressant effects of curcumin in people with major depressive disorder have now 
been investigated in two additional randomised clinical trials. As an add-on to newly 
commenced antidepressant medication (escitalopram or venlafaxine XR), curcumin, at a dose 
of 500 mg/day, did not enhance treatment efficacy compared to a placebo (Bergman et al., 
2013). In this double-blind, placebo controlled, 5-week trial, there were significant 
improvements in depressive symptoms over time in both treatment groups. In the second 
study, Sanmukhani et al. (2014) compared the antidepressant effects of curcumin alone (500 
mg twice daily), fluoxetine alone (20 mg/day) or curcumin plus fluoxetine (500 mg twice daily 
and 20 mg/day, respectively) in people suffering from major depressive disorder. In this 
randomised, single-blinded (researcher masked), 6-week trial, all three treatment conditions 
were associated with significant improvements in depressive symptoms. Group comparisons 
revealed comparable treatment efficacy across the three conditions. Weaknesses associated 
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with this study include the lack of placebo control, and non-masking of participants from the 
treatment conditions. 
The current study therefore adds to the aforementioned ones as the length of treatment was 
extended to 8 weeks, double-blind placebo controlled conditions were included, and curcumin 
was used a standalone treatment or was used in patients undergoing pre-existing, stabilised 
antidepressant or psychological therapies. Exploratory analyses on people with atypical 
depression were also conducted, and several questionnaires were used to assess depressive, 
anxiety and general health changes. Further support for the antidepressant effects of curcumin 
is provided by consistent findings of protective behavioural effects in animal models of 
depression and chronic mild stress (Jiang et al., 2013; Sanmukhani et al., 2011; Zhang et al., 
2014). 
An important finding from this study is the enhanced antidepressant and anxiolytic 
efficacy of curcumin in people with atypical depression. According to DSM-IV criteria, 
atypical depression is characterised by mood reactivity to actual or potential positive events, 
and two or more of the following features; significant weight gain or increased appetite, 
hypersomnia, leaden paralysis, and a long-standing pattern of interpersonal rejection 
sensitivity (American Psychiatric Association, 2000). Compared to healthy individuals, and 
people with melancholic or non-atypical depression, atypical depression is often associated 
with higher levels of inflammatory markers such as C-reactive protein (CRP) (Hickman et al., 
2013; Lamers et al., 2013), IL-6 and tumour necrosis factor-α (TNF-α) (Lamers et al., 2013). Due 
to the anti-inflammatory effects of curcumin, it is this immuno-inflammatory dysregulation 
that may account for the increased efficacy of curcumin in people with atypical depression. In 
a recent meta-analysis on clinical trials it was concluded that curcumin lowers CRP levels 
(Sahebkar, 2014). It can also lower IL-6 (Belcaro et al., 2010; Zhou et al., 2011) and TNF-α levels 
(Aggarwal et al., 2013).  
Chapter 5: An examination of curcumin for the treatment of major depression 
Published Paper 
- 179 - 
Limitations and Directions for Future Research 
The relatively small samples size used in this study limits the reliability and statistical 
power associated with the findings. For evaluation of curcumin’s antidepressant effects, data 
from approximately 50 participants was obtained. Sample sizes were even lower when 
evaluating the effects of curcumin on people with atypical depression. The results from this 
study therefore require replication with larger sample sizes. 
In this study, a high proportion (approx. 70%) of participants reported a history of multiple 
depressive episodes, thereby reflecting a sample with high chronicity of depression and likely 
treatment resistance. Comparative evaluations of the efficacy of curcumin with single- and 
recurrent-episode depressives would be useful, along with an examination of the influence of 
differing treatment periods and curcumin dosages.  
Investigations into the antidepressant effects of curcumin would also be strengthened by 
studies controlling for important covariates such as medication use, psychological therapies, 
medical illnesses and BMI. While this 8-week study now represents the longest investigation 
into effects of curcumin on depression, future investigations with longer follow up periods are 
certainly warranted. Because the effects of curcumin were not recognised until after week 4, 
longer treatment duration will be necessary to determine if mood improvements maintain or 
increase over time.  
Self-report instruments were used to monitor changes in mood. While this provides a valid 
index of clinical progress, the implementation of additional measures, such as reliable and 
valid clinician-rated instruments, will provide a more robust evaluation of the clinical 
effectiveness of curcumin. 
Other areas of interest include investigations into the optimal curcumin dose for best 
antidepressant effects and the frequency of intake. In two studies a dose of 500 mg twice daily 
has been used, and in the other 500 mg once daily was used. Because of problems with 
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bioavailability of curcumin, doses greater than these may be necessary to achieve optimal 
treatment efficacy. Increasing intake to 3 times a day may also be necessary to combat 
problems associated with the short half-life of curcumin (Anand et al., 2007). 
 
In conclusion, the present findings provide partial support for the antidepressant effects of 
curcumin in people with major depressive disorder, and particularly atypical depression. 
However, replication with larger clinical trials, using variable doses, and conducted over an 
extended treatment period is required. 
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Chapter 6:  
The potential utility of peripheral biomarkers 
in major depression: its application in 
curcumin treatment 
As reviewed in Chapter 4, while pharmaceutical and psychological treatments may 
influence several dysregulated biological pathways associated with depression, pre-treatment 
disturbances in these pathways can also be adversely associated with treatment resistance. In 
particular, certain levels of immuno-inflammatory and HPA biomarkers have been linked 
with treatment resistance to pharmaceutical and psychological therapies. Therefore, the use of 
biomarkers has the potential to predict treatment response, facilitate treatment matching, and 
thereby enhance treatment efficacy. Findings from studies examining peripheral markers 
associated with immuno-inflammation and oxidative stress in major depression are reviewed 
in the following published paper. 
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Abstract 
Biomarkers are regularly used in medicine to provide objective indicators of normal 
biological processes, pathogenic processes or pharmacological responses to therapeutic 
interventions, and have proved invaluable in expanding our understanding and treatment of 
medical diseases. In the field of psychiatry, assessment and treatment has, however, primarily 
relied on patient interviews and questionnaires for diagnostic and treatment purposes. 
Biomarkers in psychiatry present a promising addition to advance the diagnosis, treatment 
and prevention of psychiatric diseases. This review provides a summary on the potential of 
peripheral biomarkers in major depression with a specific emphasis on those related to 
inflammatory/immune and oxidative stress/antioxidant defences. The complexities associated 
with biomarker assessment are reviewed specifically around their collection, analysis and 
interpretation. Focus is placed on the potential of peripheral biomarkers to aid diagnosis, 
predict treatment response, enhance treatment-matching, and prevent the onset or relapse of 
major depression.  
 
Abbreviations: 8-OHdG, 8-hydroxy-2-deoxyguanosine; 8-oxoGuo, 8-oxo-7,8-dihydroguanosine; BDNF, brain-
derived neurotropic factor; BMI, body mass index; COX, cyclooxygenase; CRP, C-reactive protein; DSM, 
Diagnostic and Statistical Manual of Mental Disorders; ECT, electroconvulsive therapy; ESR, erythrocytes 
sedimentation rate; F2-isoPM, 2,3-dinor-5,6-dihydro-15-F2t-isoprostane; GPx, glutathione peroxidase; GTP-
CH1, GTP cyclohydrolase I; hs-CRP, high sensitivity CRP; IDO, indoleamine 2,3 dioxygenase; IFN, interferon; 
IL, interleukin; IL-2R, interleukin-2 receptor; KYN, kynurenine; KYNA, kynurenic acid; MDA, 
malondialdehyde; RA, rheumatoid arthritis; RBC, red blood cell; RNA, ribonucleoside; SOD, superoxide 
dismutase; SSRI, serotonin reuptake inhibitor; TNF, tumour necrosis factor; TRP, tryptophan; TRYCATs, 
tryptophan catabolites along the IDO pathway.  
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Introduction 
Currently the diagnosis of major depression is carried out through a combination of patient 
interviews, checklists and self-report questionnaires. These generally rely on a list of 
symptoms derived from the Diagnostic and Statistical Manual of Mental Disorders (4th ed.; 
DSM-IV) and now more recently, its revised 5th edition, DSM-5. Unfortunately, there is debate 
about the value and objectivity of this symptom-based assessment process (Hilsenroth, Baity, 
Mooney, & Meyer, 2004; Phillips et al., 2012; Stein et al., 2010) particularly around limitations 
associated with the development of personalised treatment plans.  
Biomarkers are indicators of normal biological processes, pathogenic processes or 
pharmacological responses to a therapeutic intervention that can be measured and evaluated 
objectively (Biomarkers Definitions Working Group, 2001). They have the potential to 
overcome some of the issues associated with symptom-based assessments. In medical and 
pharmaceutical practice, biomarkers are regularly used to support the presence or absence of 
specific diseases (diagnostic biomarkers), predict optimal treatment options (treatment 
biomarkers), measure treatment progress (treatment-response biomarkers), and predict the 
onset of future disease (predictive biomarkers) (Boksa, 2013; Kluge, Alsaif, Guest, Schwarz, & 
Bahn, 2011; Schmidt, Shelton, & Duman, 2011). Unfortunately, progress in biomarker research 
on depression is hindered by the considerable heterogeneity associated with this disorder. 
While major depression comprises changes in sleep, appetite, weight, and psychomotor 
behaviour, these can involve both increases and decreases in symptoms. Complaints about the 
most debilitating depressive symptom or constellation of symptoms can also vary 
considerably across individuals. These include variations in the severity of fatigue, 
worthlessness, suicidal ideation, and effects on memory and concentration. Further 
complications include the high comorbidity between depression and other medical and 
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psychiatric conditions (Voinov, Richie, & Bailey, 2013), and factors associated with unique 
differences across gender, age, lifestyle and other mediating or triggering factors. 
In this paper, many of the most commonly researched biomarkers in major depression are 
reviewed. Only peripheral biomarkers have been selected for review given their suitability 
and ease of collection in clinical practice. Furthermore, only biomarkers associated with 
inflammation/ immune response and oxidative stress/antioxidant defences have been selected 
for review as this is an area gaining momentum in depression research (Leonard & Maes, 
2012; Maes, Leonard, et al., 2011; Raison & Miller, 2011). 
Common oxidative and inflammatory biomarkers 
measured in depression studies 
Several commonly-researched peripheral biomarkers in major depression are listed in 
Table 1, and pathways associated with their production are detailed in Figure 2. A brief 
description of each marker is provided, and they are categorised into inflammatory/immune 
response biomarkers and oxidative stress/antioxidant defence biomarkers. However, these 
markers are not mutually exclusive as they can greatly influence the production of other 
important biomarkers. 
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Figure 1. Pathways associated with oxidative stress and inflammatory biomarkers in major depression. 
Elevated pro-inflammatory cytokines (e.g, IL-6, TNF-α, and IFN-γ) upregulate the production of 
enzymes indoleamine 2,3 dioxygenase (IDO) and GTP cyclohydrolase I (GTP-CH1), leading to 
increased production of TRYCATs and neopterin, respectively. ESR and CRP are also markers of 
inflammation. Oxidative stress is influenced by antioxidant defence systems including the 
antioxidant enzymes SOD and GPx. Elevated oxidative stress may lead to a greater production of 
OHdG, MDA and isoprostanes. A bidirectional relationship exists between inflammation and 
oxidative stress, up- or down-regulating each other’s production. 
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Table 1. Common peripheral biomarkers measured in studies on major depression 
Inflammation and immune response peripheral biomarkers 
C-reactive protein 
(CRP) 
An acute-phase protein found in the blood that rises in response to inflammation. 
Cytokines Immuno-modulating proteins, peptides, or glycoproteins (e.g., interleukins and 
interferons) secreted by specific cells of the immune system, which carry signals 
locally between cells, and have an effect on target cells. Cytokines are generally 
classified by their ability to promote or inhibit inflammatory responses and the 
type of T-lymphocytes with which they are associated (termed Th1, Th2, and 
Th17). 
Neopterin Released by macrophages and considered a marker of cell-mediated inflammation 
activation. 
Erythrocyte 
sedimentation rate 
(ESR) 
A non-specific index of inflammation which measures the rate at which red blood 
cells sediment in a period of one hour.  
TRYCATs 
(tryptophan 
catabolites along the 
IDO pathway) 
Production of TRYCATs such as kynurenine, kynurenic acid, xanthurenic acid, and 
quinolinic acid, may be increased following immune activation. An immune 
response induces indoleamine-(2,3)-dioxygenase (IDO), an enzyme which degrades 
tryptophan down the TRYCAT pathway, summarised in Figure 1. 
Oxidative stress and antioxidant defence peripheral biomarkers 
Malondialdehyde 
(MDA) 
Product of chemical damage caused by oxygen free radicals to the lipid component 
of cell membranes. 
8-hydroxy-2-
deoxyguanosine  
(8-OHdG) 
A repair product of the oxidation of guanine in DNA, can be used to estimate the 
rate of oxidative DNA damage.  
Isoprostanes Prostaglandin-like compounds produced by non-enzymatic peroxidation of 
arachidonic acid.  
Superoxide 
dismutases (SOD) 
Important antioxidant defence in nearly all cells exposed to oxygen. Enzymes that 
catalyse the dismutation of superoxide into oxygen and hydrogen peroxide.  
Glutathione 
peroxidase (GPx) 
Enzyme that catalyses the reduction of hydroxyperoxides by glutathione. Main 
function is to protect against the damaging effect of endogenously formed 
hydroxyperoxides. 
Glutathione reductase Important cellular antioxidant enzyme that reduces glutathione disulfide (GSSG) to 
the sulfhydryl form glutathione. 
Reduced glutathione Measure of glutathione status. 
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A summary of potential diagnostic biomarkers in 
depression 
Biomarkers may be used to assist clinical diagnosis. From a diagnostic perspective, their 
value is largely dependent on their ability to identify the presence (sensitivity) or absence 
(specificity) of disease. While these biomarkers are reviewed individually, it is likely that a 
combination of biomarkers will be required to increase sensitivity and specificity rates to 
levels required for diagnostic purposes (Schmidt, et al., 2011). 
Inflammation and immune response biomarkers 
C-reactive protein (CRP) – findings from meta-analyses have confirmed that major 
depression is associated with increased CRP levels (Howren, Lamkin, & Suls, 2009; 
Valkanova, Ebmeier, & Allan, 2013). In a recent meta-analysis on longitudinal studies by 
Valkanova et al. (2013) it was also established that raised CRP levels were associated with an 
increased risk of subsequent depression. However, these findings are not uniform and in 
subgroup analyses, elevated CRP was associated with atypical depression (Hickman, 
Khambaty, & Stewart, 2013), somatic symptoms (Duivis, Vogelzangs, Kupper, de Jonge, & 
Penninx, 2013), depressed men with an older age of depression onset (Vogelzangs et al., 2012), 
depressed men in general (Elovainio et al., 2009; Ford & Erlinger, 2004; Liukkonen et al., 2011), 
depressed patients with a greater history of childhood adversity (Miller & Cole, 2012), and 
cumulative depressive episodes (Copeland, Shanahan, Worthman, Angold, & Costello, 2012).  
High sensitivity CRP (hs-CRP) assays are a more sensitive measure of inflammation, 
having a range of measurement that extends below that typical of most conventional CRP 
assays. Investigations into the link between hs-CRP and depression are continuing, and on the 
whole provide further support for their relationship (Luukinen, Jokelainen, & Hedberg, 2010; 
Ma et al., 2010; Pasco et al., 2010). 
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Cytokines - along with research on CRP levels, cytokine profiles in patients with major 
depression are the most commonly measured immune biomarkers. In recent meta-analyses, 
disturbed cytokine profiles have been confirmed in patients with major depression. 
Significantly higher concentrations of tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-
6) were identified in a meta-analysis by Dowlati et al. (2010); and in a meta-analysis on 
community and clinical populations, elevated IL-1 and IL-6 were positively associated with 
depression (Howren, et al., 2009). Greater elevations in IL-6 were found in subgroups where 
depressive disorders were formally diagnosed, as opposed to a diagnosis made using 
standardised inventories. Populations obtained from inpatient and outpatient settings also 
had higher IL-6 levels compared to the general community (Hiles, Baker, de Malmanche, & 
Attia, 2012b). In a meta-analysis by Liu et al. (2012), elevated blood levels of soluble 
interleukin-2 receptor (sIL-2R), TNF-α and IL-6 in patients with depression were 
demonstrated, although effect sizes were significantly influenced by the composition of the 
blood sample. Specifically, differences in sIL-2R and IL-6 were significant both in plasma and 
serum, whereas TNF-α was significantly different from healthy controls only when it was 
measured via serum. Finally, in a systematic review and meta-analysis on longitudinal 
studies, IL-6 was associated with depressive symptoms, although after considering only 
correlations adjusted for confounding variables such as smoking, alcohol consumption, body-
mass index, cholesterol level, physical activity, medication use or chronic illness, the 
relationship became statistically non-significant (Valkanova, et al., 2013).  
Neopterin – levels of plasma neopterin are increased in depressed patients (Celik et al., 
2010; Maes et al., 2013; Maes et al., 1994; Maes, Twisk, & Ringel, 2012; Rybka et al., 2013) and 
particularly in patients suffering from melancholic symptoms (Maes, Mihaylova, Kubera, & 
Ringel, 2012; Maes, et al., 1994). Greater concentrations of neopterin were also reported in 
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patients suffering from two or more episodes of depression compared to first-episode 
populations (Celik, et al., 2010). Nevertheless, differences in concentrations of neopterin 
between depressed and healthy samples have not been identified in some studies (Hoekstra et 
al., 2001; O'Toole, Chiappelli, & Rubin, 1998).  
Erythrocyte sedimentation rate (ESR) – higher ESR was identified in depressed patients 
compared to healthy volunteers (Chavda, Kantharia, & Jaykaran, 2011), and in depressed 
smokers compared to non-depressed, never smokers (Vargas et al., 2013). ESR was also 
elevated in rheumatoid arthritis (RA) patients suffering from depression compared to non-
depressed RA sufferers (Abdel-Nasser et al., 1998).  
TRYCATs – The TRYCATs pathway is shown in Figure 2, and a summary of studies 
examining the relationship between depression and various TRYCAT analytes is provided in 
Table 2. In general, depression is associated with lowered tryptophan (TRP), increased 
indoleamine-2,3-dioxygenase (IDO) activity and reduced levels of the neuroprotective 
TRYCAT, kynurenic acid (KYNA). However, this is not uniform (Gabbay et al., 2010; Maes, 
Galecki, Verkerk, & Rief, 2011; Maes & Rief, 2012), indicating that increased TRYCAT activity 
may be related to specific subtypes of depression or depressive symptoms. IDO activity is 
increased in patients suffering from somatisation (Maes, Galecki, et al., 2011; Maes & Rief, 
2012), depressed patients with a history of suicide attempts (Sublette et al., 2011) and 
adolescents with depression and melancholic symptoms (Gabbay, et al., 2010).  
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Figure 2. TRYCATs pathway. The TRYCATs pathway starts with the degradation of tryptophan 
by the enzyme, indoleamine 2,3-dioxygenase (IDO) which is upregulated by pro-inflammatory 
cytokines (e.g. IFN-γ, TNF-α, IL-, IL-6). These TRYCATS have neuroprotective and neurotoxic 
effects on the CNS and influence monoaminergic transmission. 
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Table 2. Summary of TRYCAT depression studies. Elevated KYN and KYN/TRP indicates greater IDO activity. Elevated KYNA and KYNA/KYN ratio 
indicates greater neuroprotection. 
Population Sample used Tryptophan 
IDO activity Neuroprotection  
KYN KYN/TRP Ratio KYNA KYNA/KYN ratio Reference 
Healthy pregnant 
women  
Morning plasma 
after overnight 
fast 
No correlation with 
depression or anxiety 
postpartum 
Positively correlated 
with depression and 
anxiety postpartum 
Positively 
correlated with 
depression and 
anxiety postpartum 
  Maes et al. (2002) 
Depressed patients; 
healthy controls 
Morning plasma 
after overnight 
fast 
No difference between 
depressed and controls 
No difference  in depressed than 
controls 
 in depressed 
than controls 
 in depressed 
than controls 
Myint et al. (2007) 
 
Women high risk for 
postpartum 
depression 
Serum; time of 
collection not 
specified 
Negatively correlated 
with total depression 
score in the prepartum 
period, but not in other 
time periods. 
Not correlated with 
depressive symptoms 
over time 
Not correlated with 
depressive 
symptoms over 
time 
  Scrandis et al. 
(2008) 
Patients with 
coronary artery 
disease 
Morning plasma 
after overnight 
fast 
No correlation with 
depression scores 
 Positively 
correlated with 
depression scores 
  Swardfager et al. 
(2009) 
Depressed 
adolescents with 
melancholic features; 
non-melancholic 
depressed 
adolescents; healthy 
controls 
Morning plasma 
after overnight 
fast 
 in melancholic than 
controls and non-
melancholic. 
No difference 
between all groups 
 in melancholic 
than controls and 
non-melancholic 
  Gabbay et al. 
(2010) 
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Population Sample used Tryptophan 
IDO activity Neuroprotection  
KYN KYN/TRP Ratio KYNA KYNA/KYN ratio Reference 
Normal controls 
(NC); patients with 
somatization (SOM); 
patients with 
depression (DEP); 
patients with 
comorbid 
somatization and 
depression 
(SOM+DEP) 
Morning plasma 
after overnight 
fast 
 SOM compared to 
SOM+MDD, MDD and 
HC; No difference 
between SOM+MDD 
and MDD;  
SOM+MDD and 
MDD than HC. 
 SOM and 
SOM+DEP than NC. 
 SOM than 
SOM+MDD and 
NC; no difference 
between SOM and 
MDD or MDD 
versus NC. 
 SOM and 
SOM+MDD 
than MDD and 
NC;  MDD to 
NC. 
 SOM than 
MDD and NC;  
SOM+MDD than 
MDD and NC; no 
difference 
between MDD 
and NC. 
Maes et al. (2011) 
Depressed patients; 
healthy volunteers 
Plasma; Time of 
collection not 
specified 
 in suicide attempters 
than non-attempters; 
No difference between 
depressed and controls 
No difference 
between depressed 
and controls;  in 
suicide attempters 
than non-attempters 
 in depressed than 
controls 
  Sublette et al. 
(2011) 
Depressed patients; 
healthy controls 
Plasma collected 
in early 
afternoon 
 in depressed than 
controls 
No difference 
between groups 
 in depressed than 
controls 
No difference 
between groups 
 in depressed 
than controls 
Hughes et al. 
(2012) 
Normal controls 
(NC); patients with 
somatization (SOM); 
patients with 
depression (DEP); 
patients with 
comorbid 
somatization and 
depression 
(SOM+DEP) 
Morning plasma 
after overnight 
fast 
 SOM than all other 
groups; no difference in 
SOM+DEP and DEP. 
No difference between 
SOM+DEP and DEP;   
in SOM+DEP and DEP 
than HC 
  SOM than in NC.   SOM and 
SOM+DEP than in 
DEP and NC. 
Maes and Rief 
(2012) 
Depressed inpatients; 
healthy controls 
Morning serum 
after overnight 
fast 
 depressed than 
controls 
 in depressed than 
controls 
 in depressed than 
controls 
  Myint et al (2013) 
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Oxidative stress and antioxidant defence biomarkers 
Malondialdehyde (MDA) –  MDA concentrations in depressed patients are by-and-large 
increased compared to healthy control groups (Bilici et al., 2001; Galecki, Szemraj, 
Bienkiewicz, Florkowski, & Galecka, 2009; Khanzode, Dakhale, Khanzode, Saoji, & 
Palasodkar, 2003; Kotan, Sarandol, Kirhan, Ozkaya, & Kirli, 2011; Ozcan, Gulec, Ozerol, Polat, 
& Akyol, 2004; Sarandol et al., 2007). Elevated levels of MDA have also been identified in 
patients diagnosed with recurrent depressive disorder (Rybka, et al., 2013), and concentrations 
are even greater in depressed patients with a history of recurrent episodes of depression 
compared to patients suffering from their first episode (Stefanescu & Ciobica, 2012). Elevated 
MDA levels have also been confirmed in depressed patients suffering from chronic heart 
failure (Michalakeas et al., 2011) and newly diagnosed gastric adenocarcinoma (Wei et al., 
2009). 
8-hydroxy-2-deoxyguanosine (8-OHdG) –an association between depression and levels of 
8-OHdG has been confirmed in several cross-sectional studies. Compared to a healthy 
comparison group, urinary (Maes et al., 2009) and serum (Forlenza & Miller, 2006) levels of 8-
OHdG were greater in people suffering from major depression. Levels of 8-OHdG also 
correlated positively with the severity of depression (Forlenza & Miller, 2006; Jorgensen et al., 
2013), and participants with recurrent episodes of depression had higher levels than those 
with single episodes (Forlenza & Miller, 2006). While no differences in urinary 8-OHdG were 
identified between depressed and healthy samples, its ribonucleoside (RNA) analogue, 8-oxo-
7,8-dihydroguanosine (8-oxoGuo), was higher in depressed patients, particularly those 
suffering from severe depression (Jorgensen, et al., 2013). Increased 8-OHdG may be a 
characteristic of clinically-diagnosed depression, as no differences were found in community-
based populations suffering from depressive symptoms (Iida et al., 2011; Yi et al., 2012).  
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Isoprostanes – levels of isoprostanes are elevated in patients suffering from depression as 
demonstrated by higher urinary concentrations of 8-iso-PGF2α (Chung, Schmidt, Stein, 
Morrow, & Salomon, 2013; Milaneschi et al., 2013), and a β-oxidation metabolite of 8-iso-
PGF2α, 2,3-dinor-5,6-dihydro-15-F2t-isoprostane (F2-isoPM). It is important to note that 
Milaneschi et al. (2013) found this association in men but not women. Elevated serum (Yager, 
Forlenza, & Miller, 2010) and plasma (Dimopoulos, Piperi, Psarra, Lea, & Kalofoutis, 2008) 8-
iso-PGF2α, concentrations were also found in depressed populations compared to a healthy 
comparison group. 
Superoxide dismutase (SOD) – disturbances in SOD activity are generally found in 
depressed populations. However, findings are inconsistent in the direction of this disturbance. 
For example, decreased red blood cell (RBC) SOD activity was reported in patients diagnosed 
with recurrent depressive disorder (Rybka, et al., 2013), lowered serum SOD levels in patients 
with major depression (Herken et al., 2007; Stefanescu & Ciobica, 2012), and even greater 
reductions in serum SOD in patients with recurrent depression, compared to a first episode 
group (Stefanescu & Ciobica, 2012). However, in other studies increased RBC SOD in 
depressed patients were found (Bilici, et al., 2001; Galecki, Szemraj, Bienkiewicz, Florkowski, 
et al., 2009; Kodydkova et al., 2009; Kotan, et al., 2011; Sarandol, et al., 2007), and serum SOD 
was positively associated with increasing severity of depression (Khanzode, et al., 2003). 
Reasons for these inconsistent findings are not clear, although may be related to variable 
collection protocols, analysis methods and whether RBC or serum was analysed (e.g., RBC 
levels were elevated in four out of five studies reviewed, while serum levels were lower in 
two out of three studies reviewed). Differences in the characteristics of depressed populations 
sampled may also be important as severity (Khanzode, et al., 2003) and length of depression 
(Stefanescu & Ciobica, 2012) are important factors influencing SOD activity. 
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Glutathione –As shown in Table 3, conclusions regarding glutathione activity are difficult 
as findings have been inconsistent and often dependent on the glutathione measure used and 
type of specimen evaluated. Levels of RBC glutathione peroxidase (GPx) have been most 
commonly evaluated in depressed populations with decreases (Kodydkova, et al., 2009; 
Rybka, et al., 2013), increases (Bilici, et al., 2001), and no differences (Galecki, Szemraj, 
Bienkiewicz, Florkowski, et al., 2009) found between depressed and healthy control groups.  
 
Table 3. Summary of studies investigating glutathione status in major depression. 
 
Glutathione measure Direction of change 
compared to controls 
Study 
Glutathione peroxidase  RBC Rybka et al., (2013) 
  RBC Kodydkova et al., (2009) 
  RBC Bilici et al., (2001) 
 = RBC Galecki et al., (2009) 
  whole blood Maes et al., (2011) 
 = whole blood Kotan et al., (2011) 
 = plasma Bilici et al., (2001) 
  serum 
in recurrent depression 
Stefanescu & Ciobica (2012) 
Glutathione reductase = RBC Rybka et al. (2013) 
 = RBC Bilici et al., (2001) 
  plasma Bilici et al., (2001) 
Reduced glutathione  whole blood Rybka et al. (2013) 
() increased () decreased or (=) no change compared to controls 
 
Biomarkers associated with the treatment of depression 
The potential of biomarkers as a measure of treatment response 
Measures of treatment progress over time are provided by treatment-response biomarkers. 
Currently, assessment of treatment progress in major depression is undertaken in clinical 
practice through clinical interviews, and to a lesser extent questionnaires and inventories. 
With validation of treatment-response biomarkers, further data about treatment efficacy may 
also be obtained by monitoring changes in biomarker levels over time.  
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CRP – in a meta-analysis of eight studies investigating the effects of antidepressant 
treatment on CRP levels it was concluded that antidepressant medication (particularly 
selective serotonin reuptake inhibitors, SSRIs) marginally lowered levels of CRP (Hiles, Baker, 
de Malmanche, & Attia, 2012a). However, in a meta-regression in this review, no significant 
association between baseline CRP and change in depressive symptoms was identified. 
Moreover, a trend was noted where higher baseline CRP was associated with larger decreases 
in depressive symptoms.  
Cytokines – in a meta-analysis by Hannestad et al. (2011), antidepressant treatment was 
found to lower levels of IL-1β and possibly IL-6, but had no effect on TNF-α. In a further 
analysis of antidepressant classes, SSRIs lowered levels of IL-6 and TNFα (Hannestad, et al., 
2011). In a separate meta-analysis, it was confirmed that antidepressants lowered levels of IL-6 
and non-significantly decreased levels of IL-10. A pattern was also identified where higher 
baseline IL-6 was associated with larger decreases in depressive symptoms (Hiles, et al., 
2012a).  
Electroconvulsive therapy (ECT) also influences cytokine profiles in depressed patients. 
ECT increased IL-1β and IL-6 at 3- and 6-hour time points after treatment (Lehtimaki et al., 
2008). Hestad et al. (2003) demonstrated that the clinical improvement during repeated ECT 
was accompanied by a gradual and significant decline in TNF-α, reaching levels comparable 
with those in healthy controls at the end of the study. Such a decline was not seen in 
depressed patients not receiving ECT, who instead showed elevated TNF-α levels throughout 
the study period. 
Neopterin – a course of treatment with ECT significantly elevated neopterin levels in 
depressed responders but these levels did not change in non-responders (Hoekstra, et al., 
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2001). Anderson et al. (1992) found that a positive therapeutic response was associated with a 
reduced neopterin:biopterin ratio in patients with psychotic depression treated with ECT. 
Malondialdehyde (MDA) –changes in MDA levels following treatment with antidepressant 
medication are largely associated with reduced concentrations and a return to normal levels in 
patients recovering from major depression. After three months of treatment with SSRIs, MDA 
was reduced to levels similar to a healthy comparison group (Bilici, et al., 2001; Khanzode, et 
al., 2003). Reductions in MDA were also observed in first-episode depressive patients who 
achieved remission following three months of treatment with fluoxetine (Galecki, Szemraj, 
Bienkiewicz, Florkowski, et al., 2009). MDA also decreased significantly following 24 weeks of 
antidepressant treatment (Kotan, et al., 2011); however, no such change was observed after a 
shorter treatment period of 6 weeks (Sarandol, et al., 2007). 
8-hydroxy-2-deoxyguanosine (8-OHdG) – a single study was identified examining changes 
in 8-OHdG following psychiatric treatment. Jorgensen et al. (2013) found no change in 8-
OHdG levels following ECT although its RNA analogue, 8-oxoGuo, increased significantly.  
Isoprostanes –the effect of antidepressant treatment on isoprostane levels has been 
investigated in one study. Excretion of F2 isoprostanes increased significantly following 8 
weeks of treatment with bupropion or sertraline in patients with major depression. The 
researchers also found that increases in F2 isoprostane were associated with improvement in 
depression severity  (Chung, et al., 2013). 
Superoxide dismutase – research on the effect of antidepressant medication on SOD activity 
has been inconsistent. RBC SOD activity was lowered following treatment with different 
classes of antidepressants after 24 weeks, although no change was noted after 6 or 12 weeks 
(Kotan, et al., 2011). Serum SOD activity was lowered following 8 weeks of SSRI 
administration (Khanzode, et al., 2003), and RBC SOD was reduced after 3 months of 
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treatment with several antidepressant classes (Bilici, et al., 2001). In contrast to these findings, 
no significant change in RBC SOD was observed in patients after 3 months of treatment with 
fluoxetine (Galecki, Szemraj, Bienkiewicz, Florkowski, et al., 2009; Galecki, Szemraj, 
Bienkiewicz, Zboralski, & Galecka, 2009), or in patients following 6 weeks of treatment with 
several antidepressant classes (Bilici, et al., 2001). Further disparity in findings is 
demonstrated by Herken et al., (2007) where 8 weeks of SSRI treatment was associated with 
increased serum SOD levels. Unique to this study was the observation that baseline SOD 
levels were lowered (rather than elevated) in the depressed population compared to the 
control group.  
In sum, the effect of antidepressant medication on SOD activity is not clear. These 
inconsistent findings may be attributed to the varying antioxidant effects of different 
antidepressant classes, or to differences in the depressed populations studied, as SOD activity 
is influenced by the number of depressive episodes (Stefanescu & Ciobica, 2012) and severity 
of depression (Khanzode, et al., 2003). Blood samples used in the studies (e.g., serum or RBC) 
and the length of antidepressant treatment may also be important factors influencing findings. 
Glutathione activity - No change in GPx was observed after three months of treatment with 
fluoxetine (Galecki, Szemraj, Bienkiewicz, Florkowski, et al., 2009) or 24 weeks of 
antidepressant treatment (Kotan, et al., 2011). Galecki et al. (2009) found that the addition of 
acetylsalicylic acid to fluoxetine treatment provided no additional benefit to treatment 
efficacy, although it was able to lower GPx activity after 3 months. Plasma glutathione 
reductase and glutathione peroxidase decreased after 3 months of treatment with SSRIs (Bilici, 
et al., 2001). 
TRYCATs - Little or no change was observed in the concentrations of any of the TRYCATs 
following treatment with fluoxetine, fluoxetine plus the thyroid hormone triiodothyronine 
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(T3), or counselling (Mackay et al., 2009).  Despite this, in a correlation analysis at weeks 6 and 
18, highly significant relationships between several of the TRYCATs and psychiatric inventory 
scores were revealed. In patients treated with fluoxetine or fluoxetine and T3, positive 
correlations were observed between psychiatric rating scores and concentrations of 
tryptophan and some TRYCATs, such as kynurenic acid and 3-hydroxyanthranilic acid. That 
is, increased levels of some TRYCATs were associated with increased psychiatric severity.  
Myint et al. (2007) found no changes in the TRYCATs, kynurenine, kynurenic acid and 
tryptophan, and related ratios after 6 weeks of antidepressant treatment. The neuroprotective 
ratio of patients with their first episode of depression increased significantly after treatment, 
but this did not correlate with changes in depression severity. 
Overall, the studies reviewed above suggest that treatments for depression (particularly 
antidepressant medication and ECT) influence oxidative stress and inflammatory markers. 
Unfortunately, investigations into the significance of such findings are still in their infancy. In 
the majority of studies the relationship between biomarker variations and changes in 
depressive symptoms has not been examined, making conclusions about the value of 
biomarker evaluations as a measure of treatment success difficult. Where studies have 
investigated this relationship, findings have been inconsistent. Moreover, the mechanisms 
underlying biomarker variation are unknown. While the treatments per se may improve 
inflammatory and oxidative stress pathways, it is also possible that improved mood resulting 
from successful treatment could lead to cognitive, behavioural and lifestyle changes (e.g., 
increased exercise, improved diet, positive outlook, improved sleep) that may be responsible 
for the changes observed in biomarkers. Further research in this area is required.  
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The potential of biomarkers for enhancing treatment matching  
The potential of inflammatory and oxidative stress biomarkers to facilitate treatment 
matching and, in turn, enhance treatment efficacy has been examined in only a few studies. 
From a theoretical standpoint, assessment of pre-treatment biomarkers has the potential to 
enhance clinical decision-making by enabling clinicians to choose the most appropriate 
treatment for a specific individual or group of individuals. Monitoring changes in biomarkers 
following treatment may also provide an indication of the likelihood of treatment success.   
In a study by Raison et al. (2013), infliximab, a TNF antagonist, was administered (via 
infusion) to patients with major depression. When the depressed group was examined as a 
whole, infliximab was no more effective than placebo. However, in patients with a baseline hs-
CRP greater than 5 mg/L, a significantly greater treatment response was observed in 
infliximab-treated patients compared to placebo. Additionally, Change et al. (2012) found that 
baseline CRP levels correlated significantly with the response to antidepressant treatment at 
week 2. However, in patients with comorbid coronary heart disease and depression treated 
with antidepressants, baseline levels of hs-CRP were not associated with 10-week post-
treatment depression scores (Bot et al., 2011). 
The potential of biomarkers to predict the onset of depression 
Preventative-based efforts hold significant promise in reducing the prevalence of 
depression and other psychiatric disorders in the general community. Currently several 
psychological, lifestyle, social and physical factors are known to be associated with an 
increased risk of developing major depression or relapsing after a period of remission. 
Measurement of biomarkers presents an additional option for risk factor identification, further 
enabling decision making around early identification, treatment and relapse prevention. 
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Research into the predictive potential of inflammatory and oxidative stress markers is still 
in its early stages. However, in a prospective analysis, increasing CRP levels were associated 
with increasing risk for hospitalisation with depression (Wium-Andersen, Orsted, Nielsen, & 
Nordestgaard, 2013). Greater CRP levels were also identified as an independent risk marker 
for de novo depression in women (Pasco, et al., 2010). Liukkonen et al. (2006) also found a four-
fold increase in the likelihood of recurrent depression in men with a hs-CRP level greater than 
3 mg/L, although no such association was identified in women. In a meta-analysis of 
longitudinal studies, raised CRP, and to a lesser extent IL-6, was associated with an increased 
risk of subsequent depressive symptoms (Valkanova, et al., 2013). In a study on people 
undergoing IFN-α treatment for hepatitis C, kynurenic acid levels were positively associated 
with an increased risk of the development of depression (Wichers et al., 2005).  
Complexities in biomarker identification 
The clinical utility of biomarkers in psychiatry is still in its infancy. Although biomarker 
measurement has the potential to be an exciting addition to psychiatric assessment, it is 
associated with numerous complexities. As demonstrated in this review, a number of 
inflammatory and oxidative stress biomarkers are associated with depression. However, none 
of these has sufficient sensitivity and specificity to be used in isolation. This signifies that 
further research is required to identify alternative, more suitable single or collective 
biomarkers. However, results have also been hampered by numerous inconsistencies and 
challenges across studies. 
Inconsistencies in specimen collection are a serious drawback in research. Typically, blood, 
urine and saliva samples are collected in research studies. Within blood collections, plasma, 
serum, red blood cells, and whole blood are additional options for biomarker measurement. A 
major drawback associated with the studies reviewed above relates to variation in the 
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specimens utilised to make comparisons. This may at least partly account for the inconsistent 
findings across studies. Further research is required to determine the most appropriate and 
accurate specimen to be utilised in research and clinical practice.  
A related problem refers to inconsistency in collection, storage and measurement protocols. 
While the majority of studies utilised morning, fasting collections, this was not always the 
case. Protocols used to measure biomarkers also often lacked consistency as did storage 
conditions following collection. Further research is required to determine the most accurate 
collection, storage and measurement protocols. Such protocols also need to be cost-effective 
and easily applied in clinical settings.  
A greater understanding of patient variables such as age, sex, medication use, menstrual 
cycle and status, time of day, smoking status and BMI are also crucial factors to consider in 
protocol development (Codoner-Franch et al., 2012; Hrboticky, Leiter, & Anderson, 1989; 
Rosello-Lleti et al., 2012; Theofylaktopoulou et al., 2013). Although depression is associated 
with several inflammatory and oxidative stress biomarkers, confounding variables need to be 
accounted for. For example, despite CRP being commonly used as a marker of inflammation 
and cardiovascular disease, levels may be influenced by time of day (Koc, Karaarslan, Abali, & 
Batur, 2010; Rudnicka, Rumley, Lowe, & Strachan, 2007), gender (Khera et al., 2005; Lakoski et 
al., 2006), age (Shanahan et al., 2013; Woloshin & Schwartz, 2005), menstrual cycle (Gaskins et 
al., 2012; Wander, Brindle, & O'Connor, 2008), and BMI (Choi, Joseph, & Pilote, 2013). These 
factors will impact on the reliability of conclusions made and require consideration in 
hypothesis generation. Some of these problems may be overcome by establishing subgroup 
normative data (e.g., based on age and gender) for the varying markers discussed. 
Inconsistencies in patient populations used in research also present another serious 
problem. Major depression is a heterogeneous disorder, thereby making generalised 
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conclusions difficult. There is a need for investigation into biomarkers associated with specific 
depression subtypes, categories or even specific symptoms. Atypical, melancholic, suicidal, 
and somatic-dominant are examples of some ‘depression subtypes’ that have revealed 
differing biomarker profiles. The specificity and sensitivity of biomarkers may increase 
following examination of well-defined groups. 
The effect of treating depression on biomarkers has primarily focused on antidepressant 
medication and ECT. Research into other treatments such as psychological therapies and 
lifestyle interventions (e.g., sleep, diet and exercise) is lacking. The influence of more targeted 
anti-inflammatory treatments and antioxidant therapies on depressive symptoms and 
biomarker levels are also required. It seems logical that if oxidative stress or inflammation is 
dysregulated in an individual or a population group, then treatments targeting this 
dysregulation should be utilised. Preliminary research into anti-inflammatory medication has 
begun with some positive initial findings (Muller, Myint, & Schwarz, 2011). However, as 
recently determined by Raison et al. (2013), treatment with infliximab, a TNF antagonist, was 
effective only for individuals with high levels of CRP. Other potential treatment candidates 
include COX-2 inhibitors (Muller, et al., 2011), immune-modulating and antioxidant herbs and 
spices such as curcumin (A. L. Lopresti, Hood, & Drummond, 2012) and green tea (Cabrera, 
Artacho, & Gimenez, 2006; Rietveld & Wiseman, 2003), and the large array of antioxidant 
nutrients such as coenzyme Q10, zinc, vitamin C, vitamin E and n-acetylcysteine (Ng, Berk, 
Dean, & Bush, 2008; Zhang & Yao, 2013). Further investigation into the effects of specific 
antidepressant medications on inflammatory and oxidative stress markers may also facilitate 
better treatment matching.  
Finally, while a limited selection of more commonly assessed biomarkers in depression 
research, specifically targeting inflammation and oxidative stress, have been covered in this 
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review, there remains an array of other potential options. These include measurements of 
amino acid levels, which are the precursors to neurotransmitters; markers of neurogenesis 
such as brain-derived neurotrophic factor; neurotransmitter metabolites such as 5-
hydroxyindoleacetate, vanilmandelate and homovanillate (measures of serotonin, 
noradrenaline and dopamine respectively); growth factors such as insulin-like growth factor-1 
and vascular endothelial growth factor; endocrine markers such as cortisol; measures of 
individual antioxidant levels such as zinc, coenzyme Q10, selenium and collective antioxidant 
measures such as total antioxidant capacity; markers of nitrosative stress such as conjugated 
nitric-oxide (NO) adducts, - NO-tryptophan, NO-tyrosine, NO-arginine, and NO-cysteinyl; 
and genetic polymorphisms associated with serotonin and dopamine transporters and 
receptors. 
Before biomarkers for depression can introduced into clinical practice, substantially greater 
research is required. Major depression is a common mental disorder with current treatment 
remission rates reaching only 20 to 40% (Warden, Rush, Trivedi, Fava, & Wisniewski, 2007). 
The addition of biomarkers has the potential to advance a more personalised treatment 
approach and enhance treatment efficacy. 
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As detailed in the previous paper, the use of peripheral biomarkers has the potential to 
predict treatment response and facilitate treatment matching. However, they have been 
greatly under-utilised in major depression. The potential of peripheral biomarkers was 
therefore examined in a study investigating the antidepressant effects of curcumin in people 
with major depression. It was hypothesised that: 
1. The antidepressant mechanisms associated with curcumin can be evaluated through 
pre- and post-collections of peripheral biomarkers. 
2. Curcumin will have greater antidepressant efficacy for specific subgroups of 
individuals with major depressive disorder. These subgroups can be identified 
through baseline biomarker concentrations which may facilitate treatment matching 
and therefore increase treatment success.  
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Abstract 
In a recent randomised, double-blind, placebo controlled study conducted by our research 
group, supplementation with curcumin (500mg, twice daily) for 8 weeks was effective in 
reducing depressive symptoms in people with major depressive disorder. In the present 
study, the potential antidepressant mechanisms of action of curcumin were investigated by 
measuring several biomarkers in saliva, urine and blood at baseline and post-treatment. 
Samples were provided by 50 participants diagnosed with major depressive disorder, and the 
Inventory of Depressive Symptomatology self-rated version (IDS-SR30) was used as the 
primary depression outcome measure. Compared to placebo, 8 weeks of curcumin 
supplementation was associated with elevations in urinary thromboxane B2 (F1,19 = 8.21, p = 
.010) and substance P (F1,19 = 5.59, p = .029). Higher baseline plasma endothelin-1 (rs = -.585; p = 
.004) and leptin (rs = -.451; p = .040) in curcumin-treated individuals was associated with 
greater reductions in IDS-SR30 score after 8 weeks of treatment. Reductions in plasma leptin 
concentrations were also associated with reductions in depressive symptoms (rs =.515; p = 
.024). A further exploratory analysis revealed that in participants with a high baseline 
endothelin-1, curcumin was more effective than placebo in reducing depressive symptoms 
(F2,30 = 3.82, p = .033; Cohen’s d = 1.26). Our findings demonstrate that curcumin 
supplementation influences several biomarkers that may be associated with its antidepressant 
mechanisms of action. Plasma concentrations of leptin and endothelin-1 seem to have 
particular relevance to treatment outcome. Further investigations using larger samples sizes 
are required to elucidate these findings. 
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Introduction 
In medical and pharmaceutical practice biomarkers are regularly used to assist in the 
prediction, diagnosis and evaluation of treatments associated with disease (Biomarkers 
Definitions Working Group, 2001). However, in psychiatry, biomarkers are utilised primarily 
for research purposes and are seldom used in clinical practice. Greater understanding of 
biomarkers in psychiatry has the potential to enhance diagnostic accuracy, improve treatment-
matching and evaluate treatment progress. Evaluation of biomarkers can also expand 
understanding into the mechanisms of change associated with specific treatments for 
depression (Adrian L. Lopresti, Maker, Hood, & Drummond, 2014). 
Several dysregulated biological pathways have been identified in major depressive 
disorder including disturbances in monoaminergic activity, immuno-inflammation, oxidative 
stress, hypothalamus-pituitary-adrenal (HPA) activity and neuroprogression (Leonard & 
Maes, 2012). Examination of biomarkers is particularly relevant as there are identified 
differences between depressed and healthy populations in markers of immuno-inflammation, 
such as C-reactive protein, interleukin-6 and tumor-necrosis factor-α (Elomaa et al., 2012; 
Howren, et al., 2009); markers of oxidative stress such as malondialdehyde (MDA) (Galecki, 
Szemraj, Bienkiewicz, Florkowski, et al., 2009) and 8-Hydroxy-2-deoxyguanosine (8-OHdG) 
(Maes, et al., 2009); and markers of HPA activity such as increased baseline or post-
dexamethasone cortisol (Belvederi Murri et al., 2014). 
Because of its effects on all of these pathways, interest in curcumin for the treatment of 
major depression has increased. In animal models of depression, curcumin has demonstrated 
antidepressant and anxiolytic effects (A. L. Lopresti, et al., 2012). Three human-based trials on 
people with major depressive disorder have now been completed. In one study the addition of 
curcumin to antidepressant treatment provided no additional antidepressant benefit 
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(Bergman et al., 2013), whereas in another study curcumin had similar antidepressant efficacy 
to fluoxetine (Sanmukhani et al., 2014). However, in this latter study there was no placebo-
control or blinding of participants from treatment conditions. In a recent randomised, double-
blind, placebo controlled study conducted by our research team, curcumin was more effective 
than placebo in reducing depressive symptoms in people with major depression and was 
particularly effective in a subset of participants with atypical depression (A. L. Lopresti, Maes, 
Hood, Maker, & Drummond, 2014). In the present paper, exploratory analysis of results from 
this study is provided with an emphasis on the effects of curcumin on blood, urinary and 
salivary biomarkers, and on the potential of biomarkers to predict treatment response. The 
primary purpose of this analysis was to identify potentially important biomarkers that will 
require validation in future, greater powered studies. 
Experimental Procedures 
Study design 
Details of this study have been previously published in Lopresti et al. (2014). Briefly, this 
study was an 8-week, randomised, double-blind, placebo-controlled clinical trial (Figure 1). 
The trial protocol was approved by the Human Research Ethics Committee at Murdoch 
University, Western Australia and was registered with the Australian New Zealand Clinical 
Trials Registry (no. 12612001260819). Participants were randomly and equally allocated into 
two groups (placebo and curcumin). Both curcumin and placebo capsules were packed in 
identical containers labelled by participant code numbers and were allocated according to 
order of participant enrolment in the study. 
Participants 
Full details of inclusion and exclusion criteria are outlined in Lopresti et al. (2014). Briefly, 
male and female participants aged 18 to 65 years were eligible to participate if they met the 
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DSM-IV criteria for current major depressive disorder and had an Inventory of Depressive 
Symptomatology self-rated version (IDS-SR30) score ≥ 14. The diagnosis of major depression 
was made by the first author, an experienced clinical psychologist, using The Mini 
International Neuropsychiatric Interview 6.0 (MINI 6.0) (Sheehan et al., 1998). Participants 
with a psychotic disorder, bipolar disorder, comorbid obsessive-compulsive disorder, 
posttraumatic stress disorder, eating disorder, chronic fatigue syndrome, fibromyalgia, or any 
substance abuse or dependence disorder were excluded, as were participants assessed as high 
risk of suicide. Volunteers were also excluded if they suffered from medical illnesses including 
diabetes, autoimmune diseases, cardiovascular disease, hypertension, chronic fatigue 
syndrome, or asthma. 
Interventions 
Placebo (cellulose) and curcumin capsules were supplied by Arjuna Natural Extracts Ltd. 
Kochi, Kerala, India, and were identical in appearance. Curcumin was provided in a 500 mg 
capsule (BCM-95®) containing total curcuminoids 88% (curcumin, bisdemethoxycurcumin, 
demethoxycurcumin) and volatile oils 7% from rhizomes of Curcuma longa Linn. Participants 
were directed to take one capsule, twice daily with or without food for 8 weeks. Curcumin 
was administered in a dose of 1000 mg/day.  
Outcomes 
Depression questionnaire 
Evaluation of depression and anxiety-related symptoms occurred through the 
administration of several self-report questionnaires as detailed in Lopresti et al. (2014). The 
Inventory of Depressive Symptomatology self-rated version (IDS-SR30) was used as the 
primary assessment of depressive symptoms. Baseline and delta change in total IDS-SR30 score 
was used to examine the relationship between evaluated biomarkers and depressive 
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symptoms. The IDS-SR30 contains 30 items measuring depressive symptoms based on the 
DSM-IV criteria for major depressive episode (A. J. Rush, Gullion, Basco, Jarrett, & Trivedi, 
1996).  The IDS-SR30 has acceptable psychometric properties in depressed outpatients and 
correlates highly with common depression inventories such as the HRSD17, BDI, and MADRS 
(A.J. Rush, Carmody, & Reimitz, 2000; A. J. Rush, et al., 1996). 
Laboratory assessments 
Blood, urine and salivary specimens were collected from participants at baseline and 
endpoint (8 weeks). Participants were requested to collect blood and urine samples on the 
same day and salivary samples on the same day or within a day of their blood and urine 
collections. All collections occurred in the morning after an overnight fast. The biomarkers are 
described in Table 1. 
Urinary collections: Participants were asked to moderately restrict fluid intake the day 
before testing. Participants collected overnight urine along with their first morning urine in a 
collection container. Samples were refrigerated until collection by researchers later that day. 
Blood collections: Participants were instructed to visit a commercial local pathology centre 
to provide venous blood samples. They were requested to provide the blood sample after an 
overnight fast and before 10 am. 10mls of venous blood was drawn into lithium-heparin tubes 
and was centrifuged at 3000 rpm for 10 min to obtain plasma. Plasma samples were then 
stored at −80oC for later analysis.  
Salivary collections: Participants were instructed to dribble saliva in provided collection 
tubes within 10 minutes of awakening and 30 minutes later. Both salivary collections occurred 
before brushing the teeth and consumption of food or caffeinated beverages. Samples were 
refrigerated until collected by researchers later that day.  
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Urinary testing protocol: All urine samples were received on dry ice (-78°C) and stored at -
80°C until testing. The samples were allowed to thaw to reach room temperature. Tbx-B2 was 
tested with an ELISA kit from R&D systems (cat. number KGE011), designed on the inhibition 
principle. LTB4 was tested with ELISA test kit from R&D systems (cat. number KGE006B). 
Midkine was tested with an ELISA kit from Cellmid (cat. number MKELISA), designed on the 
sandwich principle. Cortisol was tested with an ELISA kit from R&D systems (cat. number 
KGE008), designed on the inhibition principle. SUB-P was tested with an ELISA kit from R&D 
systems (cat. number HGE007), designed on the inhibition principle. HEVM was tested with a 
test from Ray Bio (cat. Number ELH-HVEM-001), designed on the sandwich principle. 
Aldosterone was tested with a test from LDN Germany (cat. Number MS E5200), designed on 
the inhibition principle.  Preparation of the reagents and the testing was completed according 
to the procedure as described in the respective instructions for use available with all kits. The 
calculation of the concentrations were completed by linear interpolation uniformly for all tests 
(Wild, 2005). All urinary biomarkers were adjusted for creatinine concentrations. 
Salivary testing protocol: Following transportation to the laboratory, saliva samples were 
stored at 2-8oC for up to 24 hours. Untreated saliva was used directly after centrifugation. 
Salivary cortisol was assayed on the Roche Cobas e® analyser (manufacturer details) using a 
competitive polyclonal antibody immunoassay that employs a magnetic separation step 
followed by electrochemiluminescence quantification. 20 μL of sample was used and the assay 
had a measurement range of 0.5 to 1750 nmol/L (0.018-63.4 μg/dL). Results were determined 
via a 2-point calibration curve and a predefined master curve. The cortisol assay has a 
functional sensitivity of < 8.5 nmol/L (< 0.308 μg/dL) (defined as the lowest concentration 
reproducibly measured with precision coefficient of variation < 10%). The intra-assay 
coefficient of variation was < 3.6%.  
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Blood testing protocol: All plasma samples were received on dry ice (-78°C) and stored at -
80°C until testing. The samples were thawed and allowed to reach room temperature, 
centrifuged 7000xg for 5 minutes to spin down and remove any clotted fibrin particles formed. 
Tbx-B2 was tested with an ELISA kit from R&D systems (Cat. number KGE01) based on the 
inhibition principle. LTB4 was tested with an ELISA kit from R&D systems (cat. number 
KGE006B) based on the sandwich principle. Human leptin was tested with ELISA kit from 
Ray Bio (cat. number SKGE006B) based on the sandwich principle. Calprotectin was tested 
with an ELISA kit from Hycult Biotech (cat. number HK325-02) based on the sandwich 
principle. Midkine was tested with an ELISA kit from Cellmid (Cat. number MKELISA) based 
on the sandwich principle. ET-1 was tested with an ELISA kit from R&D systems (cat. number 
DET100) based on the sandwich principle. Cortisol was tested with an ELISA kit from R&D 
systems (cat. number KGE008), designed on the inhibition principle. EGF was tested with an 
ELISA kit from Ray Bio (cat. number ELH-EGF-00)1 based on the sandwich principle. Human 
TNF-R2 was tested with an ELISA kit from Ray Bio (cat. number ELH-STNFRII-001) based on 
the sandwich principle. SUB-P was tested with an ELISA kit from R&D systems (cat. number 
HGE007), based on the inhibition principle. Preparation of the reagents and the testing were 
completed according to the procedures as described in the respective instructions for use 
available with all kits. The calculation of the concentrations was completed by linear 
interpolation uniformly for all tests (Wild, 2005). 
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Table 1: Definition of measured urinary and plasma biomarkers. 
Plasma only 
Endothelin-1 (ET-1) Protein that constricts blood vessels and raises blood pressure. In the 
nervous system, ET-1 plays an important role in blood pressure 
regulation, blood-brain barrier permeability, respiratory control and 
renal sympathetic neuronal activity. 
Calprotectin (Cal) Released from activated leukocytes leading to increased concentrations 
during bacterial infections or inflammation in relevant organs. 
Leptin Adipokine that plays a key role in regulating energy intake and 
expenditure, including appetite and hunger, metabolism, and behaviour. 
Tumor necrosis 
factor receptor 2 
(TNF-R2) 
Binding of tumour necrosis factor (TNF) to TNFR2 results in activation 
and recruitment of intracellular adaptor proteins that induce signal 
transduction, promoting cell proliferation and survival. 
Epidermal growth 
factor (EGF) 
Growth factor that stimulates cell growth, proliferation, and 
differentiation. Concentrations are high in the CNS, controlling 
proliferation and differentiation of nervous tissue during neurogenesis. 
Urine only 
Cyclic adenosine 
monophosphate 
(cAMP) 
Second messenger that affects transmembrane transport, cell growth and 
morphology, cellular adhesion, and cytoskeletal organisation.  
Herpes virus entry 
mediator (HVEM) 
Plays a critical role in the regulation of inflammation and also serves as 
one of the entry receptors of herpes simplex virus. 
Aldosterone Steroid hormone that plays a central role in the regulation of blood 
pressure. When dysregulated, aldosterone contributes to the 
development and progression of cardiovascular and renal disease by 
promoting sodium and water retention, and lowering plasma potassium 
concentrations. 
Urine and plasma 
Cortisol (also 
collected in saliva) 
Hormone associated with several important processes in the body 
including the stress response, inflammatory and immune processes, 
blood sugar regulation and fat, protein, and carbohydrate metabolism. 
Substance P (SUB-P) Neuropeptide expressed predominantly in the basal forebrain, amygdala, 
hippocampus and diencephalon associated with nociception, respiration, 
cardiovascular and thermo regulation, gut motility, emetic response, and 
stress-related behaviour. 
Leukotriene B4 
(LTB4) 
Lipid inflammatory mediator, generated in leukocytes from membrane 
arachidonic acid.  
Thromboxane B2 
(Tbx-B2) 
An inactive metabolite of thromboxane A2 (Tbx-A2), an unstable 
arachidonic acid metabolite produced by activated platelets that elicits 
diverse physiological and pathophysiological actions, including platelet 
aggregation and smooth muscle contraction. In the brain, Tbx-A2 also 
contributes to peripheral adrenal catecholamine secretion. 
Midkine Strongly induced during oncogenesis, inflammation and repair. Promotes 
cell survival and cell migration, and is deeply involved in cancer 
progression, the onset of inflammatory diseases and the preservation and 
repair of injured tissues.  
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Statistical analysis 
Effect of curcumin on evaluated biomarkers 
Since the majority of the biomarkers checked by the inspection of Q-Q plots were not 
normally distributed and contained several outliers, logarithmic or reciprocal transformations 
were completed on all biomarker data. This significantly improved linearity. Therefore, 
repeated measures ANOVA were conducted to assess for changes in biomarker levels both 
within (time effects) and between groups (time x treatment). An analysis of covariance 
(ANCOVA) was used if differences in baseline biomarkers across groups were identified. 
Independent samples t-tests were used to compare baseline biomarker levels across the 
treatment groups. All analyses were based on complete case analyses. 
Relationship between biomarkers, depression and treatment outcome 
Due to the small sample sizes (approximately 20 in each condition for biomarker data), 
exploratory correlational analyses were conducted rather than multiple regression analysis. 
Correlations between delta change in IDS-SR30 (change from baseline to week 8) with baseline 
and delta change in plasma biomarkers were calculated. Correlations were examined 
separately for the two treatment groups. As data was not normalised and included outliers, 
Spearman’s rho was used for correlational analyses. Where significant predictors were 
identified, further analyses were conducted to examine the influence of the biomarker on 
treatment outcome.  
Significance values for statistical testing 
As analyses were considered exploratory, with the goal of providing directions for future 
research, adjustments to significance values for multiple comparisons were not made. While it 
is acknowledged that this increases the risk of type I error, such analyses are considered 
preliminary, requiring further confirmation in more highly powered studies. For all tests, the 
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criterion of statistical significance was P < 0.05 (two-tailed). Since correlation coefficient values 
between 0.0 and 0.3 are considered weak, only correlations above 0.4 were considered 
clinically meaningful. All data were analysed using SPSS (version 21; IBM, Armonk, NY).  
Study Population 
 
Figure 1. Systematic illustration of study design 
Baseline questionnaire and demographic information 
Eighty people were screened for participation in the study and 50 people met 
inclusion/exclusion criteria. Twenty-five people were randomised into the placebo group and 
25 into the treatment (curcumin) group. Forty-seven participants completed up to week 8. 
There were 3 drop-outs, all from the curcumin group. As detailed in Table 2, there were no 
significant differences between the two groups in IDS-SR30 scores or demographic variables, 
except for distribution of medical illnesses, with a greater number reporting medical illnesses 
in the placebo (n=14) than the curcumin (n=6) group (Χ2 (1) = 5.33, p ≤ .05).  
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Table 2: Demographic characteristics of curcumin and placebo participants. 
 
Placebo Curcumin 
p-value 
n=25 n=25 
Age (years) mean (S.D.) 48.44 (12.26) 43.00 (12.05) 0.12† 
BMI (kg/m2) mean (S.D.) 27.01 (4.90) 25.98 (5.56) 0.50† 
IDS-SR30 Total Score 33.36 (12.05) 31.24 (9.10) 0.49† 
Sex n 
Female 18 17 
1.00# 
Male 7 8 
Marital Status n 
Single 7 10 
.379# 
Married 11 9 
De facto 4 4 
Divorced 1 2 
Widowed 2 0 
Educational Status n 
Secondary 5 9 
.284# Tertiary 16 14 
Post-graduate 4 2 
General Health n 
Great 8 5 
.257# Average 17 18 
Poor 0 2 
Medical Illness n 
Yes 14 6 
.021# 
No 11 19 
Antidepressant Medication n 
Yes 9 11 
.387# 
No 16 14 
Exercise Frequency n 
Never/Rarely 6 4 
.650# 
1-2 times week 8 9 
3-5 times week 10 12 
6+ times week 1 0 
Injuries causing regular pain  n 
Yes 11 9 
.387# 
No 14 16 
†Independent samples T-test; #Chi-square Test 
Details of biomarker collections 
Plasma biomarkers: 50 baseline plasma samples (25 from each condition) were collected for 
biomarker assessment. At baseline, EGF levels were higher in the curcumin than placebo 
Chapter 6: The potential utility of peripheral biomarkers in major depression 
Paper submitted for publication 
- 228 - 
group, but all other biomarkers were similar in the two treatment groups. Post-plasma 
collections were obtained from 43 participants (curcumin, n=20; placebo, n=23).  
Urinary biomarkers: 50 baseline urinary samples (25 from each condition) were collected 
for biomarker assessment. At baseline, urinary biomarker levels were similar in the placebo 
and curcumin groups. Post-urinary collections were obtained from 46 participants (curcumin, 
n=22; placebo, n=24).  
Salivary cortisol: 50 baseline salivary samples (25 from each condition) were collected for 
cortisol assessment. Cortisol could not be measured in two samples (one from each condition) 
due to insufficient saliva collection, leaving 24 pre-salivary cortisol measurements for each 
condition.  Baseline cortisol levels were similar in the placebo and curcumin groups. Post-
salivary collections were obtained from 45 participants (curcumin, n=22; placebo, n=23).  
An examination of cortisol collection times revealed no differences in average time of 
awakening collection pre- and post-treatment (baseline mean awakening collection time = 
7.17am; week 8 mean awakening collection time = 7.14am). Average time of collection of 30-
minute salivary samples also remained similar over time (baseline 30-min collection = 36 min 
after awakening; week 8, 30-min collection = 36 min after awakening). At baseline, 7 
participants collected 30 min samples greater than 40 minutes after awakening, and at week 8, 
this occurred for 4 participants. As exclusion of the samples did not influence statistical 
outcomes and cortisol measures were not significantly different from other collections, all data 
were used in the analyses below. 
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Results 
Outcome Measures 
Effect of treatment condition on biomarkers  
Urinary biomarkers: In the curcumin group, treatment was associated with significant 
increases in Tbx-B2 (F1,19 = 8.21, p = .010), SUB-P (F1,19 = 5.59, p = .029) and a similar trend for 
LTB4 (F1,18 = 3.42, p = .081). In the placebo group, there was a trend of reduced LTB4 levels 
(F1,18 = 4.29, p = .052) over time. Group x time interactions were significant for LTB4 (F1,38 = 
7.59, p = .009), SUB-P (F1,42 = 4.38, p = .042) and a non-significant trend for Tbx-B2 (F1,42 = 3.13, p 
= .084) (Table 3). 
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Table 3: Change in biomarkers over time. 
  Treatment Baseline Week 8 
Treatment x time 
effect (p-value) 
Plasma Biomarkers 
LTB4 
Placebo (n=23) 27.70 (66.76) 35.60 (51.84) 
.511 
Curcumin (n=20) 34.90 (21.53) 27.85 (25.90) 
ET-1 
Placebo (n=23) 1.43 (0.52) 1.46 (0.45) 
.920 
Curcumin (n=19) 1.39 (0.25) 1.43 (0.37) 
Tbx-B2 
Placebo (n=23) 3.02 (6.45) 2.86 (5.12) 
.412 
Curcumin (n=20) 2.37 (7.66) 2.63 (7.30) 
Calprotectin 
Placebo (n=23) 321.60 (180.30) 390.00 (226.40) 
.945 
Curcumin (n=20) 330.90 (152.52) 393.30 (393.30) 
Leptin 
Placebo (n=23) 919.00 (1044.14) 832.00 (856.75) 
.269 
Curcumin (n=20) 494.50 (1201.54) 535.50 (1484.62) 
Midkine 
Placebo (n=23) 620.00 (1235.93) 758.00 (1114.39) 
.561 
Curcumin (n=23) 636.00 (1028.53) 575.00 (1156.54) 
TNF-R2 
Placebo (n=23) 1760.00 (682.23) 1665.00 (787.19) 
.312 
Curcumin (n=20) 1787.50 (425.23) 1690.00 (400.20) 
EGF 
Placebo (n=23) 14.85 (11.95) 28.50** (26.78) 
.012 
Curcumin (n=20) 25.15 (22.98) 21.65 (17.10) 
SUB-P 
Placebo (n=22) 396.00 (207.49) 337.00 (190.94) 
.542 
Curcumin (n=19) 375.00 (449.20) 402.00 (326.60) 
Cortisol 
Placebo (n=22) 25.73 (14.13) 21.21 (18.68) 
.971 
Curcumin (n=19) 27.31 (9.13) 24.53 (13.58) 
Urinary Biomarkers 
cAMP 
Placebo (n=23) 558.50 (218.13) 545.00 (175.79) 
.300 
Curcumin (n=20) 566.00 (206.93) 587.00 (214.83) 
LTB4 
Placebo (n=21) 59.80 (60.60) 42.10 (21.71) 
.009 
Curcumin (n=20) 40.80 (36.87) 48.10 (34.15) 
HVEM 
Placebo (n=23) 15.77 (7.15) 14.05 (7.54) 
.292 
Curcumin (n=20) 14.05 (4.55) 16.55 (4.73) 
Tbx-B2 
Placebo (n=24) 0.50 (0.63) 0.75 (0.45) 
.084 
Curcumin (n=21) 0.40 (0.66) 0.70* (1.46) 
Midkine 
Placebo (n=22) 23.76 (17.97) 26.14 (8.47) 
.771 
Curcumin (n=19) 24.15 (24.15) 24.66 (43.93) 
SUB-P 
Placebo (n=24) 9.50 (33.19) 4.43 (21.81) 
.042 
Curcumin (n=21) 16.20 (32.24) 64.12* (67.05) 
Cortisol 
Placebo (n=19) 3.87 (3.42) 2.67 (2.10) 
.141 
Curcumin (n=20) 3.58 (2.97) 4.20 (3.43) 
Aldosterone 
Placebo (n=24) 355.00 (257.06) 251.25 (187.17) 
.114 
Curcumin (n=21) 340.00 (204.48) 343.00 (147.28) 
Significant within-group time effects * (p<.05); **(p<.01) 
Data are shown as median (S.D.) 
Values expressed as plasma pg/mL and urine mg/creatinine 
 
Plasma biomarkers: EGF increased after treatment in the placebo group but remained stable 
in the curcumin group (F1,37 = 5.24, p = .028). An ANCOVA was conducted to control for the 
effects of differing baseline EGF levels across treatment groups (baseline EGF was entered as a 
covariate), and the difference between groups was no longer significant (F1,39 = 1.57, p = .218). 
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There were no other significant time or group x time interaction for other measured plasma 
biomarkers (Table 3).  
Salivary cortisol: Pre- and post-intervention levels of salivary cortisol across each treatment 
condition are detailed in Table 4. Cortisol levels did not change significantly over time in 
either treatment condition and there were no significant between-group differences.  
Table 4: Change in salivary cortisol over time. 
  
Treatment 
Baseline 
(nmol/L) 
Week 8 
(nmol/L) 
Treatment x time 
effect (p-value)   
Cortisol awake, 
median (SD) 
Placebo (n=23) 21.50 (14.14) 22.00 (14.14) 
.91 
Curcumin (n=22) 24.50 (14.14) 24.50 (21.11) 
Cortisol 30 min, 
median (SD) 
Placebo (n=23) 22.00 (15.96) 23.00 (22.05) 
.34 
Curcumin (n=22) 24.00 (10.30) 23.50 (18.04) 
Cortisol CAR, 
median (SD) 
Placebo (n=23) 1.00 (11.77) 1.00 (23.73) 
.75 
Curcumin (n=22) -1.50 (16.14) -2.50 (17.89) 
CAR = cortisol awakening response (absolute change between awakening and 30 min cortisol). 
Relationship between biomarkers, depression and treatment outcome 
 Correlations between IDS-SR30 total score and biomarker levels (baseline levels and 
change in levels) are detailed in Tables 5 and 6. In placebo group, lower baseline urinary 
cAMP was associated with a greater reduction in the IDS score after 8 weeks of treatment (rs = 
.461; p = .023). In the curcumin group, higher baseline plasma ET-1 (rs = -.585; p = .004) and 
plasma leptin (rs = -.451; p = .040) were associated with greater reductions in the IDS score after 
8 weeks of treatment.  
In the placebo group, decreases in IDS-SR30 were associated with increases in plasma 
cortisol (rs = -.544; p = .009), plasma ET-1 (rs = -.496; p = .016), and urinary HVEM (rs = -.437; p = 
.037). In the curcumin group, decreases in IDS-SR30 were associated with decreases in plasma 
leptin (rs =.515; p = .024). 
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Table 5: Spearman's rank-order correlations between IDS-SR30 total score and plasma biomarker 
levels (baseline levels and change in levels). 
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Change in 
IDS score 
and baseline 
biomarker 
level 
Placebo 
rs .160 .022 -.078 .053 .030 .003 .094 -.136 .151 -.302 
p-value .446 .916 .712 .801 .888 .987 .655 .526 .473 .142 
n 25 25 25 25 25 25 25 24 25 25 
Curcumin 
rs .307 -.585** .049 -.059 -.451* -.001 -.145 -.107 -.005 .115 
p-value .176 .004 .833 .801 .040 .996 .530 .643 .984 .621 
n 21 22 21 21 21 21 21 21 21 21 
Change in 
IDS score 
and change 
in 
biomarkers 
level 
Placebo 
rs -.377 -.496* -.373 -.404 .193 -.294 -.282 -.025 -.144 -.544** 
p-value .076 .016 .079 .056 .378 .173 .192 .910 .522 .009 
n 23 23 23 23 23 23 23 23 22 22 
Curcumin 
rs -.215 -.154 -.300 -.111 .515* .033 .290 .300 -.147 -.055 
p-value .363 .528 .199 .652 .024 .890 .229 .199 .549 .829 
n 20 19 20 19 19 20 19 20 19 18 
 
Table 6: Spearman's rank-order correlations between IDS-SR30 total score and urinary biomarker levels 
(baseline levels and change in levels). 
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Change in IDS score 
and baseline 
biomarker level 
Placebo 
rs .461* .174 .355 .144 -.065 .318 .204 .085 
p-value .023 .438 .089 .493 .769 .122 .388 .685 
n 24 22 24 25 23 25 20 25 
Curcumin 
rs -.308 -.194 -.153 -.259 .228 -.007 .194 -.053 
p-value .174 .398 .508 .245 .333 .974 .400 .814 
n 21 21 21 22 20 22 21 22 
Change in IDS score 
and change in 
biomarkers level 
Placebo 
rs -.248 -.353 -.437* -.035 -.044 -.107 -.108 -.004 
p-value .253 .117 .037 .869 .846 .619 .660 .986 
n 23 21 23 24 22 24 19 24 
Curcumin 
rs -.223 -.052 .147 .091 -.354 -.173 -.131 -.253 
p-value .344 .826 .536 .695 .137 .455 .582 .269 
n 20 20 20 21 19 21 20 21 
 
As baseline plasma ET-1 and leptin in the curcumin group, and urinary cAMP in the 
placebo-group, were significantly associated with change in the IDS-SR30 score, further 
exploratory analyses were conducted. Participants with high baseline ET-1 (defined as an ET-1 
level above the total sample mean of 1.47) (n=19) were selected for further analysis. Baseline 
demographics were similar in the curcumin and placebo groups except for significant 
differences in age (mean difference = 9.20, 95% CI [0.41, 17.02], t(17) = -2.27, p = .037) and 
medical illness (Χ2 (1) = 10.05, p- = .002). Hence, these variables were included as covariates in 
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a repeated measures ANOVA. In participants with a high baseline ET-1, curcumin was more 
effective than placebo in reducing IDS-SR30 as evidenced by a significant group x time 
interaction (F2,30 = 3.82, p = .033; Cohen’s d = 1.26) (Figure 2). No similar significant patterns 
were observed with baseline leptin or cAMP levels.  
 
 
Figure 2. Change in IDS-SR30 total score over time (± std. error) across curcumin and placebo 
groups in participants with a high ET-1 level at baseline (> 1.47). * indicates significant group x 
time interaction (p < 0.05). 
 
Discussion 
Curcumin and its effect on biomarkers 
Compared to placebo, eight weeks of curcumin supplementation was associated with 
significant changes in several measured biomarkers. Urinary levels of Tbx-B2, SUB-P, and 
LTB4 (non-significant trend) increased in curcumin-treated individuals whereas in placebo-
treated individuals plasma EGF decreased significantly and LTB4also declined (non-
significant trend). 
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SUB-P: SUB-P is a neuropeptide expressed predominantly in the basal forebrain, 
amygdala, hippocampus and diencephalon. It is associated with nociception, respiration, 
cardiovascular and thermo-regulation, gut motility, emetic response, and stress-related 
behaviour (Holmes, Heilig, Rupniak, Steckler, & Griebel, 2003). A role of SUB-P in depression 
is supported by evidence confirming that SUB-P and its preferred receptor neurokinin-1 
(NK1) are activated by stressors which, in turn, stimulate HPA axis activity (Ebner & 
Singewald, 2006). They are also associated with the modulation of noradrenaline and 
serotonin (Blier et al., 2004). Although evidence is mixed, anxiolytic and antidepressant 
properties of NK1 antagonists have been identified both in animal and human studies 
(Holmes, et al., 2003). Elevated concentrations of SUB-P in the cerebrospinal fluid (CSF) and 
serum of depressed patients have also been reported, and SUB-P levels decrease in some 
responders following antidepressant treatment (Alldredge, 2010). 
Investigations into the effects of curcumin on SUB-P are limited. In a recent randomised 
double-blind placebo-controlled trial, curcuminoids as an adjunct to chemotherapy 
significantly lowered serum SUB-P in patients with cancer (Panahi, Saadat, Beiraghdar, & 
Sahebkar, 2014). Similar effects were observed following curcumin administration in patients 
treated for pruritic symptoms induced by sulphur mustard (Panahi et al., 2012). In the present 
study, curcumin administration was not associated with changes in plasma SUB-P, but was 
associated with increased urinary concentrations. Given previous findings of increased 
plasma concentrations in major depression, this observation is contrary to what one might 
expect from an antidepressant agent. However, urinary SUB-P was not measured in any 
previous study. Potentially, urinary increases in SUB-P reflect increased excretion, followed by 
reduced plasma concentrations over the longer term. In addition, a urine collection 
comprising overnight and first morning voids may be more sensitive to changes in biomarkers 
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than a single point, fasting plasma collection. Further investigation is necessary to help 
elucidate the relevance of this finding and how it relates to depression treatment. 
LTB4: LTB4 is a lipid inflammatory mediator generated in leukocytes from membrane 
arachidonic acid by the sequential actions of cytosolic phospholipase A2, 5-lipoxygenase (5-
LOX) and leukotriene A4 hydrolase. Several inflammatory diseases, including asthma, chronic 
obstructive pulmonary disease, arthritis and cardiovascular disease, are associated with 
elevated levels of LTB4 (Singh, Tandon, Dastidar, & Ray, 2013). Although depression is 
associated with increased inflammation, surprisingly little research has specifically 
investigated LTB4 in major depression. In the only identified study, 12 single nucleotide 
polymorphisms (SNPs) in the leukotriene A4 hydrolase gene were not associated with 
depressive symptoms (Zhao et al., 2009). In an animal model of depression, inhibition of 5-
LOX, an enzyme involved in leukotriene synthesis, produced antidepressant-like effects 
(Dzitoyeva et al., 2008). In contrast to this finding, there are reports of increased suicide-
related adverse events associated with the use of leukotriene receptor antagonists (Schumock 
et al., 2011). 
Curcumin inhibits the incorporation of LTB4 into membrane lipids (Joe & Lokesh, 1997) 
and inhibits LTB4 formation in rat peritoneal polymorphonuclear neutrophils (Ammon, 
Anazodo, Safayhi, Dhawan, & Srimal, 1992). Curcumin also regulates 5-LOX activity which is 
associated with LTB4 production (Shehzad, Rehman, & Lee, 2013). In contrast to these 
inhibitory effects, curcumin administration was associated with increased urinary LTB4 
compared to a placebo in the present study. The significance of this finding is unclear as 
change in LTB4 was not associated with change in depressive symptoms. As hypothesised 
with SUB-P, urinary increases may be a more immediate or sensitive marker of change than 
plasma collections. Longer follow-up periods will be necessary to determine if this pattern 
occurs. 
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Tbx-B2: Tbx-B2 is an inactive metabolite of thromboxane A2 (Tbx-A2). Tbx-A2, an 
unstable arachidonic acid metabolite, is produced by activated platelets that elicit diverse 
physiological and pathophysiological actions, including platelet aggregation and smooth 
muscle contraction (Sellers & Stallone, 2008). In the brain, Tbx-A2 also contributes to 
peripheral adrenal catecholamine secretion (Okada, Murakami, & Yokotani, 2003). Elevated 
levels of Tbx-B2 have been found in patients with major depression , with positive correlations 
between cortisol and Tbx-B2 (Piccirillo et al., 1994). Treatment with sertraline in individuals 
with cardiac illness and comorbid depression decreased Tbx-B2 significantly after 16 weeks 
(Serebruany et al., 2003).  
Curcumin inhibits Tbx-B2 production in human platelets (Shah et al., 1999). In the present 
study, urinary levels trended upward after curcumin treatment but decreased following 
placebo intervention. This finding is contrary to what one might expect from an 
antidepressant agent, given findings of elevated blood levels in depressed patients and 
reductions associated with antidepressant therapies. However, Tbx-B2 concentrations have 
not previously been measured in urinary samples, which may account for this discrepant 
finding. As hypothesised with SUB-P and Tbx-B2, urinary increases may be transient, 
reflecting increased excretion. 
EGF:  EGF is a polypeptide that stimulates the proliferation of different cell types, 
especially fibroblasts and epithelial cells. In the central nervous system, EGF mRNA has been 
detected in several regions, including the brainstem, cerebellum, cerebral cortex, 
hippocampus, olfactory bulb, and striatum (Plata-Salaman, 1991). EGF concentrations are high 
in the CNS and play a critical role in controlling proliferation and differentiation of nervous 
tissue during neurogenesis (Xian & Zhou, 1999). EGF is also important in promoting wound 
healing and is expressed at sites of injury, inhibiting the activity of nitric oxide synthase and 
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dampening inflammation (Heck, Laskin, Gardner, & Laskin, 1992). In animal models, EGF 
deficiency results in several neurological, gastrointestinal, dermal, and pulmonary 
abnormalities (Miettinen et al., 1995). Acute and chronic pathological processes, particularly 
cancers, can stimulate the production and release of EGF in various cell systems (Bodnar, 
2013). EGF levels are also elevated during periods of prolonged stress (Asberg et al., 2009). 
Investigations into EGF concentrations in major depression are limited and in the only 
identified study, plasma EGF levels were significantly lower in depressed patients than in a 
control group (Tian et al., 2012).  
Studies on the effects of curcumin on the EGF system have largely investigated its role as 
a cancer treatment, where it down-regulates EGF receptor function and EGF expression 
(Shishodia, 2013). In the current study, curcumin did not change EGF concentrations, whereas 
placebo treatment was associated with increases in EGF levels. The causes for this are 
unknown and may simply be a reflection of differences in baseline concentrations of EGF 
across the two treatment groups (i.e., baseline EGF levels were higher in the curcumin group 
compared to the placebo group). However, it remains possible that curcumin buffered 
nonspecific increases in EGF concentrations over the course of treatment. The significance of 
this finding and its relevance to depression treatment requires further examination in more 
highly powered studies. 
Baseline biomarkers and their relationship to change in depression 
following curcumin treatment 
In curcumin-treated individuals, higher baseline plasma levels of ET-1 and leptin were 
associated with greater improvements in depressive symptoms. Further support for the 
importance of ET-1 in curcumin treatment was obtained in additional exploratory analyses. 
When individuals with high baseline ET-1 levels were examined (i.e. greater than the total 
sample mean of 1.47 pg/ml), curcumin had significantly greater efficacy in lowering IDS-SR30 
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scores (indicated by a significant group x time interaction). A large Cohen’s d effect size of 
1.26 was observed in curcumin-treated individuals compared to placebo.  
Given limitations associated with the small samples size in this study and the risk of type 
I error due to multiple correlational analyses, these findings should be considered preliminary 
and certainly require confirmation from studies with larger sample sizes. However, if this 
relationship can be replicated, treatment outcome might be enhanced by improved treatment-
matching. Potentially, depressed individuals with higher baseline ET-1 (and possibly leptin) 
have a greater likelihood of successful treatment with curcumin.  
ET-1: ET-1, a peptide with potent vasoactive effects, is widely expressed in brain cells. 
Altered expression of ET-1 in reactive astrocytes has been observed in many pathological 
conditions including infarcts, Alzheimer’s disease and inflammatory diseases of the brain 
(Schinelli, 2006). In the nervous system, ET-1 plays an important role in blood pressure 
regulation, blood-brain barrier permeability, respiratory control and renal sympathetic 
neuronal activity (Khimji & Rockey, 2010). There is also evidence that ET-1 and its associated 
receptors interact with dopamine release (van den Buuse & Webber, 2000). ET-1 also 
influences free radical production (Piechota, Polanczyk, & Goraca, 2010), HPA activity (Kiefer, 
Kellner, Jahn, & Wiedemann, 2000), and cytokine production (Giordano, Papakostas, Pecetti, 
& Nuti, 2011).  
From research on the endothelin system in major depression, an impaired endothelial 
function in depressed individuals has been demonstrated (Wagner et al., 2012), and severity of 
depressive symptoms predicted ET-1 elevations in patients with coronary artery disease 
(Burg, Martens, Collins, & Soufer, 2011). In the CSF, ET-1 concentrations were also reduced by 
approximately 50% in patients with major depression (Hoffman et al., 1989). Bosentan, a 
mixed endothelin receptor antagonist, also demonstrated antidepressant activity in mice 
(Pinho-Ribeiro et al., 2014).  
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Investigations into the effects of curcumin on the endothelin system are limited although 
curcumin inhibited ET-1 induced mitogenic and proliferative signalling events in vascular 
smooth muscle cells (Kapakos, Youreva, & Srivastava, 2012), and in diabetes-induced rats 
curcumin increased ET-1 concentrations in microvascular endothelial cells (Farhangkhoee, 
Khan, Chen, & Chakrabarti, 2006). In the present study curcumin did not alter ET-1 
concentrations, suggesting that the enhanced antidepressant efficacy of curcumin in people 
with higher concentrations of ET-1 were not due to its ET-1-lowering effects. The effects of 
curcumin may therefore be related to influences on endothelin receptor sensitivity or on 
inflammatory, HPA axis or oxidative stress processes which have been shown to be influenced 
by ET-1 concentrations.  
Relationship between change in biomarkers and change in 
depression following curcumin treatment 
In curcumin-treated individuals, reductions in leptin were associated with reductions in 
depressive symptoms. This association was not observed in placebo-treated individuals, 
indicating that it may be specifically related to the effects of curcumin. However, in placebo-
treated individuals, increases in urinary concentrations of ET-1, cortisol, and plasma HVEM 
were associated with reductions in depressive symptoms. 
Leptin, a peptide hormone secreted from adipocytes, plays a significant role in 
suppressing food intake and stimulating energy expenditure. Leptin concentrations are 
elevated in obesity, although its appetite-suppressing effects in obese individuals are thought 
to be compromised (Zhou & Rui, 2013). Leptin resistance may occur at several levels due to 
impaired transport of leptin across the blood brain barrier, a reduction in the function of leptin 
receptors, and damage to leptin signal transduction (Munzberg & Myers, 2005). Variability in 
leptin concentrations is commonly observed in major depression, though there are 
inconsistences in the direction of change. In the majority of animal-based studies lower levels 
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of leptin are associated with depressive behaviours. Human-based studies are inconsistent, 
with reports of increased and decreased leptin concentrations in depressed individuals (Lu, 
2007; Zupancic & Mahajan, 2011). It is believed that a state of leptin resistance, and factors 
such as age, sex and BMI, are major reasons for this inconsistent data (Lu, 2007).  A role of 
leptin in depression is also supported by studies showing antidepressant properties of leptin 
and its ability to influence monoamine activity, HPA regulation, neurotrophic actions, and 
immune responses (Lu, 2007). 
Investigations into the effect of curcumin on leptin levels and signalling have confirmed 
its influential effects. In animal and in vitro models, curcumin lowered leptin concentrations 
induced by various dietary and inflammatory stressors (Lee et al., 2013).  In a 6-month 
randomised, double-blind, placebo controlled trial on adults with type 2 diabetes, curcumin 
significantly decreased leptin levels (Chuengsamarn, Rattanamongkolgul, Phonrat, 
Tungtrongchitr, & Jirawatnotai, 2014). 
In the present study, the significance of leptin in major depression was further confirmed. 
At baseline, higher leptin levels were associated with greater antidepressant benefits from 
curcumin. In curcumin-treated individuals, reductions in leptin levels were also associated 
with reductions in depressive symptoms. While curcumin did not significantly lower leptin 
concentrations compared with placebo, benefits may have been derived from its effect on 
leptin receptor sensitivity or other metabolic factors associated with leptin. Alternatively, the 
lack of statistical power due to low sample sizes and lack of control for confounders (e.g., 
gender and BMI) may have hidden real changes in leptin induced by curcumin. Greater time 
intervals may also be required for curcumin to have an effect on leptin concentrations in 
plasma. 
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Limitations and Directions for Future Research 
The relatively small samples size and the large number of statistical analyses used in this 
study limits the reliability and statistical power associated with the findings. For evaluation of 
biomarker changes over time, samples of less than 40 were often used and numbers were even 
lower when examining the antidepressant effects of curcumin on people with high ET-1. The 
likelihood of type 1 error is also increased due to multiple statistical testing. The results from 
this study therefore require replication with larger sample sizes using greater controls for type 
1 error. 
Given problems associated with testing and biomarker stability, greater control around 
sample collection, storage, testing, and comparisons with non-depressed, matched samples 
will also be important. In the current study, participants were requested to collect samples in 
their home and to visit a local pathology centre for blood collection. Although convenient for 
participants, this may have increased variation in the time of collection and storage conditions 
of samples.  
Differences in findings across urine and plasma samples also require further clarification. 
In the present study, biomarker correlations across the plasma and urine samples were low 
and their response to curcumin supplementation was variable. In particular, greater 
understanding of urinary measurements are required to help decipher the most reliable and 
responsive sampling method for biomarker evaluation. 
As several markers of oxidative stress and activated immune-inflammatory pathways are 
associated with depression, testing for additional markers such as malondialdehyde, 8-oxo-2'-
deoxyguanosine, CRP, tryptophan catabolites along the kynurenine pathway, and selected 
cytokines would also be helpful (Adrian L. Lopresti, et al., 2014). Evaluation of biomarkers at 
more frequent intervals and comparisons with a healthy control group may also improve 
understanding about the mechanisms associated with the antidepressant actions of curcumin.  
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In this study the effect of curcumin on individual biomarkers was examined. However, 
given the multiple potential actions of curcumin, and the several mechanisms associated with 
major depression, it is unlikely that using a single biomarker in isolation will fully explain the 
antidepressant effects of curcumin. Improved sensitivity and specificity around diagnosis, 
treatment matching, and evaluation of treatment progress is only likely when multiple 
markers are collectively examined. This requires further research using larger sample sizes 
and the use of pattern analysis to identify relevant biomarker algorithms.   
While this 8-week study now represents the longest trial investigating the antidepressant 
effects of curcumin, greater treatment periods may be beneficial. Longer administration of 
curcumin may be necessary for curcumin to have effects on evaluated biomarkers. For 
example, in one study on people with osteoarthritis, reductions in IL-6, ESR and IL-1β 
continued for 8 months after treatment (Belcaro et al., 2010). Investigations to determine the 
optimal curcumin dosage and frequency of administration will also be useful. 
Finally, greater control for potential covariates such as medication use, medical illnesses 
and BMI will increase the strength of future findings, as will the use of clinician-rated 
instruments and the improved monitoring of curcumin intake, possibly through blood 
analysis. 
Conclusions 
In this randomised, double-blind, placebo controlled study several important preliminary 
findings were identified: 
1. Compared to a placebo, 8 weeks of curcumin supplementation was associated with 
elevations in urinary levels of LTB4, Tbx-2 and SUB-P. In placebo-treated individuals 
there were increases in plasma levels of EGF, while no changes were observed 
following curcumin treatment. Determining reasons for these increases in urinary 
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biomarkers are difficult as they were mostly opposite to what might be hypothesised 
from both curcumin and antidepressant treatment.  Investigations with larger samples 
and comparisons with non-depressed, matched populations will enhance 
understanding of these findings. One possible explanation is that baseline levels were 
low in the depressed sample and then normalised following curcumin treatment. 
Alternatively, elevated urinary levels may be a reflection of increased urinary excretion 
with a stabilisation or even reduction in urine and/or plasma over the longer term. 
Biomarkers measured through urinary samples as opposed to blood samples may also 
account for these discrepant results. The collective examination of biomarkers rather 
than in isolation may also increase clarification about the mechanisms associated with 
curcumin supplementation. 
2. In depressed individuals, higher baseline levels of plasma ET-1 were associated with an 
enhanced antidepressant benefit from curcumin supplementation. On the whole, 
people with high baseline ET-1 levels (above 1.47 pg/ml) experienced significant 
antidepressant benefits from curcumin. Interpreting this finding is difficult as curcumin 
supplementation was not associated with changes in ET-1 levels. It is speculated that 
curcumin enhanced endothelin receptor sensitivity or some other mechanism 
associated with ET-1 production which, in turn, had antidepressant effects. 
3. In depressed individuals, higher baseline levels of plasma leptin were associated with 
an enhanced antidepressant benefit from curcumin supplementation. Moreover, a 
reduction in plasma leptin levels in curcumin-treated, depressed patients was 
associated with improvements in depressive symptoms. This suggests that the 
antidepressant benefits from curcumin are at least partly derived from is effect on 
leptin and possibly leptin resistance.  
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Chapter 7:  
Conclusions & Recommendations 
As has been detailed previously, the aims of this thesis are outlined below: 
Aim 1: Review dysregulated biological pathways associated with major depression and 
examine the influence of lifestyle-based factors; and psychological and 
pharmacological interventions on these pathways. 
Aim 2: Review studies investigating the influence of curcumin on depressogenic biological 
pathways and, through a randomised, double-blind, placebo-controlled study, 
investigate its antidepressant efficacy in people with major depressive disorder. 
Aim 3: Review and investigate the potential of peripheral biomarkers to evaluate treatment 
success, identify antidepressant mechanisms of change and predict treatment 
response. This was subsequently examined in a clinical study evaluating the efficacy of 
curcumin for the treatment of depression.  
Conclusions, limitations and recommendations for future research associated with each of 
these aims are outlined below. 
Aim 1: Dysregulated biological depressogenic pathways and important influences 
In previous chapters it was demonstrated that major depression is associated with several 
dysregulated biological pathways which can be influenced by an array of past and current 
lifestyle, psychological, and biological factors. Consequently, it is hypothesised that positive 
lifestyle changes in these areas, along with psychological, pharmaceutical, nutraceutical and 
biological-based treatments, can lead to a resolution of depressive symptoms. As detailed in 
Figure 3, these changes have the potential to normalise biological pathways and consequently 
lead to improvements in depressive symptoms. Improved mood and cognitive outlook are 
Chapter 7: Conclusions & Recommendations  
- 254 - 
also likely to contribute to positive lifestyle-based changes, further normalising these 
biological pathways. 
 
Figure 3. Treatment options to reduce dysregulated biological pathways associated with major 
depression. Several lifestyle, dietary, psychological, pharmacological and nutraceutical 
options (left of figure) can promote positive changes in the dysregulated biological 
pathways (centre of figure). Improvements in depressive symptoms may ensue, leading to 
further positive lifestyle, dietary and psychological changes (represented by top arrow). A 
feed-forward process ensues with increasing symptom resolution over time.  
 
However, there remain several areas that require further investigation. While the 
reviewed lifestyle factors are commonly associated with major depression, association does 
not confirm causation, and greater control for confounding variables is necessary. High-
quality interventional studies are also needed, particularly examining dietary treatments for 
major depression. Although a healthy diet is protective against depression, there is currently a 
lack of studies examining the efficacy of dietary interventions on depressive symptoms in 
people with major depressive disorder. The same also applies with investigations into the 
efficacy of weight-loss interventions for people with depression. In addition, while it has been 
hypothesised that positive lifestyle changes normalise dysregulated biological pathways and 
lead to consequent improvements in depressive symptoms, this has received very little 
attention in the research literature. Even though positive lifestyle changes, psychological 
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therapies and pharmaceutical interventions are effective treatments for depression, it is 
currently unknown whether a normalisation in biological pathways is essential for 
symptomatic improvements to occur. This topic has been investigated in several 
pharmaceutical trials but findings are inconsistent. Finally, the efficacy of psychological 
therapies has traditionally been measured through clinician-administered and self-report 
inventories. However, the inclusion of biomarker evaluation will also help to expand 
understanding into the biological mechanisms of change associated with psychological 
therapies. 
Aim 2: Curcumin for the treatment of major depression 
While several nutraceuticals have demonstrated efficacy for the treatment of mild-to-
moderate major depressive disorder, clinical studies on the antidepressant effects of curcumin 
are scarce. Given the influence of curcumin on several antidepressant biological mechanisms, 
it was hypothesised that curcumin would be an effective treatment for major depressive 
disorder. This was evaluated in the first randomised, double-blind, placebo controlled study 
on people with major depression. Overall, findings from this study provide initial support for 
the antidepressant effects of curcumin in people with major depressive disorder. As detailed 
in Lopresti et al. (2014a) curcumin was significantly more effective than a placebo for the 
treatment of major depression, with greater improvements occurring from weeks 4 to 8. 
Limitations associated with this study and recommendations for future research have already 
been covered in Lopresti et al. (2014a) and comprise the following: 
 Problems associated with small sample sizes. 
 The examination of only a single dosage (1000 mg/day), duration (8-weeks) and 
frequency (twice daily) of curcumin supplementation. 
 The sole use of self-report inventories to measure symptomatic treatment response. 
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 Limited evaluation of potential confounding variables e.g., antidepressant medication, 
psychological therapy, acute and chronic depression, age and gender. 
 Investigation into the potential and suitability of curcumin as a stand-alone or 
adjunctive treatment for major depression. 
 Further examination into the efficacy of curcumin on differing depressive subtypes. 
This is particularly pertinent given the preliminary finding of greater antidepressant 
benefits associated with atypical depression.  
Although the primary goal of this thesis was to investigate the antidepressant efficacy of 
curcumin, there remain an array of other nutraceuticals with potential antidepressant efficacy. 
One example includes Crocus sativus (saffron) which has demonstrated efficacy for the 
treatment of mild-to-moderate depressive disorder. A published systematic review on the use 
of saffron for the treatment of major depression is included in Appendix 1 (Lopresti and 
Drummond, 2014).  
Aim 3: Peripheral biomarkers and depression: its application in a curcumin trial 
The role of peripheral biomarkers for diagnostic, treatment-evaluative and treatment-
matching purposes in major depression also comprised a significant component of this thesis. 
The following hypotheses were made: 
1. The antidepressant mechanisms associated with curcumin can be evaluated through 
pre- and post-collections of peripheral biomarkers. 
2. Curcumin will have greater antidepressant efficacy for specific subgroups of 
individuals with major depressive disorder. These subgroups can be identified 
through baseline biomarker concentrations which may facilitate patient-treatment 
matching and therefore increase treatment success.  
Overall, both these hypotheses received preliminary support. Changes in urinary leukotriene 
B4, thromboxane B2 and substance P were significantly associated with changes in depressive 
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symptoms following curcumin treatment, and provide indications of the potential 
antidepressant mechanisms of curcumin. In addition, higher baseline plasma concentrations of 
endothelin-1 and leptin were associated with increased treatment efficacy. The relevance of 
these findings has been fully explored in Lopresti, et al. (2014c). Limitations associated with 
the study and recommendations for future research have also been explored in this paper. 
Briefly, some of the limitations included: 
 No biomarker comparisons with healthy, matched populations. 
 Limited frequency of biomarker measurements i.e., collections were only undertaken 
at baseline and end-point. 
 Problems associated with multiple statistical tests and consequent increased risk for 
type 1 error. 
 Limited control and investigation into biomarker collection, storage and testing 
protocols. 
In addition, there remains an array of potential peripheral biomarkers that were not 
examined in this clinical trial, and many of them were outlined Lopresti et al. (2014b). 
Examples include biomarkers assessing immuno-inflammation such as CRP, pro-
inflammatory cytokines and TRYCATs (e.g., kynurenine, kynurenic acid and quinolinic acid); 
and markers of oxidative and nitrosative stress such as 8-hydroxy-2-deoxyguanosine, 
malondialdehyde and conjugated nitric-oxide adducts. These biomarkers could not be 
measured in this clinical trial due to financial constraints but may provide further indications 
about the potential mechanisms of change associated with curcumin treatment and may 
facilitate improved treatment-matching. 
Findings from this study have also highlighted the potential utility of biomarker testing 
in major depression and it is recommended that biomarkers be more consistently investigated 
in future clinical trials utilising lifestyle, psychological and pharmaceutical treatments. While 
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progress in improving treatment response rates over the past decade has been disappointing, 
the addition of biomarker evaluations may improve patient-treatment matching and therefore 
increase the likelihood of treatment success. 
Summary 
In sum, investigations from this thesis add to the current depression research literature 
through several areas. First, lifestyle effects on depressogenic biological pathways have been 
comprehensively reviewed and areas for future research are suggested.  Second, preliminary 
support for the antidepressant effects of curcumin in people with major depressive disorder 
has been provided. Further research is required to replicate the current findings. Third, the 
potential of peripheral biomarkers to examine antidepressant mechanisms of change and 
facilitate treatment matching has been reviewed and investigated in a clinical trial using 
curcumin. The potential of biomarker assessments to increase treatment response rates 
through improved treatment matching has also been reviewed. 
Major depression is a common disorder that causes significant suffering for individuals 
and their family. While effective treatments are available, they are far from perfect. It is hoped 
that with further research in the areas covered in this thesis, we can expand our 
understanding of this complex disorder and improve treatment efficacy.  
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Abstract 
BACKGROUND: Saffron, a spice derived from the flower of Crocus sativus, has now 
undergone several trials examining its antidepressant effects, and in a recent meta-analysis, 
was confirmed to be effective for the treatment of major depression. 
OBJECTIVE: To provide an expanded systematic analysis of the completed clinical studies on 
saffron and depression, detailing dosages, extract sources, standardisations, safety profile and 
treatment duration; and, through a narrative review, examine its potential antidepressant 
mechanisms of action. 
DESIGN: In the systematic review of clinical trials, electronic databases were searched for 
high-quality, randomised, double-blind studies, with placebo or antidepressant-controls. A 
narrative review of in vivo and in vitro studies was conducted to examine its potential 
antidepressant mechanisms of action. 
RESULTS: In the systematic review, six studies were identified. In the placebo-comparison 
trials, saffron had large treatment effects and when compared to antidepressants medications, 
had similar antidepressant efficacy. Saffron’s antidepressant effects potentially are due to its 
serotonergic, antioxidant, anti-inflammatory, neuro-endocrine and neuroprotective effects.  
CONCLUSIONS: Research conducted so far provides initial support for the use of saffron for 
the treatment of mild to moderate depression. Further research is required to expand our 
understanding of the role and actions of saffron in major depression. 
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Introduction 
Saffron is the dried elongated stigmas and styles of the blue-purple saffron flower 
(Crocus sativus, L.). At a retail price of up to USD $11,000 per kilogram it is the world’s most 
expensive spice, reflected by the labour intensiveness associated with its production. It is 
estimated that it takes approximately 150,000 crocus blossoms or 450,000 hand-picked stigmas 
to produce just one kilogram of this unique spice (Melnyk et al., 2010, Schmidt et al., 2007).  
Saffron stigmas contain four major bioactive compounds (Figure 1); crocins (family of six 
mono-glycosyl or di-glycosyl polyene esters), crocetin (a natural carotenoid dicarboxylic acid 
precursor of crocin), picrocrocin (monoterpene glycoside precursor of safranal and product of 
zeaxanthin degradation), and safranal. Crocins and crocetin are responsible for the colour, 
pricrocrocin the taste, and safranal the aroma, although collectively these compounds are 
responsible for the health-enhancing properties associated with saffron (Melnyk et al., 2010, 
Moghaddasi, 2010).  In addition to these compounds, saffron contains in excess of 150 volatile 
and aroma-yielding compounds and many non-volatile active components, many of which are 
carotenoids, including zeaxanthin, lycopene, beta-carotenes and polysaccharides (Sampathu et 
al., 1984). 
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Figure 1. Chemical structures of major components in saffron 
 
As a result of its characteristic bitter taste, pungent hay-like aroma and luminous yellow-
orange colour, saffron is used in fragrances, flavourings, colouring agents and medicines 
(Melnyk et al., 2010). In traditional medicine, saffron has been used as an anticonvulsive, 
analgesic, aphrodisiac, antispasmodic and expectorant (Hosseinzadeh and Nassiri-Asl, 2013). 
Modern pharmacological studies have demonstrated that extracts of saffron stigmas have 
anticancer, anti-inflammatory, antioxidant and antiplatelet effects (Moshiri et al., 2006, Wang 
et al., 2010). Recent clinical trials have also suggested a potential for saffron in the treatment 
and prevention of Alzheimer’s disease (Akhondzadeh et al., 2010a, Akhondzadeh et al., 2010b) 
and macular degeneration (Falsini et al., 2010, Piccardi et al., 2012). Saffron also has the 
potential to enhance mental health through it antidepressant properties and in a recent meta-
analysis was confirmed to be effective for the treatment of depression (Hausenblas et al., 
2013). The purpose of this review is to examine the potential underlying antidepressant 
mechanisms of action of saffron, and provide an expanded systematic analysis of the 
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completed clinical studies on saffron and depression, detailing dosages, extract sources, 
standardisations, safety profile and length of treatment.  
Potential antidepressant mechanisms of action of saffron 
Given the many active constituents contained in saffron it has several potential 
antidepressant mechanisms of action. A review of in vitro and in vivo animal or human-based 
studies indicate that some of the underlying mechanisms which have relevance for the 
treatment of depression include its antioxidant, anti-inflammatory, serotonergic, 
hypothalamus-pituitary-adrenal (HPA) axis-modulating and neuroprotective effects.  
Antioxidant effects 
Major depression is associated with elevated levels of oxidative stress and reduced 
antioxidant defences (Maes et al., 2011, Maes et al., 2012b, Palta et al., 2014). In a recent meta-
analysis on twenty-three studies with 4980 participants, an increased oxidative stress and 
lowered antioxidant status among individuals with depression was confirmed (Palta et al., 
2014). Depression is specifically associated with lowered antioxidant enzymes such as 
superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase, and increased 
markers of oxidative stress such as malondialdehyde (MDA) (Lopresti et al., 2014). It is 
posited that increased oxidative stress in depression influences inflammatory and immune 
responses, disrupts neurotransmitter balance and contributes to increased neurodegeneration 
(Leonard and Maes, 2012). 
Saffron, and its constituents, crocin, crocetin and safranal, are potent antioxidants. In 
animal studies, safranal and crocin increased CAT activity in liver tissue (Asdaq and Inamdar, 
2010, Farahmand et al., 2013, Samarghandian et al., 2013), while all three constituents 
increased SOD levels (Asdaq and Inamdar, 2010, El-Beshbishy et al., 2012, Farahmand et al., 
2013, Samarghandian et al., 2013, Shen and Qian, 2006), and glutathione availability 
Appendix 1: Saffron (Crocus Sativus) for depression 
Paper accepted for publication 
- 264 - 
(Farahmand et al., 2013, Razavi et al., 2013, Samarghandian et al., 2013, Shen and Qian, 2006). 
Saffron and its constituents also protected against oxidative stress, evidenced by its lowering 
effect on markers of lipid peroxidation such MDA (El-Beshbishy et al., 2012, Farahmand et al., 
2013, Samarghandian et al., 2013, Wang et al., 2012), thiobarbituric acid reactive substance 
(TBARS), (Ahmad et al., 2005, Sadeghnia et al., 2013, Shen and Qian, 2006), and 8-iso-
prostaglandin F(2 beta) (Hariri et al., 2010).   
Although safranal, crocin and crocetin each have strong antioxidant effects, it seems that 
their potency is greatest when delivered collectively. In a comparison on the effects of crocin 
only versus saffron on several antioxidant enzymes and markers of oxidative stress, both 
demonstrated benefits, although the effects of saffron were superior (Asdaq and Inamdar, 
2010). This highlights the synergistic effects of the constituents found in saffron in 
ameliorating oxidative stress. 
Anti-inflammatory effects 
Over the past decade researchers have increasingly investigated the influence of 
inflammation and immune system dysregulation in major depression. From meta-analyses it 
has been established that depression is associated with increased C-reactive protein (Howren 
et al., 2009, Valkanova et al., 2013),  interleukin-6 (IL-6) (Liu et al., 2012, Valkanova et al., 2013), 
and tumour necrosis factor-α (TNF- α) (Dowlati et al., 2010, Hiles et al., 2012, Liu et al., 2012). 
Anti-inflammatory actions from antidepressant medications have also been confirmed from 
two recent meta-analyses (Hannestad et al., 2011, Hiles et al., 2012). Further support for a role 
of inflammation in depression is provided by studies demonstrating significant co-morbidity 
between inflammatory-based diseases and major depression (e.g., cardiovascular disease, 
cancer, digestive diseases and post-viral infection), and the capacity of cytokine therapy for 
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the treatment of hepatitis C to trigger depressive symptoms (Anderson et al., 2014, Raison et 
al., 2006, Raison and Miller, 2011).  
From investigations on crocin and crocetin, it has been confirmed that saffron has strong 
anti-inflammatory effects (Poma et al., 2012). In an in vitro study, crocin exhibited dual 
inhibitory activity against the cyclooxygenase-1 (COX-1) and COX-2 enzymes and inhibited 
the production of prostaglandin E(2) PGE(2) (Xu et al., 2009). The chemical induction of 
arthritis in mice elevated serum levels of TNF-α, IL-1β, nuclear factor- κB (NF-κB), IL-6, COX-
2, and PGE(2), which was effectively neutralised by crocin (Hemshekhar et al., 2012). In 
chemically induced colitis in mice, crocin decreased the mRNA expression of TNF-α, IL-1β, 
IL-6, interferon- γ (IFN-γ), NF-κB, COX-2, and inducible nitric oxide synthase (Kawabata et 
al., 2012). Crocin and crocetin also reduced lipopolysaccharide-stimulated microglial cell 
production of TNF-α, IL-1β, and NF-κB activation (Nam et al., 2010).  
Recent evidence suggests that saffron drives a shift toward T-helper 2 (Th2) immunity. 
The oral administration of alcoholic extract of saffron to mice potentiated the Th2 response of 
humoral immunity causing an elevation of CD19(+) B cells and IL-4 cytokine. However, 
saffron had no appreciable effect on the T-helper 1 (Th1) cytokines, IL-2 and IFN-γ  (Bani et 
al., 2011). This Th2 upregulation may be particularly beneficial in depression as it is associated 
with an over activation of Th1 (or cell-mediated) immunity (Maes et al., 2012a). 
Serotoninergic effects 
Neurotransmitter imbalances are commonly cited as a primary cause of major depression, 
with greatest interest in the serotonergic system. Evidence of dysfunction in the serotonergic 
system is supported by tryptophan depletion studies which induce depressive symptoms in 
people with a history of depression (Hood et al., 2005, Toker et al., 2010), research 
demonstrating abnormalities in serotonin receptors in depressed patients (Carr and Lucki, 
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2011), and evidence of abnormalities in the expression of the enzyme tryptophan hydroxylase 
in depressed individuals (Matthes et al., 2010).  Further support is also provided by the 
popularity and effectiveness of serotonin reuptake inhibitors (SSRIs) (Cowen, 1990, Maletic et 
al., 2007).  
Investigation into saffron’s effect on serotonin availability is limited, although this is 
proposed as one potential mechanism of action. Obesessive-compulsive-like behaviour in 
rodents in the form of excessive self-grooming was induced by the administration of meta-
Chlorophenylpiperazine (mCPP), a non-selective serotonin (5-HT) receptor agonist displaying 
affinity for the 5-HT2c family receptors. These behaviours were significantly reduced by the co-
administration of crocin. These results suggest that crocins influence serotonergic mechanisms 
by having an antagonistic action at the 5-HT2c receptor site (Georgiadou et al., 2012). The 
influence of saffron on serotonin availability is also indicated by its effect on premenstrual 
symptoms, which are theorised to be at least partly associated with the serotonergic system; 
however, this requires further investigation (Agha-Hosseini et al., 2008). 
HPA-modulating effects 
Alterations in HPA activity have long been recognised in major depression, with a 
significant portion of depressed patients exhibiting HPA hyperactivity and elevated cortisol 
levels (Pariante and Lightman, 2008). Depression is also associated with an elevated secretion 
of corticotrophin releasing hormone and an impairment in the negative feedback 
responsiveness to glucocorticoids, a phenomenon known as glucocorticoid resistance (Pace et 
al., 2007, Zunszain et al., 2011). An increased size and activity of the pituitary and adrenal 
glands is also observed in depression (Kempton et al., 2011). This HPA dysregulation 
influences neurotransmitter availability, oxidative stress and inflammation, and can contribute 
to neurodegeneration (Zunszain et al., 2011).  
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The investigation of saffron on HPA modulation is limited, although preliminary 
evidence suggests a role in lowering the HPA response to stress. In mice exposed to 
electroshock stress, safranal and crocin extracts prevented elevations in plasma corticosterone 
levels (Halataei et al., 2011, Hooshmandi et al., 2011). The injection of crocin to rats over a 
period of 21 days during exposure to chronic restraint stress also significantly decreased 
plasma levels of corticosterone (Ghadrdoost et al., 2011). In a human trial on female 
participants, exposure to saffron odour for 20 minutes significantly lowered cortisol levels in 
both the follicular and luteal phases. This was also associated with reductions in symptoms of 
anxiety (Fukui et al., 2011). 
Neuroprotective effects 
Major depression is associated with compromised neurogenesis and neuronal plasticity, 
and low levels of brain-derived neurotrophic factor (BDNF) is common (Duman, 2009, Lee 
and Kim, 2010). Alterations in growth factor expression can influence neurogenesis and can 
contribute to structural changes in the hippocampus, nucleus accumbens, and prefrontal 
cortex (Jiang and Salton, 2013). The chronic administration of several classes of 
antidepressants, including monoamine oxidase inhibitors, SSRIs, tricyclic agents, and 
serotonin noradrenaline reuptake inhibitors (SNRIs) are associated with increases in BDNF 
concentrations (Duman and Monteggia, 2006, Sen et al., 2008).  
In two separate studies, the neuroprotective effects of saffron (Ghasemi et al., 2014) and 
its constituent, crocin (Vahdati Hassani et al., 2014) were examined in rats exposed to the 
forced swimming test.  A western blot analysis showed that crocin dose-dependently 
increased levels of CREB (cAMP response element binding protein) and BDNF, and at higher 
levels elevated concentrations of VGF (a neuropeptide) in the hippocampus (Vahdati Hassani 
et al., 2014). An aqueous extract of saffron also increased hippocampus concentrations of 
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BDNF, CREB, phospho-CREB, and transcription levels of BDNF (Ghasemi et al., 2014). 
Crocetin also protects neurons in the cerebrocortical and hippocampus regions in rats exposed 
to chronic cerebral hypoperfusion (Tashakori-Sabzevar et al., 2013).  Pre-treatment with 
safranal also protects the rat hippocampus from quinolinic acid-induced oxidative stress by 
lowering levels of lipid peroxidation, oxidative DNA damage and preventing decreases of 
hippocampal thiol redox and antioxidant status (Sadeghnia et al., 2013). 
From the reviewed literature, saffron has several potential antidepressant mechanisms of 
action. However, as most of the studies are in vitro or animal-based, human-based 
investigations are required to better elucidate the antidepressant actions of saffron. Because 
plant constituents undergo significant metabolism via enzymatic and hepatic processes and 
have varying levels of bioavailability, in vitro and animal studies do not necessarily translate 
to human biological processes (Sarris et al., 2011). Further human-based investigations are 
therefore required. Also, while the reviewed antidepressant mechanisms of action of saffron 
have been discussed separately, they are not mutually exclusive and greater understanding of 
their interaction will be important.  
In the subsequent sections, findings from a systematic review of clinical studies are 
detailed, and include a comprehensive appraisal of patient characteristics; dosages, extract 
sources, and standardisations used; safety profile of saffron; and length of treatment. 
Methods 
Information for this systematic review was compiled by the first author by searching 
PubMed, Google Scholar, PsycINFO and The Cochrane Library databases and by examining 
reference lists of relevant papers to locate additional studies that were not identified by the 
database searches. Databases were scanned from all years of study until April 2014. 
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Search strategy and eligibility criteria for clinical studies 
A systematic search of controlled clinical trials using the terms “depression”, “crocus”, 
“saffron” was completed. Specific inclusion criteria for clinical studies included: (1) published 
in English, (2) reported randomisation strategies, (3) used double-blind controlled protocols, 
(4) published in peer-reviewed journals, and (5) had a placebo control or antidepressant-
comparison group. When there was sufficient data from clinical trials, effect sizes as Cohen’s d 
was calculated by using change in depression scores (from baseline to endpoint) and then 
dividing this by the standard deviation of each condition. 
Quality of clinical studies 
The methodological quality of studies was assessed by using the CONSORT 2010 
checklist for clinical trials guidelines (Schulz et al., 2010) and by computing a Jadad score 
(Jadad et al., 1996). 
Results 
Search results 
Based on the systematic search of clinical studies, a total of 17 studies were identified. Ten 
studies were excluded because participants did not undergo a formal diagnosis of depression 
or were from a non-depressed population. One study was excluded because it did not have a 
placebo control or antidepressant comparison group. Six studies met all inclusion criteria and 
were included in this systematic review. In Figure 2, the process of inclusion of studies in this 
review is detailed. The main characteristics of the included studies are detailed in Table 1. Of 
the reviewed studies, all were completed by the same Iranian research group. 
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Figure 2. Process of study inclusion in systematic review
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Table 1. Summary of Clinical Studies on the Antidepressant Effects of Saffron 
Study Duration Study design Participants 
Completion 
rate 
Depression 
Measures 
Intervention Control Main Results 
Akhondzadeh 
et al., (2005) 
6 weeks Randomised, 
double blind, 
placebo 
control 
n = 40 
Baseline 
HAM-D = 23 
18 women & 
22 men 
n = 35 
No difference 
in dropout 
rate between 
groups. 
 
Diagnosis: 
SCID-IV 
Outcome: 
HAM-D 
15 mg saffron 
(stigma), BD 
Standardised extract: 
not specified 
Placebo Greater reduction in HAM-D -17 for saffron 
group compared to placebo. 
Changes at endpoint compared to baseline 
were: −12.20 ± 4.67 (mean ± SD) and −5.10 ± 4.71 
for saffron and placebo respectively 
Cohen’s d effect size 1.51 
Moshiri et al., 
(2006) 
6 weeks Randomised, 
double blind, 
placebo 
control 
n = 40  
Baseline 
HAM-D = 22 
17 women & 
23 men 
n = 36 
No difference 
in dropout 
rate between 
groups. 
 
Diagnosis: 
SCID-IV 
Outcome: 
HAM-D 
15 mg saffron (petal), 
BD 
Standardised extract: 
not specified 
Placebo Statistically significant reduction in depression 
HAM-D -17 compared to placebo. 
Changes at endpoint compared to baseline 
were: −14.01 ± 5.53 (mean ± SD) and −5.05 ± 4.63 
for saffron and placebo respectively 
Cohen’s d effect size 1.76 
Akhondzadeh 
et al., (2004) 
6 weeks Randomised, 
double blind, 
antidepressant 
control 
n = 30  
Baseline 
HAM-D = 19 
17 women & 
13 men 
All 
completed 
trial 
Diagnosis: 
SCID-IV 
Outcome: 
HAM-D 
10 mg saffron 
(stigma), TDS  
Standardised extract: 
not specified 
Imipramine 
100 mg/day 
(TDS). 
Significant reduction in HAM-D-17 for both 
groups. No significant differences between 
groups. 
Noorbala et 
al., (2005) 
6 weeks Randomised, 
double blind, 
antidepressant 
control 
n = 40 
Baseline 
HAM-D = 23 
20 women & 
20 men 
n = 38 
No difference 
in dropout 
rate between 
groups. 
 
Diagnosis: 
SCID-IV 
Outcome: 
HAM-D 
15 mg saffron 
(stigma), BD 
Standardised extract: 
0.30-0.35 mg safranal/ 
capsule 
Fluoxetine 
10 mg BD 
Significant reduction in HAM-D-17 for both 
groups. No significant differences between 
groups. 
Changes at endpoint compared to baseline 
were: −12.20 ± 4.67 (mean ± SD) and −15.00 ± 
5.88 for saffron and fluoxetine respectively 
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Akhondzadeh 
Basti et al., 
(2007) 
8 weeks Randomised, 
double blind, 
antidepressant 
control 
n = 40 
Baseline 
HAM-D = 22 
21 women & 
19 men 
n = 38 
No difference 
in dropout 
rate between 
groups. 
 
Diagnosis: 
SCID-IV 
Outcome: 
HAM-D 
15 mg saffron (petal), 
BD 
Standardised extract: 
0.30-0.35 mg safranal/ 
capsule 
Fluoxetine 
10 mg BD. 
Significant reduction in HAM-D-17 for both 
groups. No significant differences between 
groups. 
Changes at endpoint compared to baseline 
were: −12.00 ± 4.10 (mean ± SD) and −13.50 ± 
4.91 for saffron and fluoxetine respectively 
Shahmansouri  
et al., (2014) 
6 weeks Randomised, 
double blind, 
antidepressant 
control 
n = 40  
All patients 
undergone 
PCI in the 
last 6 
months 
Baseline 
HAM-D = 17 
25 women & 
15 men 
All 
completed 
trial 
Diagnosis: 
SCID-IV 
Outcome: 
HAM-D 
15 mg saffron 
(stigma), BD 
Week 1: one capsule, 
QD every 2nd day. 
Week 2: one capsule, 
QD. 
Weeks 3-6: one 
capsule, BD 
Standardised extract: 
0.13-0.15 mg of 
safranal and 1.65-1.75 
mg crocin/ capsule 
20 mg 
fluoxetine, 
BD 
Same 
regimen as 
saffron 
Significant reduction in HAM-D-17 for both 
groups. No significant differences between 
groups. 
Changes at endpoint compared to baseline were: 
-11.65 ± 4.39 (mean ± SD) and -12.30 ± 3.94 for 
saffron and fluoxetine respectively 
QD= once daily; BD = twice daily; TDS = three times daily; HAM-D -17 - Hamilton rating scale for depression; SCID-IV = structured clinical interview for DMS IV; PCI = 
percutaneous coronary intervention 
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Quality of clinical studies 
The Jadad score calculated for all clinical trials was 5, indicating high-quality research 
designs. All clinical studies also met greater than 20 of the 25 CONSORT 2010 checklist items, 
further supporting high quality of trial designs. 
Sample characteristics 
A total of 230 adult outpatients (118 women and 112 men) diagnosed with major 
depressive disorder were enrolled across all studies. In all studies, major depression was 
diagnosed based on the structured clinical interview for DSM-IV (SCID-IV), and the Hamilton 
Rating Scale for Depression (HAM-D 17-item) was used as the primary outcome measure. 
Mean baseline HAM-D ranged from 19 to 23 indicating a moderate severity of depression. 
Adult participants from the ages 18 to 55 years were included in five studies. In the study by 
Shahmansouri et al (2014) (using participants who had received a percutaneous coronary 
intervention in the past year), the age of inclusion ranged from 20 to 60 years. Mean ages 
ranged from 34 to 37 years in five studies, except for the study by Shahmansouri et al., (2014) 
where the average age was 52 years. Prior to commencement in all studies, participants were 
free from all psychotropic medications for at least 4 weeks.  
Comparison of saffron with placebo control 
In two randomised, double-blind, placebo-controlled trials, saffron was effective for the 
treatment of mild-to-moderate depression (Akhondzadeh et al., 2005, Moshiri et al., 2006). At 
a daily dose of 30mg/day of crocus sativus, stigma or petal, a large Cohen's d of 1.51 (95% CI: 
0.14 - 2.97) (Akhondzadeh et al., 2005) and 1.76 (95% CI: 0.26 - 3.34) (Moshiri et al., 2006) was 
determined.  
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Comparison of saffron with antidepressant treatment 
When compared to antidepressant medication, reflected by four published randomised, 
double-blind, placebo controlled trials, saffron had similar efficacy (Akhondzadeh Basti et al., 
2007, Akhondzadeh et al., 2004, Noorbala et al., 2005). In a 6-week trial, at a dosage of 30 
mg/day, extracts of saffron stigma were as effective as fluoxetine (20 mg/day) for the treatment 
of mild-to-moderate depression (Noorbala et al., 2005). Similar findings were obtained with 
petal extracts of Crocus sativus following an 8-week trial compared to fluoxetine 
(Akhondzadeh Basti et al., 2007). In another trial, extracts of saffron stigma (30 mg/day) had 
similar antidepressant effects to imipramine (100mg/day). In a recently published randomised, 
double-blind study, saffron was also as effective as fluoxetine in reducing symptoms of 
depression in patients who had recently undergone percutaneous coronary intervention 
(Shahmansouri et al., 2014).  
Duration of treatment 
In five studies, the intervention period was 6 weeks, and in one was 8 weeks (Akhondzadeh 
Basti et al., 2007). Statistically significant improvements in depressive symptoms were reported 
after the first week, although depressive symptoms continued to subside as treatment 
progressed. Weekly improvements generally continued throughout the length of treatment; 
however, progress after 8 weeks is unknown as no long-term follow up studies have been 
conducted. When compared to the antidepressants imipramine and fluoxetine, saffron had a 
similar recovery profile over time (Akhondzadeh Basti et al., 2007, Akhondzadeh et al., 2004, 
Noorbala et al., 2005, Shahmansouri et al., 2014). 
Dosage and standardisations 
A dosage of 30mg/day delivered in two, equal doses was used in all clinical studies. As 
summarised in Table 1, saffron extracts standardised for crocin and/ or safranal were used in 
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three studies (Akhondzadeh Basti et al., 2007, Noorbala et al., 2005, Shahmansouri et al., 2014), 
while in the remaining three studies there were no reported standardisations for the active 
constituents (Akhondzadeh et al., 2004, Akhondzadeh et al., 2005, Moshiri et al., 2006). When 
standardisations were reported, two trials used extracts containing 0.30-0.35 mg safranal / 15 
mg capsule (Akhondzadeh Basti et al., 2007, Noorbala et al., 2005) and one used 0.13-0.15 mg 
of safranal and 1.65-1.75 mg crocin/ 15mg capsule (Shahmansouri et al., 2014). From an 
examination of the magnitude of change in depressive symptoms associated with these 
standardised and non-standardised extracts, it seems that their treatment efficacy was 
comparable. In the standardised extracts there were mean reductions of 12.00 (SD = ±4.10) 
(Akhondzadeh Basti et al., 2007), 12.20 (SD = ±4.67)  (Noorbala et al., 2005) and 11.65 (SD = 
±4.39) (Shahmansouri et al., 2014) in the HAM-D. In the non-standardised extracts there were 
mean HAM-D reductions of 12.20 (SD = ±4.67) (Akhondzadeh et al., 2005), and 14.01 (SD = 
±5.53) (Moshiri et al., 2006).  
Extract source 
The stigma of Crocus sativus have been used in 4 studies and the petal has been used in 2 
studies. Efficacy rates are similar using the two extracts as indicated by mean HAM-D 
reductions ranging from 11.65 (SD = ±4.39) to 12.20 (SD = ±4.67) in studies using the stigma 
and reductions of 11.65 (SD = ±4.39) and 14.01 (SD = ±5.53) in studies using the petal. 
Adverse events 
Adverse events reported in the reviewed clinical trials are detailed in Tables 2 and 3. In 
Table 2 details of reported side effects in antidepressant-control trials (fluoxetine and 
imipramine) are provided, and in Table 3 adverse events reported in placebo-controlled trials 
are listed. The statistical significance of differences in adverse events could not be calculated 
across all treatment studies. However, an inspection of frequency data indicate increased 
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reports of sedation/drowsiness, headache, dry mouth, constipation and sexual dysfunction 
with antidepressant treatment compared to saffron. Compared to placebo treatment, 
treatment with saffron was associated with a tendency of increased reports of anxiety/ 
nervousness, increased appetite, nausea, and headache.  
 
Table 2. Number of reported adverse events in saffron and 
antidepressant comparison trials 
Adverse event Saffron Antidepressant 
control  
Anxiety/ nervousness 11 15 
Decreased appetite 13 11 
Increased appetite 7 10 
Sedation/ drowsiness 2 8 
Nausea 7 9 
Headache 8 13 
Dry mouth 2 11 
Hypomania 2 1 
Constipation 3 8 
Urinary retention 1 5 
Sexual dysfunction 3 9 
Tremor 2 9 
Sweating 2 6 
Heart pounding 3 2 
Insomnia 3 3 
 
 
Table 3. Number of reported adverse events in saffron and 
placebo comparison trials 
Adverse event Saffron Placebo 
Anxiety/ nervousness 7 3 
Decreased appetite 6 4 
Increased appetite 5 1 
Sedation/ drowsiness 1 2 
Nausea 7 3 
Headache 6 3 
Hypomania 2 1 
Tremor 3 1 
Sweating 2 1 
Heart pounding 4 2 
Stomach pain 4 2 
 
 
Discussion 
From the clinical studies reviewed, saffron has demonstrated efficacy for the treatment of 
adults diagnosed with major depressive disorder. In people with a moderate severity of 
depression, saffron had large treatment effects compared to a placebo and was as effective as 
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the antidepressants fluoxetine and imipramine. These conclusions are consistent with a recent 
meta-analysis completed by Hausenblas and colleagues (2013) who calculated an overall effect 
size of 1.62 (95% confidence interval: 1.10-2.14) for saffron supplementation versus placebo. A 
null effect size was also calculated in this meta-analysis for saffron supplementation versus 
antidepressant medication (fluoxetine and imipramine), indicating both treatments were 
similarly effective in reducing depressive symptoms. 
Dosage and extract source: Daily doses of 30mg/day of saffron stigma or petal extract were 
used with treatments lasting 6 to 8 weeks. There were no differences in treatment efficacy 
between these two extract sources. In a study directly comparing the efficacy of stigma and 
petal crocus sativus extracts, both were equally effective in reducing depressive symptoms in 
adults diagnosed with major depression (Akhondzadeh Basti et al., 2008). Although the petal 
extract does not contain crocin, it does contain the natural flavonoid, kaempferol, which has 
antidepressant effects (Hosseinzadeh et al., 2007). There are significant benefits associated 
with utilising the petal rather than stigma, as it is less expensive and easier to obtain in larger 
quantities (Melnyk et al., 2010). In an animal behavioural model, an extract of saffron corms 
(underground plant stem) also produced antidepressant effects and presents as another 
potential extract source, associated with increased accessibility and lowered costs compared to 
stigma (Wang et al., 2010). 
Standardisation and quality control: Varying standardised extracts were used in the 
reviewed studies. In half of the studies no standardisations were specified while in the 
remaining studies varying extracts standardised for safranal and crocin were used. However, 
standardisations did not influence treatment efficacy as mean reductions in HAM-D were 
similar across all studies. Despite this finding, standardisation is commonly used in herbal 
medicine as one measure of quality control and allows for greater comparability across 
studies, although as argued by Scholey et al. (2005) does not guarantee consistency. Quality 
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control is a significant issue in herbal medicine, highlighted by a recent study by Newmaster 
et al. (2013). DNA testing of 44 herbal products showed that most of the tested products were 
of poor quality, subjected to considerable product substitution, contamination and fillers. 
Given the extremely high price associated with saffron stigma and difficulties associated with 
its production, saffron is not immune to this problem and historically has been subject to 
adulteration. Natural and artificial additives such as colouring agents (e.g. ground 
paprika/turmeric), organic compounds (e.g. honey and oil), and inorganic compounds (e.g., 
borates, sulfates, chlorides, and carbonates) have been added to saffron throughout the 
centuries (Melnyk et al., 2010). To combat this problem and ensure its authenticity and quality, 
grading standards are set by the International Organization for Standardization (ISO), a 
federation of national standards bodies (Melnyk et al., 2010). ISO 3632 deals exclusively with 
saffron and establishes four grades: IV (poorest), III, II, and I (finest quality). One main 
measure of grade is determined by the spice's crocin content, revealed by measurements of 
crocin-specific spectroscopic absorbance. Greater absorbances at 440-nm light indicate greater 
crocin concentration, with colour grades proceeding from absorbances lower than 80 (category 
IV) up to 190 or greater (category I) (Alavizadeh and Hosseinzadeh, 2014, Gohari et al., 2013).  
Safety of saffron: In the antidepressant-comparison trials, anti-depressant treatment was 
associated with trends of increases in the following adverse events; sedation, dry mouth, 
constipation, sexual dysfunction and tremor. In the placebo-comparison trials, saffron was 
associated with increased reports of anxiety, increased appetite, nausea and headache. 
Information on toxicology and safety reports of saffron is inconsistent. In some reports, 
vomiting, diarrhoea and bleeding occurred after the ingestion of 2 g of saffron, although in 
vivo animal studies have shown a very low or even non-existent toxicity of both saffron and its 
extracts (Melnyk et al., 2010). In a human trial, the ingestion of 200 and 400 mg of saffron for 7 
days was associated with slight changes in haematological and biochemical parameters, 
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although these remained within the normal range and were not considered medically 
significant (Modaghegh et al., 2008). An investigation into the short-term safety and 
tolerability of crocin tablets (20mg/day) was also undertaken in healthy adult volunteers. The 
one-month ingestion of crocin tablets had little effect on haematological, biochemical, or 
hormonal parameters apart from moderately decreasing levels of amylase, mixed white blood 
cells and partial thromboplastin time (PTT) (Mohamadpour et al., 2013). 
As saffron has shown some effect on blood coagulation and platelet aggregation in in vitro 
and in vivo studies (Modaghegh et al., 2008), a recent double-blind, placebo-controlled 
investigation was undertaken using a larger sample size. One week of treatment with 200 mg 
and 400 mg saffron tablets did not change plasma levels of fibrinogen, factor VII (as coagulant 
agent), C and S protein (an anti-coagulant agent), prothrombin time or PTT (Ayatollahi et al., 
2014). 
On the whole, it seems that daily doses of up to 1.5 g of saffron are generally considered 
safe although at dosages of 5 g and above it has been reported to have toxic effects, and is fatal 
at a dose of 20 g (Schmidt et al., 2007). Since the efficacious dosage for the treatment of 
depression (30 mg/day) is much lower than these reported levels and is in accordance with the 
amount of saffron used in various cuisines, there is a very large margin of safety 
(Hosseinzadeh and Nassiri-Asl, 2013). Given past, albeit inconsistent findings of saffron on 
blood coagulation and platelet aggregation, caution is warranted on the use of saffron in 
people with blood coagulation disorders or with people on anticoagulant medications. 
Symptoms of anxiety, increased appetite, nausea and headache also require further 
monitoring. Longer trials are also necessary to help clarify the long term safety of saffron use 
in depression as no study has been greater than 8 weeks. 
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Directions for future research 
Overall, saffron presents as a promising natural option for the treatment of mild to 
moderate depression with initial clinical research supporting its efficacy, at least in the short-
term. Current evidence indicates that it is as effective as the pharmaceutical antidepressants 
fluoxetine and imipramine, with a similar recovery profile over time. Further research is, 
however, required to clarify the mechanisms associated with this spice and its optimal 
treatment schedule.  
While the evidence so far supports saffron as an effective antidepressant, its efficacy 
across varying age groups is uncertain. Studies to date have been limited to depressed 
populations aged between 18 and 60 years, so its efficacy and safety outside this age range is 
unknown. Whether effects differ in males and females has also not been investigated 
specifically, although the clinical studies reviewed in this paper commonly used depressed 
populations with approximately equal gender distributions and did not cite differing rates of 
efficacy. The effectiveness of saffron in patients with co-morbid mental health disorders and 
for the treatment of specific depression subtypes (e.g., atypical and melancholic) is also 
unknown. All studies to date have also been completed by the same research group, so 
replication in other research settings with differing sample populations will also provide 
greater validation for its antidepressant effects. 
The potential and safety of saffron as an adjunct to pharmaceutical antidepressants is an 
additional area that requires investigation. Saffron has been used in conjunction with 
fluoxetine in two clinical trials and has been proven safe and even beneficial for the treatment 
of fluoxetine-induced sexual impairment (Kashani et al., 2013, Modabbernia et al., 2012). 
However, its use with other antidepressant classes and its ability to enhance treatment efficacy 
for depression has yet to be determined. 
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Currently, clinical outcomes have been measured through depression questionnaires, 
namely the HAM-D. The use of alternative depression inventories and the measurement of 
physiological markers associated with inflammation, oxidative stress, and neuroendocrine 
balance in human clinical trials will further enhance our understanding of the antidepressant 
mechanisms of action of saffron. 
The area of herbal medicine is complicated by often considerable differences in the 
quality of herbs, which can affect clinical outcomes across studies (Sarris et al., 2011). Saffron 
is no exception as there can be considerable variability in cultivation, production and 
extraction (e.g., aqueous methanol, ethanol, or water) methods used. While the studies 
reviewed have not revealed any significant differences in outcome between the different 
extracts (e.g., stigma or petal; standardised or non-standardised), further investigation in this 
area is certainly required. 
Finally, the cited studies have only used a daily dose of 30 mg/day of saffron and follow-
up periods have been no longer than 8 weeks. Further research is required to determine 
optimal dosages and duration of treatment, and the long term efficacy and safety of this exotic 
spice.  
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